University of New Mexico

UNM Digital Repository
Biomedical Sciences ETDs

Electronic Theses and Dissertations

Spring 5-15-2020

Characterization of and Cellular Mechanisms Underlying Spinal
Non-viral Interleukin-10 Gene Therapy Formulated with Dmannose for Treatment of Peripheral Neuropathic Pain
Arden G. Vanderwall
University of New Mexico - Main Campus

Follow this and additional works at: https://digitalrepository.unm.edu/biom_etds
Part of the Molecular and Cellular Neuroscience Commons

Recommended Citation
Vanderwall, Arden G.. "Characterization of and Cellular Mechanisms Underlying Spinal Non-viral
Interleukin-10 Gene Therapy Formulated with D-mannose for Treatment of Peripheral Neuropathic Pain."
(2020). https://digitalrepository.unm.edu/biom_etds/223

This Dissertation is brought to you for free and open access by the Electronic Theses and Dissertations at UNM
Digital Repository. It has been accepted for inclusion in Biomedical Sciences ETDs by an authorized administrator
of UNM Digital Repository. For more information, please contact disc@unm.edu.

i

CHARACTERIZATION OF AND CELLULAR MECHANISMS
UNDERLYING SPINAL NON-VIRAL INTERLEUKIN-10
GENE THERAPY FORMULATED WITH D-MANNOSE FOR
TREATMENT OF PERIPHERAL NEUROPATHIC PAIN

by

ARDEN GRACE VANDERWALL
B.S., Neuroscience, University of Michigan, 2011

DISSERTATION
Submitted in Partial Fulfillment of the
Requirements for the Degree of
Doctor of Philosophy
in
Biomedical Sciences
The University of New Mexico
Albuquerque, New Mexico

May, 2020

ii

DEDICATION

The pursuit of knowledge is an adventure like none other. My journey could not
have been possible without the love and support of my family. My parents, Elizabeth
Trickey and Richard Glassman, have always taught me to be adventurous, inquisitive, and
perseverant. My brother, Andrew Trickey-Glassman, is a life-long best friend who has
always helped me see the lighter side of things, especially when they seemed most dark.
My husband, Philip Vanderwall, has truly been my rock. His unconditional love, support,
goofiness, love of cooking, sense of adventure, and limitless understanding have helped
get me through this enormous undertaking.
I have also been incredibly lucky to have two amazing role models in science, Erin
Milligan and Shahani Noor. Erin leads by example, providing a model of excellence that I
can only hope to replicate in my future scientific career. As a mentor, everything Erin has
done has been designed to make me the best scientist I can be. In helping shape my
scientific mind, Erin continues to help me realize the greater implications of our work,
always thinking ahead to consider how our research could be applied to the clinic. This
type of thinking will be critical for my future career in both science and medicine. Shahani
Noor is a brilliant scientist that I strive to emulate daily. Her mentorship and friendship
mean the world to me.

Thank you.

iii

ACKNOWLEDGMENTS
The work presented here could not have been accomplished without key collaborative
efforts of Erin D. Milligan, PhD, Shahani Noor, PhD, Lauren L. Jantzie, PhD, Nikolaos
Mellios, MD-PhD, Xuexian O. Yang, PhD, Melody S. Sun, B.S., Jacob E. Sanchez, B.S.,
and Nathan W. Harris, B.S.
I sincerely thank Dr. Hugh Martin, MD, for guiding the Dept. Anesthesiology &
Critical Care Medicine to financially support my journey towards becoming an MD-PhD.
I would also like to thank Dr. Martin and Dr. Karin Westlund High, PhD, for use of
University of New Mexico School of Medicine (UNM SOM) Dept. of Anesthesiology &
Critical Care Medicine laboratory space to perform RNA extractions. I greatly appreciate
Dr. Michael L. Paffett, PhD, of the University of New Mexico Cancer Research and
Treatment Center Fluorescence Microscopy Shared Resource for sharing his expertise in
microscope spectral imaging. I also thank Tamara Howard, MS, of the UNM SOM Dept.
of Cell Biology and Physiology for her invaluable guidance in tissue processing and
immunohistochemistry.
This work was supported by National Institute of Health grants DA018156-10,
AA023051, AA022534-01, by dedicated Health Research funds from the UNM SOM,
Research Funds from the UNM SOM Dept. of Anesthesiology & Critical Care Medicine,
and funding from the Science and Technology Corporation (STC) at UNM; Gap Fund
Project and New Mexico Angels Project.
This dissertation contains previously published material. Chapter I originally
appeared in the Primer of PsychoNeuroImmunology Research, 2016. Chapter II was
published in Brain, Behavior, and Immunity, 2018.

iv

CHARACTERIZATION OF AND CELLULAR MECHANISMS
UNDERLYING SPINAL NON-VIRAL INTERLEUKIN-10 GENE
THERAPY FORMULATED WITH D-MANNOSE FOR
TREATMENT OF NEUROPATHIC PAIN
by
Arden Grace Vanderwall

B.S., Neuroscience, University of Michigan, 2011
PhD, Biomedical Sciences, University of New Mexico

ABSTRACT
Anti-inflammatory intrathecal non-viral interleukin-10 (IL-10) gene therapy provides
enduring relief of chronic pain in numerous animal pain models. Co-administration of the
mannose receptor (MR) ligand D-mannose (DM) improves non-viral IL-10 gene
therapeutic efficacy, but questions remain regarding which pain-relevant tissues are critical
for non-viral transgene expression resulting in long-lasting pain relief. Additionally, the
role of endogenous IL-10 in non-viral IL-10 therapeutic effects is completely unknown.
Chapter I is an Introduction to the studies detailed in this dissertation, providing a
historical perspective of the field of neuroinflammation and a framework upon which
neuroimmune processes intersect with mechanisms underlying pathological pain. The
work presented in Chapter II investigates in vivo the mechanisms that underlie pain relief
following intrathecal non-viral IL-10 gene therapy formulated with DM for treatment of
peripheral neuropathic pain. Naked plasmid DNA encoding the IL-10 transgene (pDNAIL-10) was co-injected intrathecally with DM in both IL-10 wildtype (WT) and IL-10
v

deficient (IL-10 KO) neuropathic mice. We show that DM/pDNA-IL-10 is efficacious in
both backgrounds, indicating that endogenous IL-10 is not required for efficacy of
DM/pDNA-IL-10 therapy. We next demonstrate the biodistribution of the IL-10 transgene,
with key expression in the ipsilateral dorsal root ganglia (DRG) of pain-relieved mice that
induces local anti-inflammatory effects. This drives further anti-inflammatory changes at
the level of the lumbar spinal cord, which are mirrored by decreased expression of glial
activation markers. We further demonstrate that MR activation itself provides transient
pain relief in IL-10 KO mice. This supports an IL-10-independent anti-inflammatory
mechanism by which MR-mediated actions modulate pain signaling.
The work presented in Chapter III utilizes in vitro primary cell culture techniques
to explore the cellular mechanisms by which MR activation mediates IL-10 independent
anti-inflammation. This approach is also applied to examine and the cellular conditions
(basal vs. inflammatory stimulation) required for DM-mediated transgene adjuvant effects.
These preliminary studies indicate that MR activation decreases nitric oxide (NO)
production in an IL-10-independent manner. We also present evidence that the timing of
inflammation and the relative expression levels of MR dramatically impact the efficacy of
MR-mediated anti-inflammatory-like conditions.
Chapter IV discusses pain as a chronic inflammatory disease and explores the
versatility of DM/pDNA-IL-10 gene therapy in the treatment of chronic pain of different
etiologies. It also indicates that MR activation by DM has utility beyond the realm of nonviral gene therapy and puts forth that MR should be explored as a therapeutic target in its
own right for treatment of chronic pain.
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CHAPTER I
Introduction to Pain and the Neuroimmune Interface

1. Overview

Since the time of the ancient Greeks pain has been considered a cardinal sign of
inflammation. However, modern science has been slow to appreciate that pain and the
immune system are interrelated. There has been growing recognition since the 1970s that
the nervous and immune systems play intertwining roles in behavior and physiology
(Watkins and Maier, 2005). It was first noted that sick or injured animals often display a
broad array of ‘sickness responses’(Hart, 1988). Characteristic physiological changes
include fever and increased sleep, as well as changes to activity of the hypothalamicpituitary axis and the sympathetic branch of the autonomic nervous system. These biologic
changes are paired with behavioral stereotypes including decreases in ingestion of food
and water, motility, and social/sexual behavior. Intriguingly, sickness responses also
include sickness-induced hyperalgesia, a pathological pain state when pain from noxious
stimuli is enhanced (Maier et al., 1992; Watkins and Maier, 2000).
These alterations all require changes in brain functioning, suggestive of an avenue
of communication from the periphery to the brain to specifically relay that something
serious (e.g. injury or infection) has happened (Watkins and Maier, 2005). It has since been
demonstrated that pro-inflammatory cytokines produced by peripheral immune cells,
especially interleukin-1β (IL-1β), IL-6, and tumor necrosis factor-α (TNF-α), provide this
critical signal to the central nervous system (CNS) (Milligan and Watkins, 2009; Mika et
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al., 2013; Grace et al., 2014; Ji et al., 2016). Additionally, glia (astrocytes and microglia)
and neurons (both CNS and peripheral nervous system [PNS]) express a variety of cytokine
receptors like the IL-1β receptor (IL-1βR) and the TNF-α receptor (TNF-αR) (Milligan and
Watkins, 2009). Glia are also known to respond to important chemokines such as
chemokine C-C motif ligand 2 (CCL2) (Grace et al., 2014). Not only can glia respond to
peripherally derived pro-inflammatory mediators, but consequent glial activation results in
further production of pro-inflammatory mediators. Importantly, these centrally derived
glial cytokines are both necessary and sufficient for the production of sickness responses
(Rothwell and Luheshi, 1994; Watkins and Maier, 2005).
This introduction to the topic of pain and neuroimmunology will discuss key
aspects of neuronal-mediated pain signaling under acute and chronic conditions following
a brief overview of normal pain processing. Major findings will be discussed addressing
why pathological pain is now considered a product of neuroimmune dysfunction involving
neurons, glia, and peripheral immune cells. Finally, the reader will be introduced to
potential avenues for improvements in therapeutic approaches for pain control using
methods that target neuroimmune glial cells.

2. Chronic Pain is a Global Health Problem

Pain lasting greater than three months is considered chronic. Worldwide, chronic pain is
estimated to afflict more than 1.5 billion people, and in 2013 pain was ranked in a global
top ten list of causes for years lived with disability (YLD) (Yaqub, 2015). A different
survey in Europe found that 60% of respondents had experienced chronic pain from two to
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15 years, with nearly a fifth of respondents reporting pain suffering for >20 years (Breivik
et al., 2006). In the United States alone, chronic pain exacts an estimated $560-635 billion
per year in costs for treatment and loss of productivity and, for many patients, adequate
pain control remains out of reach (Institute of Medicine Committee on Advancing Pain
Research and Education, 2011). Neurons are clearly critical in pain signaling, and many
pharmaceutical agents are designed to control pain through limiting neuronal activity.
Unfortunately, such medications offer insufficient analgesia. Furthermore, as is the case
with opioids like morphine, they can be associated with the rapid onset of tolerance and a
high potential for abuse.

3. Function and Anatomy of Physiological Pain

3.1 Pain vs. Nociception

Physiological pain is an evolutionarily advantageous sensory warning system and can be
understood as the conscious awareness of nociceptive information (Nash, 2005; Tracey and
Mantyh, 2007). Nociception is the ‘pre-conscious’ process by which potentially harmful
stimuli, such as intense thermal, mechanical, or chemical insults, are detected by a
subpopulation of peripheral neurons called nociceptors (Basbaum et al., 2009). Primary
nociceptors that innervate the body have peripheral sensory receptors in target tissues (e.g.
skin) and house their cell bodies in the dorsal root ganglia (DRG) found at each level of
the vertebral column (Basbaum et al., 2009). Importantly, these nociceptors synapse with
second order neurons in the spinal cord dorsal horn (Tracey and Mantyh, 2007; Watkins et
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al., 2007b; Basbaum et al., 2009). For example, pricking one’s forefinger should activate
nociceptors traveling in the median nerve to the dorsal horn within the cervical spinal cord
(Standring, 2016a). The dorsal horn of the spinal cord is a CNS locale with a complex
assortment of pain transmitting neurons, interneurons, and non-neuronal glial cells. Unlike
nociceptors found in the rest of the body, those traveling within cranial nerves (e.g. the
trigeminal nerve) communicate not with second order neurons in the dorsal horn, but rather
with second order neurons found in brainstem nuclei (Standring, 2016b).

3.2 Nociceptor Subtypes and Pain Projection Pathways

There are two main types of nociception-specific neurons, those with thin unmyelinated
axons (C fibers) or medium diameter lightly myelinated axons (Aδ fibers) (Watkins et al.,
2001a; Basbaum et al., 2009; Milligan and Watkins, 2009). Generally, Aδ fibers mediate
acute well-localized ‘fast’ pain, whereas C fibers are characterized by slow conduction
velocity and ‘slow’ pain (Basbaum et al., 2009; Milligan and Watkins, 2009). These
nociceptor subtypes are distinct from the large diameter heavily myelinated Aβ fibers that
are critical for relaying non-noxious information (e.g. mechanical stimulation such as light
touch). Within the dorsal horn, sufficiently noxious nociceptive inputs can initiate
protective spinally-mediated withdrawal reflexes designed to remove oneself from
immediate harm (e.g. withdrawing one’s fingertips from a hot pan) (Schouenborg and
Sjolund, 1983). Nociceptive information is also processed by higher order structures in the
brainstem and brain, leading to perception of pain, promotion of learning, and fostering of
healing behaviors (Tracey and Mantyh, 2007; Basbaum et al., 2009). Information about
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noxious stimuli can ascend within the spinal cord to the thalamus via the contralateral
spinothalamic tract (STT) or to the medulla and midbrain through the spinoreticular and
spinomesencephalic tracts (Tracey and Mantyh, 2007). The most common cerebral regions
activated during acute pain experiences are the primary and secondary somatosensory,
insular, anterior cingulate, and prefrontal cortices (Tracey and Mantyh, 2007).
Descending modulation of nociceptive signaling (particularly that which alters
activity in the spinal cord dorsal horn) can be utilized to either facilitate or inhibit pain
(Fields and Basbaum, 1978; Porreca et al., 2002). Many of the higher order structures
mentioned to be activated by acute pain also play roles in spinal mechanisms of pain
modulation, including the frontal lobe, anterior cingulate cortex (ACC), insula, amygdala,
hypothalamus, periaqueductal gray (PAG), nucleus cuneiformis (NCF), and rostral
ventromedial medulla (RVM) (Porreca et al., 2002; Tracey and Mantyh, 2007). There is
also interest in understanding how cognitive processes like attention can influence
brainstem activity, leading to changes in spinal nociceptive processing (Tracey and
Mantyh, 2007).

3.3 Acute Pain Neurotransmitter Signaling

During acute pain transmission, peripheral nociceptor activation leads to glutamatergic
signaling in the spinal cord dorsal horn, which in turn leads to excitatory postsynaptic
currents (EPSCs) in second order pain projection neurons (Basbaum et al., 2009). Under
‘normal pain’ conditions, glutamatergic signaling is mediated by postsynaptic AMPA
receptors. Though NMDA receptors are present, they are inhibited by the presence of a
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magnesium ion ‘plug’ (Basbaum et al., 2009). Summation of subthreshold EPSCs mediated
by AMPA activation eventually causes action potential firing of the second order pain
projection neurons, allowing for transmission to higher order structures in the brain
(Basbaum et al., 2009).

4. Neuronal Mechanisms of Pathological Pain

4.1 Pathological Pain

‘Normal’ physiological pain correlates with acute or potential tissue damage.
Unfortunately, damage to the CNS or PNS by disease, injury, or infection can lead to
pathological pain. That is, pain that is now maladaptive, extending beyond the window of
usefulness (Grace et al., 2014). Such pathological pain can be observed in a variety of
conditions including inflammatory pain such as that following joint injury (e.g. arthritis),
cancer pain, neuropathic pain following peripheral nerve damage (e.g. trauma, diabetic
neuropathy, or chemotherapeutic side effects), or CNS damage (e.g. stroke, trauma, or HIV
infection) (Milligan and Watkins, 2009; Grace et al., 2014). In such cases, pain resulting
from normally nociceptive stimuli, such as heat, may now be exaggerated (hyperalgesia)
(Milligan and Watkins, 2009). Pain may even occur in response to non-nociceptive stimuli
(allodynia) such as light touch, which is referred to as mechanical allodynia (Milligan and
Watkins, 2009).
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4.2 Peripheral and Central Sensitization

Incremental changes in neuronal activity are required to elicit pathological pain. One such
change in neuronal signaling is called peripheral sensitization in which primary nociceptors
become overly responsive as result of exposure to pro-inflammatory mediators released by
local immune cells at the site of tissue injury or infection (Basbaum et al., 2009). One
mechanism facilitating heightened exposure is known as neurogenic inflammation.
Neurogenic inflammation is possible, in part, because nociceptive activation of C fibers
not only leads to orthodromic signaling to the spinal cord, but also to antidromic signaling
back to the periphery as a result of axonal or dorsal root reflexes (Chiu et al., 2012). This
causes peripheral nociceptor terminal release of neuropeptides like substance P (Sub P),
calcitonin gene-related peptide (CGRP), neurokinin A (NKA), NKB, vasoactive intestinal
protein (VIP), and neuropeptide Y (NPY) (Chiu et al., 2012). These neuropeptides lead to
local increases in blood flow, vascular permeability, and immune cell accumulation (Chiu
et al., 2012). Trafficking immune cells release a host of pro-inflammatory mediators for
which sensory neurons express receptors, such as IL-1βR and TNF-αR (Scholz and Woolf,
2007). Activation of these receptors on nearby C fibers and Aδ fibers leads to enhanced
membrane excitability and sensitization to subsequent stimulation (Scholz and Woolf,
2007; Littlejohn, 2015).
Peripheral nerve sensitization can in turn lead to enhanced nociceptor release of
excitatory neurotransmitters at their terminal synapses within the spinal cord dorsal horn.
Key spinal pain neurotransmitters include glutamate, Sub P, CGRP, and adenosine
triphosphate (ATP) (Grace et al., 2014). Unlike during acute pain conditions, the enhanced
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excitatory signaling enables sufficient postsynaptic depolarization for removal of the once
inhibitory magnesium ion from the NMDA receptor pore. This results in increased cation
(e.g. Ca2+) influx and strengthened synaptic connections between primary nociceptors and
secondary pain transmission neurons in the dorsal horn of the spinal cord (Latremoliere
and Woolf, 2009). This type of neuronal plasticity is known as central sensitization and
can be observed clinically as hyperalgesia, allodynia, and the expansion of receptive fields
that enables input from non-injured tissue to produce pain (secondary hyperalgesia)
(Basbaum et al., 2009; Latremoliere and Woolf, 2009). While the NMDA receptormediated mechanism of central sensitization is the best understood, alternatives have been
proposed. For example, peripheral nerve injury could induce phenotypic changes in Aβ
fibers, leading to ectopic expression of CGRP and Sub P (neuropeptides associated with
nociceptive C- and Aδ- fibers) (Nitzan-Luques et al., 2011).

4.3 Traditional Neuron-Centric Pain Control Therapeutics and Their Shortcomings

To combat pathological pain, clinicians have traditionally relied on medications that target
neuronal activity. Common treatments include opioid and non-opioid analgesics including
anti-depressants (e.g. tricyclic anti-depressants [TCAs] or serotonin norepinephrine
reuptake inhibitors [SNRIs]) and anticonvulsants (e.g. gabapentin or pregabalin) (Dworkin
et al., 2007; Colloca et al., 2017). For most patients, initial treatment for neuropathic pain
involves anti-depressants or anticonvulsants, but are almost inevitably followed by opioid
use, the second-line option (Dworkin et al., 2007). Opioids such as morphine mimic
endogenous endorphins by acting on opioid receptors, such as the μ, κ, and δ subtypes,
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found on sensory neurons within the brain and spinal cord (Hutchinson et al., 2011;
Jamison and Mao, 2015). Activation of μ opioid receptors on ascending pain projection
neurons decreases neuronal firing, thereby limiting the perception of pain (Hutchinson et
al., 2011). Though opioids are known to produce powerful analgesia, they are also
associated with rapid development of tolerance, paradoxical hyperalgesia, and potential for
opioid use disorder (Song and Zhao, 2001; Raghavendra et al., 2002; Milligan and Watkins,
2009; Hutchinson et al., 2011; Grace et al., 2014). Current neuron-centric treatments offer
insufficient pain control, but a growing body of evidence suggests that neuroimmune glial
cells can serve as novel targets for development of future chronic pain control therapeutics.

5. Glial Pro-inflammatory Activation is Both Necessary and Sufficient for
Pathological Pain

5.1 Spinal glial activation: more than simple homeostasis

A great deal of work has begun to focus on astrocytes and microglia and their roles in pain
dysregulation (Watkins et al., 2001a). Astrocytes arise from neuroepithelium and are found
throughout the brain and spinal cord (Rowitch and Kriegstein, 2010), outnumbering
neurons and accounting for 40-50% of all CNS glia (Lee et al., 2000). In contrast, microglia
possess a mesodermal hematopoietic origin and constitute only 5-10% of all glia and are
considered the resident mononuclear phagocytes of the CNS (Watkins et al., 2007a;
Rowitch and Kriegstein, 2010). Previously, astrocytes and microglia were thought to serve
purely homeostatic and surveillance functions, but it has become clear that they are far
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more than “housekeepers.” For instance, following infection or injury of the CNS, both
cell types can assume ‘activated’ phenotypes, experiencing changes in morphology (e.g.
switch from highly ramified to amoeboid appearance) as well as upregulation of cell-type
specific activation markers like astrocytic glial fibrillary acidic protein (GFAP) and
microglial complement receptor 3 (CR3; CD11b) (Watkins et al., 2001b; Milligan and
Watkins, 2009). Astrocytes and microglia also release increased levels of proinflammatory mediators including cytokines, chemokines, ATP, excitatory amino acids
(EAAs), and nitric oxide (NO) (Watkins et al., 2007a). Importantly, spinal glia are closely
associated with neural synapses and are known to express many of the same
neurotransmitter receptors as neighboring neurons, making them well-positioned to
modulate neural communication or to become reactive in response to abnormal or
heightened neuronal signaling (Watkins et al., 2001b; De Leo et al., 2006; Scholz and
Woolf, 2007; Milligan and Watkins, 2009).
Oligodendrocytes are another important glial cell type found throughout the CNS,
though their potential role in pain dysregulation remains poorly understood.
Oligodendrocytes are derived from neuroepithelium and are critical for CNS myelination
(Rowitch and Kriegstein, 2010). They are capable of producing pro-inflammatory
cytokines and chemokines, and a recent study by Zarpelon et al. suggests that proinflammatory IL-33 produced by oligodendrocytes may be important for neuropathic pain
following peripheral nerve injury in mice (Zarpelon et al., 2016). Overall, the relationship
between oligodendrocytes and pain has been understudied and is worth further
investigation.
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5.2 Initial evidence for glial activation following peripheral nerve damage

Interestingly, glia increase their expression of activation markers following peripheral
nerve damage (Watkins and Maier, 2005). Garrison et al. provided the first anatomical
evidence that spinal glia may play a role in pain modulation through the observation that
astrocytes of the lumbar spinal cord demonstrate signs of activation (e.g. changes in
morphology and increased GFAP expression) following chronic constriction injury (CCI)
of the rat sciatic nerve (Garrison et al., 1991). Though prior work had identified CNS glial
activation following peripheral nerve damage, Garrison et al. were the first to connect glial
activation with a functional outcome (Garrison et al., 1994). They found that administration
of an NMDA receptor antagonist (MK-801) known to alleviate neuropathic pain (clinically
and in animal models) leads to a dramatic decrease in the level of glial activation markers
in the spinal cord dorsal horn normally observed following sciatic nerve damage (Garrison
et al., 1994).

5.3 Glial activation observed in a variety of animal models of neuropathic pain

Glial activation and the notion that glia are potent contributors to exaggerated pain states
is further supported by the observation that pain in animal models can be prevented or
reversed by application of agents that inhibit glial activation or production of proinflammatory mediators. Meller et al. showed that following intraplantar injection of
zymosan (an inflammatory component of yeast cell walls) and subsequent hyperalgesia,
intrathecal (i.t.; delivery into subarachnoid cerebrospinal fluid) injection of fluorocitrate (a
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selective metabolic inhibitor of astrocytes) results in pain relief (Meller et al., 1994). Later,
Watkins et al. demonstrated that i.t. fluorocitrate, IL-1 receptor antagonist (IL-1Ra), or
semapimod (CNI-1493; inhibitor of both NO synthesis and p38 MAP Kinase activation)
all block hyperalgesia caused by subcutaneous formalin injection (Watkins et al., 1997).
Milligan et al. then established that i.t. fluorocitrate, IL-1Ra, and TNF binding protein
(TNFbp) all prevent pain induced by i.t. HIV-1 envelope glycoprotein gp120, a model of
spinal glial inflammation (Milligan et al., 2001). Additionally, Sweitzer et al. found that
propentofylline (a methylxanthine derivative found to attenuate astrocyte activation) could
both prevent and reverse mechanical allodynia (pathological sensitivity to light touch, as
noted above) in a rodent L5 spinal nerve transection model of neuropathic pain (Sweitzer
et al., 1999). Importantly, microglial activation was further implicated in neuropathic pain
by Ledeboer et al. who showed that i.t. minocycline (a selective inhibitor of microglial
activation) attenuates mechanical allodynia following either acute or persistent sciatic
inflammatory neuropathy (SIN) or i.t. HIV-1 gp120 (Ledeboer et al., 2005).
Since then, the observation that glial activation and resultant production of proinflammatory mediators are both necessary and sufficient for neuropathic pain has been
shown in a wide variety of animal models. Spinal cord glial activation is observed in
virtually every animal model of enhanced pain, and this pain can be reversed or prevented
through inhibition of glial activation or nullification of pro-inflammatory actions (Watkins
et al., 2001a; Watkins and Maier, 2003; Marchand et al., 2005). It is worth noting that
recent work in pre-clinical animal models have begun to reveal a role for leukocyte (e.g.
macrophages and T-cells) infiltration of the spinal cord following peripheral nerve damage
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in mechanisms of neuropathic pain (Ji et al., 2016). The role of the peripheral immune
system in chronic pain will be examined in greater detail in Chapters III and IV.

5.4 Opioids: Their newly recognized role in glial pro-inflammatory actions

Opioid analgesics are associated with a variety of unwanted side effects. Some of these can
be partly explained by neuronal mechanisms, but glial activation is now recognized as a
major contributor. Opioid receptors are stereoselective and become activated only through
binding with [-]-isomers (Hutchinson et al., 2011). Interestingly, classical opioid receptors
are not the only avenue for opioid-induced effects. For instance, glia express a variety of
receptors designed to recognize pathogen associated molecular patterns (PAMPs) and
endogenously derived markers of insult such as danger associated molecular patterns
(DAMPs) (Grace et al., 2014; Ji et al., 2016). Key among these are toll-like receptors
(TLRs). TLR4 is a well characterized pathogen recognition receptor (PRR) known for its
ability to become activated by the PAMP lipopolysaccharide (LPS; endotoxin; cell wall
component of gram negative bacteria) and DAMPs such as heat shock proteins (HSPs) or
high mobility group box 1 (HMGB1) protein (Agalave et al., 2014; Grace et al., 2014).
Intriguingly, Hutchinson et al. demonstrated that both [+]- and [-]-opioid isomers can
activate TLR4 through binding its co-receptor, myeloid differentiation factor 2 (MD2)
(Hutchinson et al., 2007). Prior to this, it was known that morphine administration leads to
dramatic increases in spinal levels of mRNA for pro-inflammatory cytokines, with
consequent increases in observed cytokine release (Watkins et al., 2007a). Additionally,
co-administration of morphine with glial inhibitors is known to abolish the development
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of opioid tolerance (Song and Zhao, 2001). Interestingly, spinal pro-inflammatory
cytokines in neuropathic pain have been shown to produce a state of “naïve morphine
tolerance” in which activated glia overreact to morphine compared to glia from sham
treated controls, thereby preventing the anti-nociceptive effects of acute morphine
(Raghavendra et al., 2002; Raghavendra et al., 2003). Opioids are just one example for
which a clear understanding for neuroimmune function will be key in improving pain
control approaches.

6. Neuroimmune Targets for Improved Pain Control

It has become clear that glial activation is a major reason why widely used neuron-centric
therapeutics, like opioids, fail to provide adequate pain control for a majority of patients.
Thus far the development of neuroimmune modulators for pain control has targeted three
areas: 1) direct inhibition of neuroimmune pro-inflammatory signaling, 2) stimulation of
anti-inflammatory pathways, and 3) pro-resolution lipid mediators (Grace et al., 2014).

6.1 Direct inhibition of neuroimmune pro-inflammatory signaling

Pro-inflammatory cytokine actions can be targeted at several different levels including
cellular activation, production of pro-inflammatory mediators, and interaction with specific
receptors. Fluorocitrate is a well-known astrocytic activation inhibitor shown to be highly
effective at blocking neuropathic pain in animal models (Meller et al., 1994; Milligan and
Watkins, 2009). Unfortunately it has a narrow dose range with heightened neurotoxic risk
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at higher doses, making it less than ideal for human application (Romero-Sandoval et al.,
2008). Propentofylline is another glial activation modulator that specifically inhibits
phosphodiesterases (Sweitzer and De Leo, 2011). Minocycline, a second generation
tetracycline, is a blood-brain-barrier (BBB) permeable activation inhibitor of mononuclear
phagocytes like microglia (Mika, 2008). Ibudilast (formerly AV411, now MN-166)
administration

results

in

decreased

microglial

activation

by

inhibiting

both

phosphodiesterase function and TLR4 signaling (Ledeboer et al., 2007a; Johnson et al.,
2014). Other TLR4 antagonists that have shown promise as pain control therapeutics alone
or as adjuvants to opioids include [+]-naloxone and [+]-naltrexone (Hutchinson et al.,
2008). Interestingly, some pain control medications thought to solely target neurons have
been found to modulate glial pro-inflammatory functions, such as the anti-depressant
amitriptyline, a TCA that also inhibits TLR4 activation through binding to the MD2 coreceptor (Hutchinson et al., 2010; Grace et al., 2014). Cytokine antagonists like the biologic
agents anakinra (recombinant human IL-1 receptor antagonist; IL-1RA) and etanercept
(recombinant human soluble TNF receptor) have also shown beneficial effects in animal
models of neuropathic pain (Milligan and Watkins, 2009). Unfortunately host development
of neutralizing antibodies, compromised host defenses against infection, or BBB
impermeability make these biologic agents less than ideal for neuropathic pain control
(Fleischmann et al., 2006; Milligan and Watkins, 2009; Rider et al., 2016).
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6.2 Stimulation of Anti-inflammatory pathways

Gene therapeutic delivery of anti-inflammatory cytokines offer unique advantages over
small molecule approaches. For instance, the vector can be applied directly to the relevant
portions of the nociceptive pathway (e.g. level of the spinal cord) (Milligan and Watkins,
2009). Anti-inflammatory IL-2, IL-4, and IL-10 gene therapies have all been demonstrated
efficacious in the reversal of neuropathic pain in a variety of animal models (Goss et al.,
2007; Milligan and Watkins, 2009). Transgene expression and pain reversal is associated
with decreased phosphorylation of the pro-inflammatory transcription factor p38-MAPK
and decreased production of pro-inflammatory mediators like TNF-α, IL-1β, and
prostaglandin E2 (PGE2) (Grace et al., 2014). There is also a dramatic decrease in the
expression of glial activation markers like GFAP (Grace et al., 2014).
Both viral and non-viral methods are effective in treating rat models of chronic
neuropathic pain. Non-viral gene transfer methods, such as i.t. injection of naked plasmid
DNA (pDNA) provide several advantages over viral methods (e.g. problems with
immunogenicity or insertional mutagenesis) (Glover et al., 2005). Gene transfer adjuvants,
such as the recently reported D-mannose, have been shown to greatly enhance the enduring
efficacy of non-viral IL-10 gene therapy, reversing established neuropathic pain for greater
than 80 days in rats (Dengler et al., 2014). Work reported in this dissertation addresses
important questions that had long remained unanswered regarding the identities of the
tissues and cell types responsible for IL-10 transgene uptake and pain reversal, which are
now detailed in Chapter II.
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6.3 Pro-resolution Lipid Mediators

An emerging area of chronic pain research focuses on pro-resolution lipid mediators
(PRLMs) such as resolvins, protectins, and lipoxins (Grace et al., 2014; Ji et al., 2014).
PRLMs act to restore normal sensitivity through re-establishment of neuroimmune
communication. Resolvins were originally identified from inflammatory exudates
associated with the resolution of inflammation in rodents and humans(Ji et al., 2014).
Resolvins and protectins are derived from dietary essential fats such as the omega-3
polyunsaturated fatty acids docohexaenoic acid (DHA) and eicopentaenoic acid (EPA),
while lipoxins are derived from arachidonic acid (Ji et al., 2014). PRLMs have been found
to signal through G protein-coupled receptors (GPCRs) found on both glia, neurons, and
peripheral immune cells, and have great promise for neuropathic pain treatment based on
data from experiments showing pre-surgical prevention of neuropathic pain associated with
nerve damage in mice (Ji et al., 2014).

7. Conclusions

In this introductory chapter, the differences between acute and pathologic pain were briefly
described. Traditional mechanisms of pain processing from a purely neuronal perspective
were examined, followed by current clinical approaches to the treatment of chronic pain
and the insufficient pain control of neuron-centric therapeutics. A succinct history of the
realization that glial activation and production of pro-inflammatory mediators are critical
for the onset and maintenance of chronic pain was detailed, supporting that glia should be

17

targeted in the development of novel pain control therapeutics. Though it has been nearly
25 years since glia were first recognized as central actors in pain pathology, there is still
much

to

be

learned

about

the

neuroimmune

interface

in

this

field

of

psychoneuroimmunology.

Chapter I previously published in the Primer of PsychoNeuroImmunology Research, 2016,
and included here with publisher’s permission. Citation as follows:
Vanderwall AG, Milligan ED (2016) Introduction to Pain and the Neuroimmune Interface.
In: Primer of PsychoNeuroImmunology Research (Opp, MR, Editor), pp 289-296.
Los Angeles, CA: PsychoNeuroImmunology Research Society.
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CHAPTER II: PREFACE

While considerable progress has been made towards understanding the anti-inflammatory
actions on neuroimmune dynamics of pathological pain, questions remain regarding the
underlying mechanisms of anti-inflammatory intrathecal non-viral IL-10 gene therapy. The
focus of this second chapter is to elucidate the role of endogenous IL-10 in enduring pain
relief mediated by intrathecal non-viral IL-10 gene therapy for treatment of neuropathic
pain.
Though a significant body of work demonstrates the efficacy of this therapeutic
approach in a variety of animal pain models, these studies were performed in the presence
of endogenous IL-10. Consequently, it remained unclear whether endogenous IL-10 is
required for any component or phase of intrathecal non-viral IL-10 gene therapy. Further,
prior work utilized an IL-10 transgene that possessed a non-silent point mutation that could
interfere with IL-10 homodimerization, a preliminary requirement for activation of the IL10 receptor. Thus, it was previously unknown whether the exogenous transgene’s mutant
protein product requires heterodimerization with wildtype (e.g. endogenous) IL-10 for
sufficient receptor interaction leading to downstream anti-inflammatory signaling.
Additionally, due to the presence of endogenous IL-10, prior works could not
unambiguously indicate in which pain-relevant anatomic regions IL-10 transgene uptake
and expression drives relief of peripheral neuropathic pain.
This chapter also examines the role of IL-10 in D-mannose-mediated improvement
of non-viral IL-10 gene therapy. A prior report demonstrated that D-mannose enhances
therapeutic efficacy (i.e. transgene uptake and expression with consequent pain relief) if
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co-injected with non-viral plasmid DNA encoding the IL-10 transgene. Additionally, a
single intrathecal dose of D-mannose alone provides transient pain relief in neuropathic
wildtype rats. Whether IL-10 is required for these desirable effects is further explored here.
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CHAPTER II
Effects of spinal non-viral interleukin-10 gene therapy formulated with
D-mannose in neuropathic interleukin-10 deficient mice: behavioral
characterization, mRNA and protein analysis in pain relevant tissues.
Abstract

Studies show that spinal (intrathecal; i.t.) interleukin-10 (IL-10) gene therapy reverses
neuropathic pain in animal models, and co-administration with the mannose receptor (MR;
CD206) ligand D-mannose (DM) greatly improves therapeutic efficacy. However, the
actions of endogenous IL-10 may be required for enduring pain control observed following
i.t. IL-10 gene therapy, potentially narrowing the application of this non-viral transgene
delivery approach. Here, we show that i.t. application of naked plasmid DNA expressing
the IL-10 transgene co-injected with DM (DM/pDNA-IL-10) for the treatment of
peripheral neuropathic pain in IL-10 deficient (IL-10 KO) mice results in a profound and
prolonged bilateral pain suppression. Neuropathic pain is induced by unilateral sciatic
chronic constriction injury (CCI), and while enduring relief of light touch sensitivity
(mechanical allodynia) in both wild type (WT) and IL-10 KO mice was observed following
DM/pDNA-IL-10 co-therapy, transient reversal from allodynia was observed following i.t.
DM alone. In stably pain-relieved IL-10 KO mice given DM/pDNA-IL-10, mRNA for the
IL-10 transgene is detected in the cauda equina and ipsilateral dorsal root ganglia (DRG),
but not the lumbar spinal cord. Further, DM/pDNA-IL-10 application increases antiinflammatory TGF-β1 and decreases pro-inflammatory TNF mRNA in the ipsilateral DRG
compared to allodynic controls. Additionally, DM/pDNA-IL-10 treated mice exhibit
decreased spinal pro-inflammatory mRNA expression for TNF, CCL2 (MCP-1), and for
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the microglial-specific marker TMEM119. Similarly, DM/pDNA-IL-10 treatment
decreases immunoreactivity for the astrocyte activation marker GFAP in lumbar spinal
cord dorsal horn. Despite transient reversal and early return to allodynia in DM-treated
mice, lumbar spinal cord revealed elevated TNF, CCL2 and TMEM119 mRNA levels.
Both MR (CD206) and IL-10 receptor mRNAs are increased in the DRG following CCI
manipulation independent of injection treatment, suggesting that pathological conditions
stimulate upregulation and availability of relevant receptors in critical anatomical regions
required for the therapeutic actions of the DM/pDNA-IL-10 co-therapy. Taken together,
the current report demonstrates that non-viral DM/pDNA-IL-10 gene therapy does not
require endogenous IL-10 for enduring relief of peripheral neuropathic pain and does not
require direct contact with the spinal cord dorsal horn for robust and enduring relief of
neuropathic pain. Spinal non-viral DM/pDNA-IL-10 co-therapy may offer a framework
for the development of non-viral gene therapeutic approaches for other diseases of the
central nervous system.

Chapter II previously published in Brain, Behavior, and Immunity, 2018, and included here
with publisher’s permission. Citation as follows:
Vanderwall AG, Noor S, Sun MS, Sanchez JE, Yang XO, Jantzie LL, Mellios N,
Milligan ED (2018) Effects of spinal non-viral interleukin-10 gene therapy
formulated with d-mannose in neuropathic interleukin-10 deficient mice:
Behavioral characterization, mRNA and protein analysis in pain relevant tissues.
Brain, Behavior, and Immunity 69:91-112.
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1. Introduction

Non-viral transgene delivery is one of the least efficient methods of gene transfer for
therapeutic applications (Glover et al., 2005), but due to its improved safety profile and
reduced cost burden, it has been pursued for the treatment of diseases of the central nervous
system (CNS) (Jayant et al., 2016). While non-opioid treatments for the control of chronic
neuropathic pain are limited, one promising avenue is the application of spinal non-viral
interleukin-10 (IL-10) gene therapy, an approach previously demonstrated to provide
enduring pain relief in a variety of animal models (Milligan et al., 2006b; Milligan et al.,
2006a; Ledeboer et al., 2007b; Sloane et al., 2009b; Soderquist et al., 2009; Soderquist et
al., 2010b; Milligan et al., 2012; Dengler et al., 2014; Grace et al., 2017).
IL-10 is a powerful anti-inflammatory cytokine that pleiotropically inhibits the
actions of many pro-inflammatory factors by mechanisms that include the destabilization
of mRNA transcripts for the pro-inflammatory cytokines tumor necrosis factor (TNF) and
interleukin-1β (IL-1β) (Moore et al., 2001; Lobo-Silva et al., 2016). Following peripheral
nerve injury, a brief compensatory upregulation in IL-10 protein production is followed by
decreased IL-10 expression below baseline levels in pain-relevant anatomic locations
(Jancalek et al., 2010; Jancalek et al., 2011; Khan et al., 2015). Studies show that spinal
non-viral IL-10 gene delivery in neuropathic animals produces pain relief through elevated
spinal IL-10 production with corresponding reduction of pro-inflammatory mediators of
pathological pain (Ledeboer et al., 2007b; Sloane et al., 2009a; Soderquist et al., 2010a;
Dengler et al., 2014). However, whether endogenous IL-10 is required for the long-lasting
pain relief observed following i.t. spinal non-viral IL-10 gene therapy remains unknown.
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Additionally, the anatomical regions in the pain pathway necessary for IL-10 transgene
expression that leads to pain relief are still unclear.
While a single large dose of naked plasmid DNA encoding the IL-10 transgene
(pDNA-IL-10; 100μg) or repeated doses (100μg followed by >25μg within 3-72hr) result
in transient or enduring pain relief, respectively (Milligan et al., 2006a; Ledeboer et al.,
2007b; Sloane et al., 2009b), the doses used render these approaches clinically unfeasible.
A novel gene delivery formulation, whereby a single co-injection of as little as 1μg of
naked pDNA-IL-10 with the immune cell adjuvant D-mannose (DM), a known mannose
receptor-specific (MR; CD206) ligand, greatly improves the efficacy of spinal non-viral
IL-10 gene therapy in rats, allowing for stable long lasting pain relief following a single i.t.
injection (Dengler et al., 2014). The MR is expressed by subpopulations of macrophages
and dendritic cells, as well as by microvascular endothelial cells (Taylor et al., 2005). In
the CNS, the MR is expressed by astrocytes, microglia, and some neurons (Burudi et al.,
1999; Burudi and Regnier-Vigouroux, 2001), and in the PNS by Schwann cells (Baetasda-Cruz et al., 2009). Increased MR expression is often associated with anti-inflammatory
macrophages (Gordon, 2003). Macrophages and other trafficking lymphocytes (i.e. T
cells), along with non-leukocytic resident cell types such as satellite glia, are present within
the DRG following sciatic nerve injury and likely contribute to neuropathy (Hu et al., 2007;
Hanani, 2015). Notably, MR expression is present on leukocytes (Martinez-Pomares,
2012), and MR-activation itself leads to anti-inflammatory signaling as well as transient
pain relief (Dengler et al., 2014). However, the transcriptional regulation of critical proand anti-inflammatory cytokines and chemokines in the pain pathway following DMmediated pDNA-IL-10 co-therapy is not known.
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In the current report, we applied spinal non-viral DM/pDNA-IL-10 co-therapy to
neuropathic wild type (WT) mice and IL-10 deficient (IL-10 KO) mice. Sciatic nerve
chronic constriction injury (CCI) was induced, an established mouse model of peripheral
neuropathy, resulting in reliable pathological sensitivity to light touch known as allodynia
(Bennett and Xie, 1988; Colleoni and Sacerdote, 2010; Jaggi et al., 2011b). Both central
and peripheral nervous tissues associated with the pain pathway were analyzed for IL-10
transgene mRNA, as well as transcriptional regulation of pro- vs. anti- inflammatory
cytokine and chemokine mRNA and protein. The findings reported here support that DM
acting as an immune adjuvant for improved spinal non-viral pDNA-IL-10 gene transfer
provides a new strategy for gene therapeutics to treat chronic pain, with the potential for
application to other chronic CNS diseases.

2. Materials and Methods

2.1 Animals

All experiments were performed using adult male mice (8-12 weeks of age). C57BL/6J
(WT; RRID: IMSR_JAX:000664) or B6.129P2-Il10tm1Cgn/J (IL-10 KO; RRID:
IMSR_JAX:002251) mice were purchased from Jackson Laboratories or bred in-house
from breeders also purchased from Jackson Laboratories (Bar Harbor, ME, USA). Mice
were maintained in specific-pathogen free conditions confirmed negative for detection of
Helicobacter spp. Prior to handling, all animals were acclimated to the mouse colony at
the University of New Mexico (UNM) Health Sciences Center Animal Facility for a
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minimum of 7 days. Animals were housed in groups of 3-5 at 23˚ + 2˚C in light controlled
rooms (12:12 light:dark; lights on at 6:00am) and fed standard rodent chow and water ad
libitum. All procedures were approved by the Institutional Care and Use Committee
(IACUC) of the UNM Health Sciences Center, conducted in accordance to the NIH
Guidelines for the Care and Use of Laboratory Animals, and closely adhered to
recommendations from the International Association for the Study of Pain for the use of
animals in research.

2.2 Animal Model of Peripheral Neuropathy

A modification of the sciatic nerve chronic constriction injury (CCI) model developed by
Bennett and Xie (Bennett and Xie, 1988) was used for application in the mouse (Costa et
al., 2008; Martucci et al., 2008; Liu et al., 2017) and briefly described here. Under
isoflurane anesthesia (induction at 3.0 followed by 2.0-2.5 vol.% in oxygen, 2.0L/min), the
lower back and dorsal left thigh were shaved and then cleaned with diluted Bacti-Stat AE
(EcoLab Health Care Division, Mississauga, Ontario, Canada), followed by water, and
lastly swabbed with 70% EtOH that was allowed to air dry before proceeding. Using
aseptic procedures, the left sciatic nerve was carefully isolated by gentle blunt dissection
through the fascia between the gluteus superficialis and biceps femoris muscles. The
exposed sciatic nerve was snuggly ligated with three segments of sterile 4-0 chromic gut
suture (Ethicon; Cat#:635H) proximal to the nerve’s trifurcation and without pinching of
the nerve. To allow enhanced malleability of the thick suture material, thereby reducing
the risk of unintended damage, segments of chromic gut material were briefly soaked in a
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bath of isotonic sterile saline (Hospira; Cat#:NDC 0404-4888-10) prior to application.
Additionally, great attention was paid to keeping the sciatic nerve moist via regular
irrigations with isotonic sterile saline. Sham surgery was identical to the CCI surgery but
without nerve ligation. The overlying muscle was sutured closed with one 3-0 sterile silk
suture (Ethicon; Cat#:K572H). The overlying skin was closed using two ReflexTM wound
clips (Kent Scientific Corp.; Cat#:INS750344). Full recovery from anesthesia was
observed within 10-15 minutes following surgery. At this time, mice that had undergone
CCI showed minor ventroflexion of the ipsilateral hindpaw while Sham mice revealed no
postural abnormalities. Animal body weights were monitored prior to and following
surgery. One day after surgery, animals were monitored for wound condition, hindpaw
health, and general activity level. If autotomy was present at any point during the
experiments, mice were immediately euthanized (less than 1.0% of all mice).

2.3 Behavioral Assessment of Mechanical Allodynia

Hindpaw threshold responses to innocuous light mechanical touch were assessed in mice
by adopting principles from the von Frey fiber test. The von Frey behavioral testing
approach used in this report blends components of previously described von Frey
behavioral assessment in rodents (Chaplan et al., 1994; Sommer and Schafers, 1998;
Milligan et al., 2000; Bonin et al., 2014). Following habituation to the testing environment
(30-45 minutes per day, 4 days), baseline (BL) responses were assessed as follows. A series
of calibrated monofilaments were applied randomly to the plantar surface of left and right
hindpaws for a maximum of 3.0s per application. A >30s interval was required between
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applications to the same mouse. The log stiffness of the nine monofilaments used is defined
as log10 (grams x 10,000) with the following range of filaments having log stiffness values
(the value in grams is given in parentheses) of 2.36 (0.022g), 2.44 (0.028g), 2.83 (0.068g),
3.22 (0.166g), 3.61 (0.407g), 3.84 (0.692g), 4.08 (1.202g), 4.17 (1.479g), and 4.31
(2.042g). The first monofilament applied was always 3.22 (0.166g). If a positive response
(i.e. lifting, licking, or shaking of the paw) was observed, then the next weaker hair was
applied. In contrast, a negative response indicated that the next stronger monofilament be
applied to that hindpaw in the subsequent round. This testing sequence progressed for a
total of six applications per hindpaw. Testing was stopped prematurely if a positive
response was observed following application of the weakest filament (2.36). This testing
paradigm requires far fewer hair applications (a maximum of 6 times) to a given paw as
compared to previous methods, thereby curbing artifacts caused by overstimulation. The
total numbers of positive responses and negative responses at each of the tested
monofilaments were used to calculate the absolute (50%) paw withdrawal threshold via the
computer program PsychoFit (http://psych.colorado.edu/~lharvey; RRID: SCR_015381),
as previously described (Milligan et al., 2000; Dengler et al., 2013). This software fits a
Gaussian integral psychometric function to the observed withdrawal rates for each of the
tested von Frey hairs using a maximum-likelihood fitting method (Milligan et al., 2000).
The computed log stiffness threshold values were then used for subsequent statistical
analyses, but graphical representations present data as stimulus intensity in grams. A
considerable benefit of this new method of assessment and analysis is that all hairs tested,
(i.e. the entire pattern of responses) collectively contribute to calculating the stimulus
threshold, whereas prior approaches in mouse heavily depend on the observed response to
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the final hair applied (Sommer and Schafers, 1998; Bonin et al., 2014). All behavioral
hindpaw-response assessments were performed within the first four hours of the light cycle
to minimize physiological influences regulated by circadian rhythms.
Behavioral assessment was conducted at BL prior to and after surgery. Timepoints
for behavioral assessment on Days post-surgery were carefully chosen to avoid disruption
of behavioral responses that may result from frequent testing. For the long-duration
timecourse study, behavioral assessment was conducted at BL, Days 3 and 5 post-surgery,
and Days post-injection 1, 3, 5, 7, 10, 14, 17, 22, 26, 30, 35, and 40. In the short-duration
studies that terminated prior to tissue collection for mRNA, protein, and
immunohistochemical analysis, behavioral assessment occurred at BL, Days 3 and 5 postsurgery, and Days post-injection 1, 2, 3, 4, 5, 6, 7, 10, and 12. For immunohistochemical
analysis, an additional control group of IL-10 KO CCI mice (N = 4) received no injection,
and was behaviorally verified at BL, and Days post-surgery 3, 5, 7, 10, and 17. Pilot studies
(data not shown) were conducted using this approach to validate hindpaw response
thresholds demonstrated in previous reports (Sommer and Schafers, 1998; Shimoyama et
al., 2002).

2.4 Preparation of Plasmid DNA

The plasmid vector pDNA-IL-10 (also called pTR2-CB-mIL10F129S) used in these studies
(Fig. 1C) is the mouse IL-10 equivalent of a rat IL-10 plasmid that was fully described
previously and is derived from an adeno-associated virus-2 (AAV-2) expression cassette
(Milligan et al., 2005b; Milligan et al., 2006b). It consists of a 5.9 kilobase circular plasmid
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DNA (pDNA) containing a transcriptional cassette consisting of a hybridized
cytomegalovirus enhancer/chicken beta-actin promoter (CMV enh/CB pro) driving
expression of the mouse Il10 gene containing a point mutation (mIL-10F129S), and a simian
virus 40 (SV40) polyadenylation signal (SV40 poly(A)). The transcription cassette is
flanked by 149 bp inverted terminal repeat (ITR) sequences. The plasmid backbone
contains an ampicillin resistance (Ampr) gene, as well as components unique to the original
AAV-2 expression cassette such as an intervening sequence (IVS; intron). The control
plasmid (pDNA-Ctrl) is an analogous plasmid cassette that instead drives expression of
enhanced jellyfish green fluorescent protein (eGFP) (Milligan et al., 2006b). Plasmids were
amplified in SURE2 Supercompetent Cells (Agilent Technologies; Cat#:200152) because
the ITR elements are often deleted in conventional E. coli strains (Milligan et al., 2006b)
resulting in reduced transgene expression. Plasmid DNA was isolated using an EndoFree
Plasmid Giga Kit (Qiagen; Cat#:12391) according to manufacturer’s instructions. Purified
endotoxin-free plasmids were resuspended in sterile Dulbecco’s PBS (1x) (Gibco;
Cat#:14190-144) with 3% sucrose, aliquoted, and stored at -20˚C.

2.5 Intrathecal Injections

Intrathecal (i.t.) injections were acutely administered under isoflurane anesthesia following
behavioral assessment on Day 5 post-surgery and conducted as previously described
(Hylden and Wilcox, 1980) with modification as indicated here. Injector units were
constructed as follows. First, a needle adaptor was created by inserting an intact sterile 27G
x 0.5in needle (PrecisionGlide, Becton Dickinson & Co.; Cat#:305109) into one end of a
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30cm long segment of PE20 polyethylene tubing (Becton Dickinson & Co; Cat#:427406).
At the opposite end, a second 27G needle with the needle hub removed was inserted such
that the blunt end was inserted inside the tubing while leaving the beveled sharpened end
available for lumbar puncture. These needle adaptors were placed in a sterile dry place
until the time of use. At the time of injection, sterile isotonic saline (Hospira; Cat#: NDC
0404-4888-10) was used to fill the line as well as to check for leakage. Sterile isotonic
saline was also used to fill a sterilized 50μL gastight calibrated syringe (Hamilton Co.;
Cat#:CAL80901) which was then connected to the needle adaptor via the intact needle hub.
Excess saline was expelled from the syringe leaving saline only within the tubing. The line
was then loaded with the following four components in this order: (1) a 1μL air bubble is
drawn into the tubing followed by (2) 3μg of plasmid DNA (in 7.5μL), (3) a second 1μL
air bubble, and finally (4) either 25μg D-mannose (Sigma-Aldrich; Cat#:M6020) dissolved
in 3μL of sterile isotonic saline or sterile isotonic sterile saline alone.
Under isoflurane anesthesia (induction at 2.5% followed by 1.5% volume in oxygen
at 2.0 liters per minute), the mid- to lower-back was shaven and swabbed with 70% ethanol.
The beveled sharpened end of the 27G needle of the injector unit was inserted
percutaneously between lumbar vertebrae 5 and 6 (L5-L6). A tail flick was considered
indicative of a successful i.t. puncture. Next, the i.t. injection bolus was slowly
administered over the course of 30s. The total time required for each injection was ~3
minutes, excluding anesthesia induction. Following injection, all mice resumed motor
activity consistent with that observed prior to i.t. injection.
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2.6 Tissue Collection and Total RNA Isolation

Following behavioral assessment on Day 12 post-injection (Day 17 post-surgery), mice
were deeply anesthetized (>10min, 5% volume in oxygen at 2 liters per minute) followed
by transcardial perfusion with ice-cold 0.1M phosphate buffered saline (pH = 7.40). The
body was then placed on a frozen gel refrigerant pack (Glacier Ice, Pelton Shepherd
Industries) previously maintained on dry ice. Rapid laminectomy followed by tissues
dissection in the following order: lumbar spinal cord (L3-L6), contralateral lumbar (L3L5) dorsal root ganglia (DRG), ipsilateral L3-5 DRG, cauda equina, and lastly ipsilateral
sciatic nerve (~1cm). Samples were placed in DNase/RNase-free 1.5mL centrifuge tubes
(VWR International; Cat#:47747-362), quickly frozen on dry ice, and then stored at -80˚C
for future analysis.
Total RNA was extracted from ipsilateral DRG, contralateral DRG, lumbar spinal
cord, and cauda equina using the miRNeasy Mini Kit (Qiagen; Cat#:217004) per
manufacturer’s instructions. Homogenizations were performed using a motorized VWR
Disposable Pellet Mixer and cordless motor pestle system (VWR International;
Cat#:47747-3). For ipsilateral sciatic nerves, special care was taken to process samples so
that they could be analyzed for both RNA and protein. To accomplish this, frozen tissues
were placed in 100μL chilled 1x phosphate buffered saline (10x PBS diluted to 1x with
DNase/RNase free water; Sigma-Aldrich; Cat#: P7059) and quickly chopped with scissors,
and then briefly homogenized with the motorized pestle system. Within 1.5min from initial
chopping, 40% of the PBS-suspended homogenate was transferred to chilled Qiazol Lysis
Reagent (Qiagen) and further homogenized. Total RNA was extracted using an miRNeasy
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Micro Kit (Qiagen; Cat#:217084) per manufacturer’s instructions but with single
additional RPE and 80% EtOH wash steps in order to remove excess salts introduced by
PBS. The remaining 60% of the PBS-suspended homogenate was pelleted at full speed
(20,627 x g) for 1.5 minutes, the PBS aspirated, 35μL of protease inhibitor solution
(MesoScale Discovery) added, frozen on dry ice, and finally stored at -80˚C for future
protein analysis (see section 2.7).
RNA concentration and quality was assayed by NanoDrop (Thermo Scientific).
RNA samples were then diluted to a standardized RNA concentration for the following
tissues: ipsilateral DRG (30ng/μL), contralateral DRG (30ng/μL), cauda equina
(100ng/μL), and ipsilateral sciatic nerve (50ng/μL), and lumbar spinal cord (100ng/μL).
Total RNA reversed transcribed to cDNA per sample was 1,400ng for lumbar spinal cord,
1,000ng for cauda equina, and 525ng for ipsilateral sciatic nerve. For DRG, which had low
total RNA yields due to the typically small DRG tissue volumes, 390ng of total RNA were
reverse transcribed for contralateral DRG, while 165ng and 390ng were used in two
separate rounds of cDNA for ipsilateral DRG. Reverse transcription was performed for
DRG, lumbar spinal cord, and sciatic nerve using a SuperScript™ IV VILO™ cDNA
Synthesis Kit (Invitrogen; Cat#:11754250) per manufacturer’s instructions but required
further optimization by extending the 42˚C-incubation step to 2hr in order to improve
cDNA yields from small samples such as the DRG. Reverse transcription was performed
for cauda equina using a SuperScript IV First-Strand Synthesis System (Invitrogen;
Cat#:18091050) per manufacturer’s instructions.
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2.7 mRNA Analysis by Quantitative Real-Time PCR

Levels of mRNA expression were measured and analyzed as previously described (Mellios
et al., 2014). The following dilution factors (indicated in parentheses) were applied to
cDNA samples for assessment of transcripts of interest in given tissues: ipsilateral DRG
(undiluted), contralateral DRG (undiluted), lumbar spinal cord (1:4), cauda equina (1:6),
ipsilateral sciatic nerve (1:2.5). The following cDNA dilutions were used for assessment
of the normalizer, mouse 18S rRNA: ipsilateral and contralateral DRG (1:40), lumbar
spinal cord and cauda equina (1:200), ipsilateral sciatic nerve (1:100). Levels of mRNAs,
as well as “Normalizer” 18S rRNA (Rn18s, Taqman Assay ID#: Mm03928990_g1), were
assayed in triplicate via quantitative real-time PCR (qRT-PCR) with Taqman Gene
Expression Assays (ThermoFisher Scientific). All selected mouse gene expression assays
were identified by the manufacturer to be “best coverage” assays, unless otherwise noted,
and to exclude detection of genomic DNA. mRNA levels were analyzed with the formula
C = 2^CTNormalizer/2^CTTarget, as previously described (Livak and Schmittgen, 2001;
Schmittgen and Livak, 2008; Mellios et al., 2014).
The IL-10 Taqman Gene Expression Assay was selected to target sequences that
span exons 1 and 2 (Il10; Taqman Assay ID#: Mm00439614_m1) in order to ensure that
IL-10 transcripts detected in IL-10 KO mice truly represent exogenous transgene, versus
the possible endogenous null mutant transcript. IL-10 KO mice possess a null copy of IL10 in which a 500bp fragment of exon 1 (codons 5-55) has been replaced by a 24bp linker
sequence, a neo expression cassette, and a termination codon (Kuhn et al., 1993).
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Therefore, any potential endogenous null IL-10 transcripts are predicted to be
unrecognizable by the IL-10 Taqman Gene Expression Assay.
Because mannose receptor activation by DM is sufficient to improve non-viral IL10 gene therapy (Dengler et al., 2014), mannose receptor gene expression was assayed
(Mrc1; Taqman Assay ID#: Mm01329362_m1). Additionally, IL-10 transgene expression
is known to limit the actions of many pro-inflammatory mediators (Moore et al., 2001;
Milligan et al., 2012). Consequently, transcripts for the following pain-relevant proinflammatory cytokines were assessed: interleukin-1β (IL-1β, Il1b, Taqman Assay ID#:
Mm00434228_m1) and tumor necrosis factor (TNF, Tnf, Taqman Assay ID#:
Mm00443258_m1).
To address whether IL-10 deficient knockout mice possess compensatory changes
in other anti-inflammatory pathways, the anti-inflammatory cytokine transforming growth
factor β1 (TGF-β1, Tgfb1, Taqman Assay ID#: Mm01178820_m1) was evaluated. To
investigate basal and post-CCI expression levels of the IL-10 receptor in IL-10 KO mice,
transcript levels for IL-10R alpha (IL-10Rα, a.k.a. IL-10 R1; Il10ra, Taqman Assay ID#:
Mm00434151_m1) were examined.
To assess whether actions of transgenic IL-10 may modulate microglia in the
lumbar spinal cord, we tested the newly identified microglial specific marker (Bennett et
al., 2016) transmembrane protein 119 (TMEM119, Tmem119, Taqman Assay ID#:
Mm00525305_m1). The “best coverage” option was not available for the TMEM119
Taqman gene expression assay.

35

2.8 Multiplex Determination of Cytokine and Chemokine Expression

Ipsilateral sciatic nerve homogenates (see section 2.6) previously stored in a buffer with
protease inhibitors (MesoScale Discovery) were kept on ice, further homogenized using a
motorized homogenization system (VWR International; Cat#:47747-3), and subsequently
sonicated. Tissue samples were centrifuged at 4,200 x g at 4°C for 10min to pellet cellular
debris. Cellular lysates were collected from the supernatant and protein concentrations
were determined by QuickstartTM Bradford Protein Assay (BioRad; Cat#:500-0201).
Sciatic nerve protein expression levels were then determined using a V-PLEXTM
immunoassay (MesoScale Discovery; detailed below) panel for quantification of the
following cytokines and chemokines: TNF, IL-1β, IFN-γ, IL-6, CXCL1 (a.k.a. KC/GRO),
and IL-12p70. All V-PLEXTM immunoassays were conducted according to manufacturer’s
instructions.
The V-PLEXTM immunoassay is well validated for quantifying protein from small
CNS tissue samples (Maxwell et al., 2015; Robinson et al., 2016; Noor et al., 2017). The
methods

are

briefly

described

here.

V-PLEXTM

immunoassays

apply

electrochemiluminescence technology to precisely measure protein concentrations of
multiple protein targets simultaneously with high sensitivity and reproducibility. Tissue
lysates from experimental tissue samples, or calibrator (provided by kit), were loaded onto
a ‘multi-spot’ plate. Each plate-well is pre-coated with antigen-specific ‘capture’
antibodies on independent spatially well-defined ‘spots’ that are in turn connected to a
working electrode surface. Following incubation with protein lysates, immobilized
proteins are next recognized by SULFO-TAGTM-conjugated antigen-specific ‘detection’
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antibodies. A Quickplex SQ120 Imager (MesoScale Discovery) was used to detect signal
in each well in the plate via application of an electrical current to the plate electrodes and
subsequent measurement of light intensity emitted by SULFO-TAG labeling. Where
possible, 35µg total protein was loaded per well in duplicate, but due to limitations in tissue
availability singlets were also accepted. For some samples, especially those from Sham
mice, less than 35µg total protein was available, therefore all assay outputs were
normalized by dividing the measured concentration for a specific analyte (e.g. 0.12pg TNF)
for a given well by the total protein loaded to that same well, yielding units of (pg
Analyte)/(μg

Protein).

In

the

two

conditions,

CCI+DM/pDNA-IL-10

and

CCI+DM/pDNA-Ctrl, pairs of “low-protein” samples were combined once per condition
to make a single N with a protein load of 35μg, yielding N = 6 and N = 8, respectively. The
V-PLEXTM immunoassay system has high content validity and inter-assay variations less
than 12% in our laboratory.

2.9 Tissue Preparation for Immunohistochemistry

Lumbar spinal cord tissue was collected from Naïve IL-10 KO and WT mice (N = 3
mice/group), and from CCI-treated IL-10 KO mice (N = 3-4 mice/group) following
behavioral assessment on Day 12 after intrathecal injection (Day 17 post-surgery). Samples
were processed similarly as previously described (Dengler et al., 2014). Briefly, a lethal
dose of pentobarbital (Fatal-Plus Solution, Vortech Pharmaceuticals, LTD.) was
administered by intraperitoneal injection. Mice then underwent transcardial perfusion with
0.1M phosphate buffered solution (PBS; pH = 7.40) for 4min at 5mL/min, followed by
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room temperature 4% paraformaldehyde (PFA; pH = 7.40) (Sigma-Aldrich; Cat#:P6148)
for 4min at 5mL/min, and finally ice cold 4% PFA for 4min at 5mL/min. Entire intact
spinal vertebral columns (cervical 2 to coccygeal vertebrae) were collected and post-fixed
24hr in 4% PFA at 4˚C. Columns were then washed 24hr in 0.1M PBS at 4˚C and
decalcified 4 weeks in 1.5L water containing 10% ethylenediaminetetraacetic acid (EDTA;
Cat#:M101; VWR International) with 0.01% sodium azide (Sigma-Aldrich; Cat#:S2002)
and 0.5% PFA with gentle consistent agitation atop a stir plate at room temperature. The
method was used to allow examination for intact meninges and visualization of the
subarachnoid matrix. The decalcification solution was changed every 5-7 days. Lumbar 36 (L3-L6) spinal vertebral column segments were paraffin processed according to
previously described standard methods (Wilkerson et al., 2012b) and later sliced on a
microtome, with 7μm tissue sections mounted on VWR VistaVision™ HistoBond®
Adhesive Slides (VWR International; Cat#:16004) and stored in slide boxes at room
temperature.

2.10 Immunohistochemistry

To investigate potential changes in lumbar dorsal horn spinal astrocytic activation
following intrathecal non-viral IL-10 gene therapy, we analyzed the expression of the
astrocyte marker glial fibrillary acidic protein (GFAP) in L4-L5 spinal segments, as
previously described (Wilkerson et al., 2012b; Noor et al., 2017). Briefly, randomly
selected paraffin-processed L4-L5 spinal cord tissue sections underwent deparaffinization
in Hemo-De (Scientific Safety Solvents; Cat#: HD-150A) followed by rehydration via
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descending alcohols to 0.1M PBS (pH = 7.40). Antigen retrieval was applied by placing
tissue slices in Nuclear Decloaker (Tris-based buffer (pH = 9.50); BioCare Medical; Cat#:
CB911M) and heating the samples in a conventional rice cooker (15min, ~94˚C). After
sufficient cooling, blocking was performed using 5% normal donkey serum (Jackson
ImmunoResearch Labs; Cat#: 017-000-121, RRID: AB_2337258) (2hr, room
temperature), followed by overnight primary antibody incubation at 4˚C with 1:1,000
chicken anti-mouse GFAP (Abcam, Cat#: ab4674, RRID: AB_304558). The next day
tissues were washed 4 x 3min in 0.1M PBS (pH = 7.40) followed by a 2hr incubation at
room temperature with 1:200 donkey anti-chicken Alexafluor488-conjugated secondary
antibody (Jackson ImmunoResearch Labs; Cat#: 703-545-155, RRID: AB_2340375).
Slices were washed 4 x 3min in 0.1M PBS and then stained with 4’,6-Diamidino-2phenylindole dihydrochloride (DAPI) (Sigma-Aldrich; Cat#:D9542) before coverslipping.
All incubation steps were performed using a humidity chamber.

2.11 Microscope Spectral Imaging for Immunofluorescent Quantification

Image acquisition for spectral analysis was performed using the Nuance Multispectral
Imaging System (PerkinElmer Inc.; RRID:SCR_015382) (Mansfield, 2014), as described
previously (Wilkerson et al., 2012b; Dengler et al., 2014; Noor et al., 2017). Briefly,
lumbar spinal cord dorsal horn images were obtained using a 20X objective with a Nikon
TE-200 U inverted fluorescence microscope. Flat-field correction was applied in order to
remove artifacts, including uneven field illumination, to produce a uniform illumination
during image acquisition. Images of single-labeled control slides (one each for AF488 and
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DAPI) and a label-free (autofluorescence) slide were used to create a ‘spectral library’.
Pure signals for each fluorophore were then computed by separating a known spectral
profile (autofluorescence) from a ‘mixed’ spectrum profile (single labeled +
autofluorescence). This allowed for the un-mixing of multi-labeled slides to obtain
composite images containing only the labels of interest. Composite images were then used
for further analysis using Slidebook 6 software (see Section 2.11).

2.12 Slidebook software image analysis

Composite images were analyzed using Slidebook 6 software (Intelligent Imaging
Innovations; RRID: SCR_014300). To eliminate signals originating from artifact, an
experimenter created a ‘threshold mask’ designed to limit the lowest-level fluorescent
emissions in such a way that the final image file replicated that which was visible when the
specimen was viewed through the microscope eyepiece, as described previously (Dengler
et al., 2014). Additionally, an individualized ‘area mask’ was created for each image such
that only the spinal cord dorsal horn gray matter was included in analyses, thereby
excluding surrounding white matter and peri-spinal blank space. The location of nuclei, as
indicated by the DAPI channel image, for each slice was used to more accurately
approximate the true borders of the dorsal horn when making the ‘area mask’. These masks
were further refined to create a ‘final analysis mask’ for each slice that included only signal
above the predetermined lower threshold (defined by the ‘threshold mask’) within the
outlined region. ‘Fluorescence Intensity’ was calculated using the equation Fluorescence
Intensity = (Sum Intensity)/(Area), where ‘Sum Intensity’ (the total signal measured by the

40

‘final analysis mask,’) is divided by ‘Area’ (the total area of the dorsal horn as indicated
by the original ‘area mask,’ in microns squared [μm2]). The average Fluorescence Intensity
of four slices (2 slice pairs taken ~140μm apart, mounted on a single slide) from one slide
per animal was calculated to determine the value for each respective animal. Data from
individual animals were analyzed as indicated in section 2.12, below.

2.13 Experimental Design and Statistical Analysis

To determine the efficacy of the DM/pDNA-IL-10 formulation in mice and to test whether
endogenous IL-10 is required for long-lasting pain reversal, a complete timecourse of nonviral IL-10 efficacy for controlling allodynia was assessed in IL-10 KO mice compared to
WT mice (N = 6-8 mice/group). In this long-duration timecourse, animals were followed
behaviorally until Day 45 post-surgery (Day 40 post-injection), a timepoint by which pilot
experiments (data not shown) indicated both IL-10 KO and WT mice reveal complete
spontaneous reversal from CCI-induced allodynia. No tissues were collected.
All subsequent behavioral studies were performed using only IL-10 KO mice in
order to (1) replicate initial observations, (2) to better understand the biodistribution of IL10 transgene mRNA, (3) to examine the underlying mechanisms of long-lasting pain
reversal independent of endogenous IL-10, and (4) to further explore the role of D-mannose
in improved efficacy of non-viral transgene uptake and expression.
Behavioral results from the long-duration characterization were used to design a
truncated timecourse such that tissues could be collected at a time when therapeutically
treated neuropathic IL-10 KO mice had achieved stable reversal from allodynia (Day 12
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post-injection; Day 17 post-surgery). In the first replication study (behavioral N = 6-12
mice/group), the following conditions were manipulated: surgery (Sham vs. CCI), plasmid
DNA (pDNA-IL-10 vs. pDNA-Control), and adjuvant (DM vs. Saline). Collected tissues
were analyzed by qRT-PCR (N = 5-8 mice/group). For ipsilateral sciatic nerve, samples
from each animal were split for use in both qRT-PCR (Section 2.6) mRNA analysis and
V-PLEXTM Immunoassay protein expression analysis (Section 2.7), and assessed typical
injury-associated pro-inflammatory changes following peripheral nerve damage (Okamoto
et al., 2001; Kleinschnitz et al., 2006; Uceyler et al., 2007). All corresponding tissues were
collected from naïve WT (N = 3) and IL-10 KO (N = 2) mice to serve as IL-10 expression
positive and negative controls, respectively, and to identify potential baseline
transcriptional differences that may result from developmental IL-10 deficiency.
In a third study designed to replicate behavioral non-viral IL-10 efficacy for
controlling allodynia, tissues were collected to assess changes in astrocytic activation
markers at the level of the lumbar spinal cord. IL-10 KO mice given CCI-surgery were
behaviorally verified and followed through Day 12 post-injection (N = 4 mice/group). On
Day 12 post-injection (Day 17-post-surgery), the entire spinal cord enclosed within the
vertebral column was collected from each mouse for subsequent immunohistochemical
analysis. Decalcification and paraffin-embedding procedures were followed as described
above. Prior work examining immunoreactive markers for spinal cord astrocytes following
decalcification and paraffin-embedding procedures demonstrated through power analysis
(Noor et al., 2017) and previously documented reports using similar methods (Wilkerson
et al., 2012a; Wilkerson et al., 2012b; Noor et al., 2017) that N = 3 spinal cords per
experimental condition was sufficient to yield reliable group differences. Therefore, to
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minimize unnecessary duplication, animal numbers were restricted to N = 3-4 per
experimental condition.
All baseline behavioral data of hindpaw threshold responses were analyzed by Oneway analysis of variance (ANOVA) using GraphPad PRISM version 7.02 (GraphPad
Software Inc.; RRID:SCR_002798) to ensure no group differences were present at
baseline, as well as to confirm complete spontaneous reversal from allodynia on Day 40
post-injection. Two-way repeated measures (RM) ANOVA using SPSS (IBM; RRID:
SCR_002865) was performed for all other behavioral timepoint analyses. The assumption
of sphericity for Two-way RM ANOVAs was assessed using Mauchly’s Test of Spericity
(α = 0.05). If the assumption of sphericity was violated (P < 0.05), to protect against Type
I errors, the reported degrees of freedom and p-values were adjusted using the conservative
Greenhouse-Geisser correction. Data from microscope-acquired images reflecting
immunoreactivity, relative mRNA transcript levels from qRT-PCR, and protein VPLEXTM immunoassays were analyzed using One-way ANOVA with GraphPad PRISM.
To control the type I error rate during all multiple comparisons, Fisher’s LSD test (reported
with adjusted P values) was applied for post hoc examination of possible group differences
selected a priori. The threshold for statistical significance for all sets of multiple
comparisons was set a priori to α = 0.05. All data are presented as the Mean + Standard
Error of the Mean (SEM). For mRNA and protein analyses, within-group outliers where
tested for by Grubbs’ Test using the GraphPad QuickCalc Outlier Calculator
(https://graphpad.com/quickcalcs/grubbs1/) with α = 0.05.
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3. Results

3.1 Intrathecal non-viral IL-10 gene therapy provides stable long-lasting relief of allodynia
in mice, and is efficacious in the absence of endogenous IL-10.

Previous investigations (Milligan et al., 2006b; Milligan et al., 2006a; Ledeboer et al.,
2007b; Sloane et al., 2009b; Soderquist et al., 2010b; Dengler et al., 2014) of non-viral IL10 gene therapy were conducted in rodent models that were capable of expressing
endogenous IL-10. Consequently, these studies were not able to unambiguously
demonstrate whether enduring non-viral therapeutic efficacy relies on the actions of
endogenous IL-10. To address this possibility, long-duration efficacy of i.t. non-viral IL10 gene therapy was examined in IL-10 deficient mice, that is, IL-10 KO mice. In addition,
D-mannose has previously been shown to improve the therapeutic efficacy of i.t. non-viral
IL-10 gene delivery in rats for the treatment of allodynia (Dengler et al., 2014). However,
the possibility that DM induces endogenous IL-10, acting as an immune adjuvant to
enhance phagocytosis of pDNA-IL-10, suggests that endogenous IL-10 may be necessary
for enduring pDNA-IL-10 efficacy. Therefore, the therapeutic efficacy DM/pDNA-IL-10
gene therapy in IL-10 KO vs. WT mice was examined in the current report.
Light mechanical touch assessed at BL revealed similar levels of hindpaw sensory
threshold responses between all groups (Fig. 1A-D), which demonstrates that basal IL-10
is not required to maintain normal healthy sensory responses. Following surgery, CCItreated WT and IL-10 KO mice develop clear bilateral allodynia by Day 3-5 post-surgery.
All groups received an i.t. injection following behavioral assessment on Day 5 post-surgery
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(Fig 1A-B). By Day 2 post-injection, both IL-10 KO and WT CCI-treated mice given
DM/pDNA-IL-10 reveal similar bilateral reversal of allodynia compared to CCI-treated
mice given Saline/pDNA-IL-10, suggesting that possible additional actions of endogenous
IL-10 in WT mice are not outwardly observable following gene therapy. Both WT and IL10 KO CCI control groups given Saline/pDNA-Ctrl demonstrate spontaneous reversal of
allodynia, with hindpaw responses similar to those observed in Sham-treated mice, on Day
35 post-injection (Day 40 post-surgery). However, both WT and IL-10 KO mice treated
with CCI+DM/pDNA-IL-10 exhibit long-lasting and stable pain relief, never returning to
allodynia.
Lastly, it is additionally important to note that the non-silent point mutation present
in the mouse IL-10 gene (IL-10F129S) used in the current study and previously characterized
in rat (Milligan et al., 2006b; Milligan et al., 2006a; Ledeboer et al., 2007b; Sloane et al.,
2009b; Soderquist et al., 2010b; Dengler et al., 2014) supports predicted IL-10 proteinreceptor interaction. That is, IL-10 protein homodimerizes prior to binding to and
activating the IL-10 receptor (Moore et al., 2001). The current report demonstrates that the
IL-10F129S product does not require interaction with endogenous wild type IL-10 protein to
achieve stable and enduring IL-10 transgene efficacy. This is the first demonstration that
both non-viral IL-10 gene therapy and DM, the non-viral gene therapy adjuvant, are
efficacious in mice and do not require endogenous IL-10.
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3.2 The combination of DM/pDNA-IL-10 is necessary for long-lasting relief of allodynia

To better understand the effective relationship between pDNA-IL-10 and DM to induce
long-lasting pain relief, i.t. DM/pDNA-IL-10 co-therapy was compared to various control
conditions in neuropathic IL-10 KO mice (Fig. 2A-B). Threshold responses at BL were
similar between all groups for both the ipsilateral and contralateral hindpaws, and
following surgery, Sham-treated mice maintain normal levels of light touch sensitivity,
replicating that observed in Fig. 1. CCI-treated mice exhibit bilateral allodynia by Day 3
post-surgery, and CCI+Saline/pDNA-Ctrl-treated mice maintain stable allodynia through
Day 12 post-injection. Surprisingly, CCI mice given DM with control plasmid DNA
(lacking IL-10 transgene) exhibited delayed onset bilateral reversal from allodynia
beginning on Day 3 post-injection. However, reversal of allodynia was transient, with
increased hindpaw light touch sensitivity occurring by Day 6 post-injection and full
allodynia by Day 12 post-injection. The data presented here support that DM-mediated
relief of pathological light touch sensitivity is independent of IL-10. Overall, these data
reveal that it is the combination of pDNA-IL-10 plus DM that is required for long-lasting
relief of allodynia.

3.3 I.t. non-viral IL-10 transgene mRNA is expressed in lumbar dorsal root ganglia

To investigate the IL-10 expression patterns that underlie i.t. non-viral IL-10 transgenemediated pain relief in the absence of endogenous IL-10, nervous tissues were collected
from behaviorally verified IL-10 KO mice (See section 3.2) on Day 12 post-injection (Day
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17 post-surgery). This “midway” timepoint was chosen for tissue analysis because
CCI+DM/pDNA-IL-10 mice are stably reversed from allodynia compared to all other CCItreated groups (Fig. 2A-B). IL-10 transgene expression was examined in relevant “pain
pathway” tissues, including ipsilateral and contralateral lumbar (L3-5) DRG, cauda equina,
lumbar spinal cord, and ipsilateral sciatic nerve. Of note, the i.t. injections were performed
such that pDNA was deposited into the spinal subarachnoid area at the level of the cauda
equina (acute transcutaneous puncture between vertebral L5 and L6 interspinous
processes). In IL-10 KO Naïve (no surgery and no injection) mice, IL-10 mRNA was
undetectable in ipsilateral and contralateral DRG, but was present in samples from WT
Naïve mice serving as positive controls (Fig2C-D). In ipsilateral DRG (Fig. 2C), IL-10
transgene mRNA was significantly elevated in pain relieved IL-10 KO+CCI+DM/pDNAIL-10 mice compared to chronically allodynic CCI+DM/pDNA-Ctrl controls and uninjured Sham controls. In contralateral DRG (Fig. 2D), IL-10 transgene expression was not
significantly different across treatment groups. However, an a priori comparison revealed
that contralateral DRG from CCI-treated mice given DM co-treated with the IL-10
transgene contained significantly greater IL-10 mRNA levels than DRG from CCI-treated
mice given DM with the control plasmid (P < 0.05) or Sham-treated mice with DM and
the control plasmid (P < 0.05). Similar findings in the cauda equina (Fig. 2E) revealed IL10 transgene was significantly increased in pain-relieved CCI-treated mice given DM plus
the IL-10 transgene compared to either CCI-treated mice given DM plus the control
plasmid or Sham-treated mice given DM plus the control plasmid. While IL-10 mRNA
levels were not significantly different between WT Naïve and IL-10 KO Naïve cauda
equina samples, a strong trend for positive expression in WT animals was observed (P =
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0.06). Surprisingly, IL-10 transgene mRNA was not detectable in lumbar spinal cord (Fig.
2F) of any experimental condition, though it was readily detectable from spinal cords of
WT Naïve positive controls. As expected, IL-10 mRNA levels were not detected in
ipsilateral sciatic nerve in any treatment condition, nor were IL-10 mRNA levels detected
in the uninjured WT Naïve tissue (data not shown; WT Naïve vs. IL-10 KO Naïve, P =
0.226). Similarly, though IL-10 protein was detected in ipsilateral sciatic nerve tissue of
WT Naïves (Fig. 2G), it was not observed in IL-10 KO sciatic nerve tissues from any
treatment condition. These data demonstrate that long-duration relief of allodynia is likely
mediated by long-term survival of the IL-10 plasmid and corresponding protein expression
in the DRG. Additionally, non-viral gene therapeutic modulation of the lumbar DRG is
sufficient to relieve bilateral light touch sensitivity following unilateral peripheral nerve
damage.

3.4 IL-10 transgene mediates pain relief through anti-inflammatory changes in ipsilateral
lumbar DRG.

To further characterize the cytokine environment in the presence of elevated IL-10
transgene mRNA levels, the mRNA expression levels of pro- and anti-inflammatory
cytokines in the ipsilateral and contralateral lumbar (L3-L5) DRG were assessed in tissues
collected on Day 12 post-injection (See section 3.3). Interestingly, significantly greater
mRNA levels for the pro-inflammatory TNF (Tnf) were observed in ipsilateral DRG of IL10 KO Naïves compared to WT Naïves (Fig. 3A), but not in contralateral DRG (Fig. 3B).
In addition, while TNF mRNA transcript levels were elevated in ipsilateral DRG following
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CCI, significantly less TNF mRNA expression was observed in pain-relieved mice treated
with DM plus the IL-10 transgene compared to allodynic CCI-treated mice given Saline
plus the IL-10 transgene (Fig. 3A). No differences in TNF mRNA levels were detected in
un-injured contralateral DRG (Fig. 3B). Expression of mRNA for the pro-inflammatory
cytokine IL-1β (Il1b) in ipsilateral DRG was similar across all conditions and was not
different between WT Naïve and KO Naïve mice (Fig. 3E).
Given existing evidence that the anti-inflammatory cytokine TGF-β1 relieves
neuropathic pain in animal models and is increased by IL-10, the current study examined
potential changes in DRG TGF-β1 (Tgfb1) mRNA levels as a consequence of DM/pDNAIL-10 gene therapy. TGF-β1 mRNA expression is significantly elevated in ipsilateral DRG
(Fig. 3C) of only pain-relieved CCI+DM/pDNA-IL-10 mice. Additionally, allodynic
CCI+Saline/pDNA-IL-10 mice have significantly less TGF-β1 mRNA expression
compared to both non-injured Sham controls and CCI+DM/pDNA-IL-10 mice. In contrast,
no significant changes in TGF-β1 mRNA levels are observed in the contralateral DRG
(Fig. 3D).
Several striking aspects of the behavioral response to the DM plus pDNA-IL-10
co-therapy are: 1) the dramatic improvement of enduring pain control over the individual
treatment of DM or pDNA-IL-10, and 2) the complete, albeit transient, allodynic reversal
following DM treatment alone (no IL-10 transgene). These results support that the mannose
receptor (MR; CD206) is not simply promoting phagocytosis of surrounding material, but
rather MR-mediated signaling is able to induce significant changes in the DRG
microenvironment. Therefore, to confirm that the DRG environment is amenable to DM
treatment strategies, mRNA levels for the mannose receptor (Mrc1) were assessed. In
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addition, alterations in IL-10 receptor (IL-10R) expression could exist in IL-10 KO mice
thereby underlying unforeseen behavioral adaptations. Thus, comparisons of mRNA levels
for IL-10Rα (a.k.a. IL-10R1; Il10ra), the IL-10R component responsible for binding IL10, between WT and IL-10 KO Naïve mice, and between various gene therapy treatment
groups were assessed in the ipsilateral lumbar DRG (Fig. 3F-G). While there were no
significant differences for MR or IL-10Rα mRNA levels between WT and IL-10 KO
Naïves, mRNA expression levels for both IL-10Rα and MR were significantly elevated in
the ipsilateral DRG following peripheral nerve injury (i.e. CCI). Surprisingly, though
stably pain-relieved CCI+DM/pDNA-IL-10 mice had elevations in MR mRNA expression
compared to Sham controls, their levels were significantly less than those observed in
allodynic CCI+Saline/pDNA-IL-10 controls. Similarly, MR mRNA levels were also
decreased in mice that had undergone transient pain reversal following DM treatment
(CCI+DM/pDNA-IL-10). Together, these findings support that non-viral IL-10 transgene
therapy acts at the level of the ipsilateral lumbar DRG to promote an anti-inflammatory
environment and consequent relief of allodynia. Given that MR mRNA expression is
elevated following CCI, these data further suggest that an initial pro-inflammatory
environment may be beneficial for the “transgene adjuvant” effects of DM.
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3.5 Transcriptional and protein characterization of the CCI-damaged sciatic nerve: i.t.
non-viral gene therapy relieves pain in IL-10 KO mice despite an ongoing proinflammatory environment at the level of the sciatic nerve

Ipsilateral sciatic nerve collected on Day 12 post-injection (See section 3.3) was analyzed
for typical injury-associated pro-inflammatory transcriptional changes following
peripheral nerve damage (Fig. 4). There were no significant differences observed between
WT Naïve and IL-10 KO Naïve mice for any mRNA transcript examined (P > 0.05). The
transcript levels for the key pro-inflammatory cytokines TNF and IL-1β (Fig. 4A-B), and
the pro-inflammatory chemokine CCL2 (Ccl2) (Fig. 4C) were significantly elevated in all
IL-10 KO CCI conditions compared to Shams. To further assess typical immune cellular
responses to sciatic nerve injury, markers for macrophages and T cells were examined.
mRNA levels for the macrophage marker CD11b (Itgam) were significantly elevated
compared to Sham-treated mice (Fig. 4D). Additionally, mRNA transcript levels for the
general T cell marker CD3e (Cd3e) were elevated in CCI mice compared to Shams (Fig.
4E). mRNA transcript levels for the anti-inflammatory cytokine TGF-β1 were examined
(Fig. 4F) as a possible compensatory cytokine in the absence of endogenous IL-10. Tgfb1
transcript expression was significantly elevated in all CCI conditions following injury.
While mRNA analysis provides strong evidence for the presence of key factors,
their protein products could be quickly degraded resulting in little to no physiological
impact. Consequently, complementary protein analysis provides a balanced approach to
characterizing the damaged sciatic nerve. Here, multiplex protein analysis of injuryassociated pro-inflammatory chemokines and cytokines in the sciatic nerve ipsilateral to
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the CCI surgery were examined in samples from the same animals previously assessed for
injury-induced changes in mRNA (Fig. 4G-L). While no significant differences between
WT Naïve and IL-10 KO Naïve nerves for any protein target examined were observed (data
not shown; P > 0.05), not surprisingly, pro-inflammatory TNF protein levels were elevated
in all CCI conditions (Fig. 4G). Additionally, the detected protein levels for the proinflammatory cytokines IL-1β, IFN-γ, and IL-6 were significantly elevated in both
allodynic CCI+Saline/pDNA-IL-10 mice and non-allodynic CCI+DM/pDNA-IL-10 mice
compared to Sham controls (Fig. 4H-J). CXCL1, a neutrophil chemoattractant molecule,
was elevated in all CCI conditions compared to Sham controls (Fig. 4K). No differences
in bioactive IL-12p70, a pro-inflammatory cytokine downstream of CpG-activated TLR-9,
were observed (Fig. 4L).
Together, these mRNA and protein observations support that all IL-10 KO CCI
animals experienced similar local responses to peripheral nerve damage regardless of i.t.
gene therapy manipulation. Furthermore, the pain-suppressive actions of intrathecally
delivered DM and IL-10 transgene co-therapy appear to occur in the DRG in IL-10 KO
mice, despite a potent pro-inflammatory milieu at the level of the sciatic nerve.

3.6 I.t. non-viral IL-10 gene therapy alters lumbar cytokines and microglial activation.

To assess the spinal impact of DRG-mediated IL-10 transgene expression, mRNA levels
were assessed in lumbar spinal cord tissue collected on Day 12 post-injection (See section
3.3). Levels of mRNA for the pro-inflammatory cytokine TNF (Tnf) (Fig. 5A) and the proinflammatory chemokine CCL2 (Ccl2) (Fig. 5C) were significantly elevated in allodynic
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mice given non-IL-10 control gene therapy, while spinal cords from pain-relieved IL-10
gene therapy-treated mice (CCI+DM/pDNA-IL-10) revealed a significant decrease in TNF
and CCL2 mRNA compared to Sham-treated controls. Additionally, significant decreases
for both targets were observed in pain-relieved mice compared to allodynic
CCI+Saline/pDNA-IL-10 controls. (Fig. 5B) Surprisingly, no significant differences in
pro-inflammatory cytokine IL-1β (Il1b) mRNA transcript levels were observed between
any condition.
Interestingly, though mRNA levels for the anti-inflammatory cytokine TGF-β1
(Tgfb1) were found to be elevated only in ipsilateral DRG from pain-relieved DM/pDNAIL-10 mice (Fig. 3D), no significant differences in Tgfb1 levels were observed in the
lumbar spinal cord for any condition (Fig. 5D).
Spinal microglial activation is a critical component of pathologic pain (Hughes et
al., 2009) but has not yet been examined following naked non-viral IL-10 gene therapy. A
previously described novel transmembrane protein 119 (TMEM119) identifies solely
microglia (Bennett et al., 2016). Though TMEM119 has not been previously identified as
a marker of microglial activation, we chose to examine changes in TMEM119 mRNA
expression to assess whether spinal non-viral IL-10 gene therapy reduces pathological
microglial activation. Examination of TMEM119 (Tmem119) mRNA (Fig. 5E) revealed
spinal cords from allodynic CCI-treated mice given control gene therapy treatment
(CCI+DM/Ctrl or CCI+Saline/IL-10) have significantly elevated Tmem119 transcript
levels compared to Sham controls. However, Tmem119 mRNA expression is decreased in
pain-relieved (CCI+DM/pDNA-IL-10) mice compared to allodynic CCI+Saline/pDNAIL-10 controls. This evidence suggests that changes in expression of TMEM119 may serve

53

as a useful marker of both pathologic microglial activation and a biomarker of therapeutic
efficacy. Furthermore, these data support that non-viral DM/pDNA-IL-10 gene therapeutic
actions at the level of the DRG lead to decreased microglial activation at the level of the
lumbar spinal cord.
Together, these data support that the therapeutic actions of IL-10 transgene at the
level of the ipsilateral DRG lead to decreased lumbar spinal microglial activation in parallel
with decreased spinal production of classic pain-relevant pro-inflammatory cytokines and
chemokines.

3.7 I.t. non-viral IL-10 gene therapy decreases astrocyte activation in the dorsal horn of
the lumbar spinal cord.

While lumbar spinal glial activation has been extensively examined in a variety of animal
models (Garrison et al., 1991; Meller et al., 1994; Watkins et al., 1997; Colburn et al.,
1999; Sweitzer et al., 1999; Hashizume et al., 2000; Milligan et al., 2001; Watkins and
Maier, 2002), the underlying glial mechanisms at the level of the lumbar spinal cord
following naked non-viral IL-10 gene therapy were previously unknown. It has not yet
been characterized whether subarachnoid IL-10 gene therapy that alleviates allodynia also
reduces L3-L5 dorsal horn astrocyte activation. Therefore, the current study aimed to
examine whether subarachnoid IL-10 gene therapy that alleviates allodynia in behaviorally
verified mice also reduces L3-L5 dorsal horn astrocyte activation as indicated by
immunoreactive levels of glial fibrillary acidic protein (GFAP). GFAP is an astrocytic
protein that increases in expression as astrocyte activation increases. At BL prior to surgery
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and i.t. injection, all mice revealed similar responses to light mechanical touch (Fig. 6AB). CCI-treated IL-10 KO mice develop clear bilateral allodynia by Day 3 post-surgery.
All groups received an i.t. injection following behavioral assessment on Day 5 postsurgery. On Day 2 post-injection, mice given DM/pDNA-IL-10 reveal bilateral reversal of
allodynia compared to CCI mice treated with various control transgene injections. As
before, IL-10 KO mice treated with CCI+DM/pDNA-IL-10 exhibit stable pain relief for
the remainder of the timecourse. Mice given i.t. DM/Saline or i.t. DM/pDNA-Ctrl reveal
transient pain reversal beginning on Day 3 post-injection, and returning to allodynia
beginning on Day 6 post-injection. The additional control group of un-injected IL-10 KO
CCI mice (N = 4) was behaviorally verified and revealed bilateral allodynia on Day 17
post-surgery with the following stimulus intensity thresholds (Mean + SEM) 0.032g +
0.004g and 0.048g + 0.009g for the left and right hindpaws, respectively (data not shown).
Following behavioral assessment on Day 12 post-injection, lumbar spinal tissues
were collected and assessed for GFAP immunoreactivity (IR) by immunohistochemistry.
Representative photomicrographs (Fig. 6C-J) of ipsilateral lumbar dorsal horn are shown.
As expected, GFAP IR is present at low levels in Naïve conditions, but notably elevated in
most CCI conditions. Importantly, GFAP IR for pain relieved CCI+DM/pDNA-IL-10 mice
reveals GFAP IR levels similar to those observed for Naïve mice. Analysis of (Fig. 6K)
ipsilateral and (Fig. 6L) contralateral (contralateral lumbar dorsal horn images not shown)
lumbar dorsal horn GFAP IR quantification show no significant difference between WT
and IL-10 KO Naïves. However, significantly more GFAP fluorescence intensity is
observed in the ipsilateral dorsal horn following CCI surgery, with no significant difference
between CCI alone, CCI+Saline, and CCI+DM/Saline groups. Curiously, the greatest
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levels of GFAP IR in the spinal cord were observed bilaterally in control therapy treated
CCI-mice (DM/pDNA-Ctrl and Saline/pDNA-IL-10), which are also significantly greater
than those observed in pain-relieved DM plus IL-10 gene co-therapy treated mice
(CCI+DM/pDNA-IL-10).
Several key comparisons, were predicted, a priori, to be significantly different.
Unpaired t-test revealed differences between CCI+DM/pDNA-IL10 vs. CCI alone (P <
0.001) and CCI+Saline (P < 0.05). Conversely, GFAP IR levels for CCI+DM/pDNA-IL10 mice are strikingly similar (not significantly different) to Naïve conditions. The
heightened GFAP IR observed in DM/pDNA-Ctrl and Saline/pDNA-IL-10 treated mice
supports the possibility that the IL-10 transgene does not influence GFAP IR. Rather, it is
hypothesized that pDNA itself (either lacking or encoding IL-10) at the DRG creates
additional pro-inflammatory signaling downstream of TLR-9 activation via unmethylated
CpGs present in the plasmid vector (Hughes et al., 2009). Indeed, pDNA treatment leads
to increased production of pro-inflammatory mediators (Hughes et al., 2009). Thus,
elevated DRG pro-inflammatory drive results in elevated spinal GFAP. Though painrelieved DM/pDNA-IL-10 treated mice were also exposed to unmethylated CpGs, these
mice additionally received D-mannose. That is, MR activation, in conjunction with IL-10
transgene expression, increases TGF-β1 mRNA transcription in the DRG resulting in
greater anti-inflammatory drive from the DRG with a consequent reduction of the proinflammatory drive to the spinal cord. Thus, reduced spinal astrocyte activation following
DM/pDNA-IL-10 co-therapy is a predicted result despite the presence of CpG DNA.
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Therefore, these data support that i.t. non-viral gene therapy leading to DRG
expression of IL-10 transgene modulates pro-inflammatory factors in the lumbar spinal
cord dorsal horn, supporting an anti-inflammatory spinal milieu.

4. Discussion

While i.t. non-viral IL-10 gene therapy is efficacious for the treatment of chronic pain in
several rat models of peripheral neuropathy (Milligan et al., 2006b; Milligan et al., 2006a;
Ledeboer et al., 2007b; Sloane et al., 2009b; Sloane et al., 2009a; Milligan et al., 2012;
Dengler et al., 2014), the current data provide new insight into underlying mechanisms by
which a unique non-viral vector formulation results in robust and enduring pain control.
Here, the unique combination of delivering D-mannose (DM) with non-viral plasmid DNA
encoding the IL-10 transgene (DM/pDNA-IL-10) unambiguously demonstrates that
endogenous IL-10 is not required for enduring and profound pain reversal following
DM/pDNA-IL-10 co-therapy. Additionally, the biodistribution of transgene IL-10 mRNA
expression following i.t. DM/pDNA-IL-10 co-therapy in IL-10 deficient mice is robustly
observed in the ipsilateral DRG and cauda equina, but not in the lumbar spinal cord. The
corresponding pain-associated pro-inflammatory cytokine TNF mRNA expression is
decreased in pain-relieved mice given DM/pDNA-IL-10 co-therapy compared to allodynic
controls. In contrast, the anti-inflammatory cytokine TGF-β1 mRNA expression is
increased in the DRG of gene therapy-treated pain-reversed animals. Robust mRNA
changes observed in the DRG of neuropathic mice prompted examination of mRNA levels
for the mannose receptor (MR) and the IL-10 receptor (IL-10Rα), both of which are

57

significantly upregulated following peripheral nerve damage, supporting their availability
and action for DM/pDNA-IL-10 co-therapy in treatment of pathological conditions.
IL-10 transgene mRNA expression is predominantly present in the DRG and not in
the lumbar spinal cord, while dramatic pain-related cytokine changes are observed in the
lumbar spinal cord. Specifically, mRNA levels for TNF and the pro-inflammatory
chemokine CCL2, but not IL-1β or TGF-β1, are upregulated in spinal cords of allodynic
CCI mice. In contrast, pain-relieved mice given DM/pDNA-IL-10 co-therapy have spinal
levels of TNF and CCL2 mRNA no different from uninjured Sham controls. Upon
examination of the lumbar spinal mRNA expression for the microglial-specific
transmembrane protein 119 (TMEM119), previously reported to upregulate upon increased
microglial activity (i.e. proliferation) (Bennett et al., 2016), the activation state of microglia
is significantly reduced in DM/pDNA-IL-10-treated pain-reversed mice. Similarly,
immunohistochemical analysis for changes in astrocyte activation in the dorsal horn of the
spinal cord reveal a profound reduction in GFAP immunoreactivity in DM/pDNA-IL-10
treated pain-reversed mice. Importantly, cytokine mRNA and protein levels from the
injured mouse sciatic nerve reveal equivalently strong upregulation of pro-inflammatory
cytokines, as well as general monocyte and T cell involvement regardless of injection
formulation. Thus, these data support that i.t. non-viral DM/pDNA-IL-10 co-therapy
provides stable and long-lasting relief from peripheral neuropathic pain through antiinflammatory actions at the level of the DRG and consequent anti-inflammatory actions at
the level of the lumbar spinal cord.
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4.1 Endogenous IL-10 is not required for efficacy of therapeutic mouse IL-10 gene
containing a known non-silent point mutation: mIL-10F129S

We show for the first time that the known point mutation present in the mouse IL-10 (mIL10F129S) transgene expressed by the pDNA-IL-10 used in these studies (Fig 1E) does not
require endogenous IL-10 to exert IL-10 action. IL-10 monomers associate as homodimers
prior to binding with the interleukin-10 receptor via IL-10Rα (a.k.a. IL-10R1) (Moore et
al., 2001). Though this point mutation lies outside the IL-10 dimer’s known receptor
binding region, it may still interfere with IL-10 homodimerization resulting in the
possibility that the IL-10F129S protein could require wildtype IL-10 for adequate
dimerization, receptor binding, and downstream anti-inflammatory function. However,
preliminary in vitro work using macrophages and B cells suggest IL-10F129S may result in
greater anti-inflammatory actions than wildtype IL-10 alone (Sloane et al., 2009b). While
it is currently unknown whether pDNA-IL-10F129S lacks the requirement for dimerization,
the findings in the current report demonstrate two critical issues: that 1) wildtype IL-10/IL10F129S heterodimerization is not required for IL-10F129S efficacy, and 2) exogenous mIL10F129S produces profound stable and long-lasting pain suppressive effects in the absence
of endogenous wildtype IL-10.

4.2 The immune system has built-in anti-inflammatory redundancy.

An interesting behavioral finding in the current report is that loss of endogenous IL-10 may
not lead to dramatic susceptibility to injury-induced pain pathology. This is surprising
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given that IL-10 deficiency and IL-10R mutations observed in humans and animal models
(i.e. IL-10 KO mice and IL-10R KO mice) are associated with increased risk of
enterocolitis (Kuhn et al., 1993; Ward et al., 1996; Spencer et al., 1998). In these cases,
absence of IL-10 signaling leads to loss of intestinal mucosal immune homeostasis and
consequent enhanced intestinal inflammation in response to the presence of gut microbiota
(Shouval et al., 2014). In the current report, no sensory differences were observed between
WT and IL-10 KO mice at BL, which is consistent with previous findings that IL-10 KO
mice do not differ in their basal light touch sensitivity thresholds (da Silva et al., 2015;
Siqueira Mietto et al., 2015; Krukowski et al., 2016), though there is some evidence that
uninjured IL-10 KO mice may differ in their thermal nociceptive response (Tu et al., 2003).
There are mixed reports regarding intensity and duration of allodynia in IL-10 KO mice
following various models of injury (da Silva et al., 2015; Siqueira Mietto et al., 2015;
Krukowski et al., 2016). For example, in a paclitaxel model of peripheral neuropathic pain,
WT and IL-10 KO mice exhibited both a similar onset of hindpaw mechanical allodynia
and a similar peak intensity of allodynia. However, the duration of the timecourse of
allodynia was extended in paclitaxel-treated IL-10 KO compared to their WT counterparts
(Krukowski et al., 2016). In a model of intramuscular carrageenan, no differences in IL-10
KO vs. WT were observed for allodynic intensity or timecourse of duration in response to
non-noxious cutaneous or muscular stimulation (da Silva et al., 2015). In a sciatic nerve
crush model, the onset and duration of allodynia in WT vs. IL-10 KO mice was similar,
though IL-10 KO mice were significantly more allodynic on the last day (Day 28 postsurgery) of the reported timecourse (Siqueira Mietto et al., 2015). Data from the current
report indicate a similar onset, intensity, and duration of allodynia following peripheral
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nerve damage in IL-10 KO mice compared to WT mice, and both WT and IL-10 KO CCI
mice given control gene therapy remain stably responsive throughout the entire timecourse.
However, it is possible that the intensity of allodynia could be greater in IL-10 KO mice
relative to WT mice, as the behavioral assessment assay may be limited in detecting
maximal hindpaw sensitivity.
The similar levels of allodynia observed between IL-10 KO and WT mice following
CCI may be a result of the functional redundancy that occurs within the immune system.
Compensatory anti-inflammatory mechanisms could be engaged that reduce the enhanced
allodynia one would have predicted in an IL-10 KO model of CCI. While the data reported
here reveal a potent pro-inflammatory mRNA and protein environment at the level of the
sciatic nerve congruent with previous characterizations of WT mice following sciatic CCI
(Okamoto et al., 2001; Kleinschnitz et al., 2006; Uceyler et al., 2007), a clear concurrent
upregulation of anti-inflammatory TGF-β1 mRNA was observed in the ipsilateral DRG of
pain relieved DM/pDNA-IL-10 co-therapy treated mice.
One possible mechanism by which i.t. non-viral DM/pDNA-IL-10 co-therapy
generates enduring pain suppression is via consequent elevated TGF-β1 expression in the
DRG. TGF-β1 and IL-10 have bidirectional regulation, as prior work demonstrates
astrocytes previously stimulated in vitro with lipopolysaccharide (LPS; a potent TLR-4
agonist) can be redirected by incubation with IL-10 to produce TGF-β (Norden et al.,
2014). Additionally, IL-10 prevents enterocolitis through increased TGF-β production
(Fuss et al., 2002). In turn, TGF-β promotes IL-10 upregulation in macrophages (Maeda et
al., 1995) and is known to induce differentiation of IL-10-producing regulatory T cells
(iTregs) and T regulatory type 1 cells (Tr1) (Kleinewietfeld and Hafler, 2014).
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Furthermore, TGF-β1 non-viral gene therapy administered intranasally for treatment of
enterocolitis promotes beneficial effects via enhanced production of IL-10 (Kitani et al.,
2000). In line with the anti-inflammatory function of TGF-β, prior work reveals that i.t.
recombinant TGF-β1 attenuates neuropathic pain following partial ligation of the sciatic
nerve in rats (Echeverry et al., 2009). However, in contrast to IL-10, which exerts
predominantly anti-inflammatory actions (Saxena et al., 2015), TGF-β actions are
determined by the nearby cellular and receptor milieu (Bottner et al., 2000). For example,
TGF-β can act as either a dynamic tumor promoter or a tumor suppressor, thereby making
the modulation of TGF-β alone a challenging and unpredictable therapeutic approach
(Bottner et al., 2000; Colak and Ten Dijke, 2017). The possibility that the IL-10 transgene
works synergistically with TGF-β1 for control of allodynia while potentially attenuating
the untoward effects of TGF-β upregulation warrants further investigation.

4.3 Gene therapeutic modulation of the ipsilateral DRG is sufficient for enduring relief of
bilateral allodynia

It is increasingly apparent in the literature that cytokine changes at the level of the DRG
are deeply involved in the modulation of sensory information and the development of
neuropathic pain (Krames, 2015). Therefore, it is noteworthy in this report that IL-10
transgene mRNA expression was detected in the ipsilateral DRG but not in the lumbar
spinal cord where centrally projecting nociceptive terminals are communicating to pain
projection neurons. What is most striking about the current data is that anti-inflammatory
cytokine expression in the DRG is sufficient to drive anti-inflammatory changes at the level
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of the lumbar spinal cord (i.e. decreased mRNA for TNF and CCL2). The spinal antiinflammatory bias following DM/pDNA-IL-10 co-therapy is further supported by
decreased lumbar mRNA levels of the microglial marker TMEM119 (upregulates upon
activation/proliferation), concurrent with bilateral decreases in GFAP IR in the lumbar
spinal cord dorsal horn. In combination, the data reveal a profound reduction of lumbar
spinal cord GFAP IR following DM/IL-10 combination therapy, but with less striking
mRNA decreases in spinal TNF and CCL2 and DRG TNF, suggesting that the role of other
factors critical for ongoing astrocyte activation may generate greater effects on spinal pain
processing. Most importantly, the pro- vs. anti-inflammatory rebalancing in the lumbar
spinal cord is reflected in the behavioral responses of stably pain-relieved mice treated with
non-viral IL-10 gene therapy. These findings further suggest that the protein product of the
IL-10 transgene does not require direct contact with pain projection neurons in the dorsal
spinal cord, but rather, interaction with cell bodies in the DRG alone is sufficient to induce
pain relief.
There are several potential mechanisms by which IL-10 expression at the DRG
leads to changes in neuronal signaling. For instance, several key mediators of neuropathic
pain, such as TNF, increase neuronal excitability (Kagan et al., 1992; Watkins and Maier,
2005; Leung and Cahill, 2010; Grace et al., 2014; Ji et al., 2016). The current report
demonstrates decreased TNF mRNA expression in the ipsilateral DRG of pain relieved
DM/pDNA-IL-10 treated mice. This, in conjunction with synergistic IL-10/TGF-β1
actions, may lead to a decrease in TNF protein actions resulting in decreased neuronal
excitability. While prior reports document neuronal IL-10R1 is present in the DRG and
direct activation of neuronal IL-10R1 may help mediate decreases in pathologic neuronal
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signaling (Shen et al., 2013; Alvarez et al., 2017), it is speculated in the current report that
immune- and glial cell-derived IL-10R1 is predominantly responsible for the anti-allodynic
effect because neurons do not produce the cytokines measured here (i.e. TNF, IL-10 and
TGF-β1). Currently, the source of pain-controlling TGF-β1 and IL-10 is thought to be from
glial and immune cells following IL-10R1 activation. However, whether IL-10R1
activation on DRG neurons is required for the beneficial effects of DM/pDNA-IL-10 cotherapy will provide an intriguing avenue of future study.
In the current report, we demonstrate that unilateral DRG IL-10 transgene
expression is sufficient for relief of bilateral allodynia. Our behavioral observations in the
context of absent contralateral DRG pro-inflammatory cytokine changes support that
bilateral relief is mediated through events occurring at the level of the lumbar spinal cord.
Unfortunately, the mechanisms that underlie allodynia contralateral to the side of injury,
clinically referred to as “mirror pain,” are not completely understood (Huang and Yu,
2010), though spinal glial activation is strongly implicated. For instance, work by Spataro
et al. revealed that astrocyte communication via gap junctions may be critical for
contralateral allodynia (Spataro et al., 2004). They elegantly demonstrated that i.t.
administration of the gap junction decoupler carbenoxolone relieves contralateral, but not
ipsilateral, mechanical allodynia following sciatic CCI in rats. They further argue that: 1)
astrocytic gap junctions far outnumber those found on neurons, 2) though astrocytes are
slow to activate, gap junctions are quickly upregulated (within 45 minutes post-nerve
injury) and dynamically modifiable, and 3) astrocytes possess extensive gap junctionmediated glial connectivity throughout the spinal cord (Spataro et al., 2004). A competing
hypothesis is that contralateral allodynia results from diffusion of ipsilaterally released pro-
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inflammatory cytokines through cerebrospinal fluid to act on contralateral pain-relevant
anatomic structures (Milligan et al., 2001; Cheng et al., 2014). Alternatively, neurons of
the ipsilateral spinal cord dorsal horn may directly communicate with neurons, and likely
glia, in the contralateral spinal cord dorsal horn (Fitzgerald, 1982; Fitzgerald and Woolf,
1982). In the current report, the astrocyte activation marker GFAP revealed bilateral
upregulation in the spinal cord dorsal horn in chronically bilaterally allodynic CCI animals.
Interestingly, the presence of DM/pDNA-IL-10 co-therapy in bilaterally pain-relieved
animals was sufficient to reduce bilateral CCI-induced GFAP IR to basal levels. These
findings support a role for the actions of spinal astrocytes in the production and resolution
of contralateral allodynia. Though mRNA levels for the microglial activation marker
TMEM119 were decreased in pain-relieved mice compared to allodynic controls, we
cannot draw conclusions about laterality as both ipsilateral and contralateral spinal cord
segments were analyzed together as single mRNA samples. However, the literature so far
demonstrates that microglia are not dramatically altered in the contralateral spinal cord, as
assessed by common markers of microglial activation (Ji et al., 2013).

4.4 Changes in TMEM119 expression as a possible marker of microglial activation

It is well understood that nervous tissue insults, such as damage to peripheral nerves, lead
to CNS “microgliosis,” a condition that describes microglial proliferation as well as
changes in microglial morphology, gene expression profiles, and behavior (Calvo and
Bennett, 2012). Additionally, microglial proliferation has been clearly linked to
neuropathic pain pathology (Liu et al., 2000; Inoue and Tsuda, 2009; Zhuo et al., 2011).
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While increased microglial activation can occur without proliferation (Nimmerjahn et al.,
2005; Chen et al., 2012), increased microglial proliferation does not occur without
stimulation, reflecting the diverse responses microglia generate under healthy or
pathological conditions (Ulland et al., 2015).
TMEM119 was recently identified as a microglial specific marker in the mouse and
human CNS (Bennett et al., 2016; Satoh et al., 2016). Work by Satoh et al. reveal
TMEM119 mRNA levels are elevated in microglia from humans with Alzheimer’s disease.
Further, they report that TMEM119 exhibits a positive correlation with Iba-1 mRNA
expression (Satoh et al., 2016), a microglial/monocyte marker known to increase in the
CNS under pathological conditions (Echeverry et al., 2008). Another recent report used
TMEM119 to distinguish microglia and macrophages in lesions found in post-mortem
brain samples from humans diagnosed with multiple sclerosis (Zrzavy et al., 2017). They
identified TMEM119 expression in activated microglia present within early active lesions.
Such lesions are known to have increased microglial populations and are associated with
demyelination, oxidative injury, and antigen presentation (Zrzavy et al., 2017). However,
Bennett et al. report increased immunoreactivity for Iba-1 (a widely-used marker for
microglial activation) but not TMEM119 in the CNS following either sciatic nerve crush
injury or LPS-induced systemic inflammation (Bennett et al., 2016). Additionally, Satoh
et al. did not find an association between TMEM119 immunoreactivity and markers of
“M1” classical activation (CD80) or “M2” alternative activation (CD163), speculated to
reflect neuroprotective conditions (Satoh et al., 2016). However, it is worth considering
that the applicability of the M1/M2 polarization paradigm to microglia is still under dispute
(Ransohoff, 2016). Taken together, TMEM119 may not readily reflect the activation state
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of diversely functional microglia, changes in TMEM119 mRNA levels can be an indicator
of a shift from homeostatic microglial behavior.
The current report provides evidence that TMEM119 mRNA is elevated in the
lumbar spinal cord following sciatic CCI, which is consistent with prior reports of
increased expression of microglial markers following peripheral nerve damage (Eriksson
et al., 1993; Echeverry et al., 2008). Further work must be performed to determine whether
increases in TMEM119 mRNA levels reliably predict increases in TMEM119 protein
expression and whether these increases positively correlate with other markers of
microglial activation.

4.5 Mannose receptor structure, expression, and activation

MR is a c-type lectin receptor commonly associated with endocytosis and pathogen
recognition, and possesses an extracellular cysteine rich domain (CR; binds sulfated
oligosaccharides), a fibronectin II domain (FNII; binds collagen fragments), and a
carbohydrate recognition domain (CRD; binds mannose, fucose, and N-acetyl-Dglucosamine) (Martinez-Pomares, 2012; Sedaghat et al., 2014). MR is expressed by
macrophages, dendritic cells, and microvascular endothelial cells (Taylor et al., 2005), as
well as in the CNS by astrocytes, microglia, and some neurons (Burudi et al., 1999; Burudi
and Regnier-Vigouroux, 2001), and in the PNS by Schwann cells (Baetas-da-Cruz et al.,
2009). Increased MR expression is often associated with anti-inflammatory macrophages
(Gordon, 2003). It is important to note that macrophages are known to infiltrate the DRG
following sciatic CCI (Hu et al., 2007).
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While partial ligation of the sciatic nerve in WT mice increases MR in the ipsilateral
DRG, (Komori et al., 2011), the data in the current report offer critical new information
because elevated MR mRNA in the ipsilateral DRG of all CCI conditions occurs
independently of IL-10 actions. Additionally, it is interesting to note that CCI mice given
the MR agonist (DM/pDNA-IL-10 and DM/pDNA-Ctrl) exhibit significantly less
elevation in MR mRNA expression compared to CCI mice that did not receive the MR
agonist (Saline/pDNA-IL-10). For example, a recent report by Xu et al. demonstrated in
vivo that intravenous mannose treatment in a mouse model of acute lung injury induced by
intratracheal instillation of LPS dose-dependently attenuates LPS-induced decreases in MR
mRNA expression in lung homogenates 3 hours following mannose administration (Xu et
al., 2015). Additionally, in vitro mannose pretreatment of RAW 264.7 macrophages
prevents LPS-induced decreases in MR mRNA levels while also dose-dependently
increasing MR protein levels as compared to unstimulated cells (Xu et al., 2015). The same
group demonstrated increased MR protein expression by primary alveolar macrophages 16
hours after ex vivo stimulation with DM plus LPS compared to LPS alone (Xu et al., 2010).
Lastly, monocyte-derived dendritic cells differentiated in the presence of glycosylated
mucins (tumor-derived MR agonist) for a continuous 7 day exposure exhibit increased MR
expression at the cell surface compared to controls (Rughetti et al., 2005). Taken together,
these data suggest that acute and chronic exposure to MR agonists increase both MR
protein and mRNA expression, suggesting MR agonists do not overtly generate tolerance.
Curiously, DRG from chronically allodynic Saline/pDNA-IL-10-treated mice
revealed the highest MR expression levels, suggesting that both the pro-inflammatory or
anti-inflammatory peripheral immune cell response to nerve injury can be identified by

68

local alterations in MR levels. Though MR upregulation is commonly considered a
phenotypic marker of alternatively activated “M2” macrophages (Gordon, 2003; Martinez
and Gordon, 2014a), the applicability of classically activated “M1” vs. “M2” macrophage
phenotypes to the ipsilateral DRG following sciatic nerve injury has not been fully
established. Furthermore, while macrophages are known to infiltrate the DRG following
sciatic CCI (Hu et al., 2007), the possible contribution of other cell types within the DRG
following sciatic CCI, such as satellite glial cells and additional trafficking leukocytes (e.g.
T cells), in modulating both MR expression and the “balance” between M1 vs. M2 factors
is not well understood. Therefore, changes in MR expression reported here are interpreted
within the context of the DRG cytokine profile balance. Specifically, chronically allodynic
Saline/pDNA-IL-10 mice express the greatest MR and TNF mRNA levels while
simultaneously expressing the lowest TGF-β1 mRNA levels. In contrast, pain-relieved
CCI+DM/pDNA-IL-10 mice express significantly elevated IL-10, MR, and TGF-β1
mRNA levels with low TNF mRNA expression. In future studies aimed at distinguishing
the biochemical effects of IL-10 gene therapy from DM, analysis of CCL2 in DRG may be
useful to elucidate the mechanisms by which DM alone generates transient pain reversal.
Given that the lumbar spinal cord, for which no IL-10 transgene was identifiable,
exhibited substantial decreases in key inflammatory markers, the M1-to-M2 changes
within the DRG suggest that DM/pDNA-IL-10 alters the ability of injured primary sensory
neurons to relay pathological pain information to spinal pain projection neurons. That is,
DM/pDNA-IL-10 actions at the level of the DRG diminish the salience of incoming
peripheral nociceptive signals, with the level of MR expression potentially serving as a
useful biomarker of the degree of influence.

69

4.6 Non-viral naked plasmid gene therapy for treatment of pathological pain

Non-viral gene therapies provide promising avenues for the treatment of CNS diseases
(Jayant et al., 2016), and methods using naked plasmid DNA have been previously
explored for treatment of pathological pain. Yao et al. demonstrated pain relief following
a single i.t. injection of naked pDNA (25μg) encoding human interleukin-2 in CCI-treated
Sprague-Dawley rats. However, anti-nociceptive effects disappeared 5-6 days postinjection (Yao et al., 2002). More recently, Hu et al. demonstrated about ~2 weeks of
inflammatory pain reversal in mice following i.t. or intramuscular (i.m.) delivery of naked
pDNA (20μg) encoding the human proenkaphalin gene. While promising, their pain model
exhibits >3 weeks of allodynia, making the value of ~2 weeks of pain relief unclear.
Milligan et al. were the first to explore i.t. delivery of naked pDNA-IL-10 for relief of
peripheral neuropathic pain following CCI in rats. While a single i.t. injection of pDNAIL-10 (100μg) provides only ~2 days of pain relief, an appropriately timed second i.t.
injection (100μg) produces long-lasting pain reversal for greater than 40 days (Milligan et
al., 2006b). Later work by Sloane et al. further optimized this repeated injection paradigm,
revealing that an initial i.t. pDNA injection (100μg) induces a sensitization which when
followed by a smaller plasmid load (25µg pDNA-IL-10) provides greater than 3 months of
pain relief (Sloane et al., 2009b). Non-viral naked pDNA-IL-10 gene therapy was further
improved by Dengler et al., who demonstrated that i.t. co-injection of D-mannose (DM)
with naked pDNA-IL-10 (25µg) provides greater than 90 days of pain relief in CCI-treated
Sprague-Dawley rats (Dengler et al., 2014). The current report demonstrates that coinjection of DM with just 3μg of naked pDNA-IL-10 in neuropathic mice leads to enduring
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pain relief for the remainder of the full behavioral timecourse. Notably, data in the current
report reveal spontaneous recovery from CCI allodynia occurs sooner in mice than in rats
(45 days). Especially given its long-lasting pain suppression profile, these intriguing
findings support that non-viral IL-10 gene therapy formulated with DM is the preferred
non-viral naked pDNA approach for treatment of neuropathic pain conditions. Future
investigations may support use of this unique formulation in treatment of other pain
conditions, and perhaps other diseases of the CNS.

4.7 Naked plasmid DNA co-injected with D-mannose is safe, inexpensive, and easy to use

Naked plasmid DNA must face numerous extra- and intracellular obstacles to achieve
transgene expression (Glover et al., 2005). To address this, both physical and chemical
(e.g. carrier-based) methods have been utilized in an effort to improve the efficacy of nonviral gene therapy (Jayant et al., 2016). Physical methods of gene delivery, such as
electroporation, gene gun, ultrasound, or magnetofection, sidestep the numerous obstacles
faced by naked pDNA, but are often both costly and labor intensive (Oliveira et al., 2017).
Carrier-based methods of non-viral gene therapy, such as polyethynlamine (PEI) pDNA
complexes, liposomes, and PLGA microparticles, work to shield pDNA from cellular
degradation and aid in cell entry (Slivac et al., 2017) but are not without their
disadvantages. For instance, in addition to traditionally low efficacy and transient
expression observed in non-viral approaches, PEI exhibits moderate toxicity, liposomes
can have a low-to-moderate inflammatory response, and many polymer-based methods
require surface modification for improved targeting (Jayant et al., 2016). The current report
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supports that DM co-therapy provides a safe, inexpensive, and easy alternative for
improving pDNA uptake and expression.

4.8 Role of MR-activation in non-viral gene therapy

The current report supports that MR activation alone transiently attenuates pathologic
sensitivity to light touch stimulation by an IL-10-independent mechanism, but it is unclear
how MR activation leads to changes in intracellular signaling. Though we show that this
mechanism is IL-10 independent, it is likely that MR-mediated pain relief arises from the
potential MR role in anti-inflammatory immunomodulation (Nigou et al., 2001; Pathak et
al., 2005; Zhang et al., 2005; Gazi and Martinez-Pomares, 2009; Dengler et al., 2014).
Many studies of MR signaling are performed under inflammatory states, with MRactivation associated with enhanced pro-inflammatory signaling (Fernandez et al., 2005;
Lopez-Herrera et al., 2005; Tachado et al., 2007). However, the “mode” of MR signaling
may be dependent on the cellular activation state, with certain phenotypes leading to MRactivated anti-inflammation (Martinez-Pomares, 2012; Hussell and Bell, 2014). For
instance, in vitro dendritic cell cultures treated with “activating” anti-MR monoclonal
antibodies potently increase IL-10 and IL-1 receptor antagonist (IL-1Ra) secretion with
concurrent decreases in IL-1β and TNF production (Chieppa et al., 2003). In line with these
findings, MR-activation has also been repeatedly demonstrated to prevent LPS-induced
acute lung injury (Zhang et al., 2004; Zhang et al., 2005; Xu et al., 2008; Xu et al., 2015)
through downstream activation of the anti-inflammatory transcription factor peroxisome
proliferator activated receptor gamma (PPARγ) and decreased production of TNF (Xu et
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al., 2015). Furthermore, in vitro pretreatment with DM prior to LPS stimulation of RAW
264.7 mouse macrophage cells reduces release of pro-inflammatory TNF, IL-1β, and nitric
oxide, while increasing the secretion of IL-10 (Dengler et al., 2014). Zhou et al. recently
reported that bone marrow derived monocytes from MR-deficient Mrc1-/- mice reveal
greater mRNA levels for pro-inflammatory “M1” phenotypic markers (IL-1β, IL-6, and
nitric oxide synthase-2) following LPS-challenge, and lower mRNA levels for markers of
an “M2” phenotype (Fizz1, Ym1, and Arginase-1) (Zhou et al., 2017). They further
demonstrated that overexpression of miR-511-3p, an intronic miRNA encoded by both
mouse and human Mrc1/MRC1 and transcriptionally co-regulated with Mrc1 in
macrophages, reverses the M1 bias and instead promotes an anti-inflammatory M2
phenotype. Moreover, vesicular accumulation of cockroach allergens in macrophages, an
MR-dependent process, is not associated with the lysosomal compartment (Zhou et al.,
2017). This observation is reminiscent of prior studies illustrating ways MR activation in
the presence of intracellular pathogens is appropriated to activate anti-inflammatory
signaling with delayed phagosome-lysosome fusion (Shibata et al., 1997; AstarieDequeker et al., 1999; Shimada et al., 2006; Garcia-Aguilar et al., 2016). These MRdependent delays in phagosome-lysosome fusion offer a possible mechanism by which MR
activation improves transgene expression, and is worthy of future investigation. The
behavioral evidence of transient anti-allodynia reported in the current study supports MRmediated anti-inflammatory effects, and it is reasonable to imagine that MR itself may
serve as a novel target for the development of pain therapeutics.
As MR-targeting for enhanced non-viral gene therapy is explored for other CNS
pathologies, consideration must be taken to ensure availability of MR prior to application
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of this DM/pDNA approach. While MR is widely expressed in a variety of cell types, there
is some evidence that priming by pro-inflammatory processes may be beneficial to this
non-viral approach. For instance, significant levels of IL-10 transgene were observed in
ipsilateral, but not contralateral, DRG of CCI+DM/pDNA-IL-10 mice. Furthermore, it is
possible that the non-significant levels of IL-10 transgene expression in the ipsilateral DRG
of Sham+DM/pDNA-IL-10 treated mice are linked to expression of only basal levels of
MR. While the current report further validates targeting MR activation to facilitate
efficacious non-viral transgene uptake and expression for treatment of neuropathic pain,
further investigation is needed to assess the translatability of this gene therapeutic approach
for other CNS pathologies.

4.9 Exploration of MR-targeting therapeutics

D-mannose, the MR agonist applied here, is an inexpensive and commonly available
dietary supplement (Hu et al., 2016) used in a phase 3 clinical trial for prevention of
recurrent urinary tract infections (#NCT01808755, clinicaltrials.gov) (Porru et al., 2014).
N-acetyl-D-glucosamine is another MR ligand examined in an early phase 1 clinical trial
to improve wound healing of venous stasis ulcers (#NCT00720239, clinicaltrials.gov)
(Kelechi et al., 2012). The FDA recently approved the use of the MR-targeting agent γTilmanocept, also known as [99mTc]-DTPA-mannosyl-dextran, for imaging of sentinel
lymph nodes in solid tumor staging (Vera et al., 2001; Azad et al., 2015). Mannitol is
another FDA approved mannose derivative considered an osmotic diuretic, though whether
it may interact with MR on leukocytes or vascular endothelial cells is not yet known.
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Depending on the pain etiology, such as for peripheral neuropathic pain or
inflammatory pain, activation of MR by small molecules like D-mannose could be explored
for therapeutic treatment, especially for patients that would not be good candidates for
intrathecal gene therapy. Furthermore, targeting MR could be harnessed to improve the
anti-inflammatory response for treatment of diseases where inflammation has become
pathologic.

5. Conclusion

In summary, our findings provide evidence that spinal non-viral DM/pDNA-IL-10 gene
delivery for chronic neuropathic pain does not require endogenous IL-10 for enduring pain
relief, with uptake and expression of the IL-10 transgene predominantly in the DRG.
Reliable and significant anti-inflammatory changes in the DRG and the lumbar spinal cord
are observed as a consequence of this safe non-viral gene therapy approach. MR-mediated
improvements in transgene efficacy and transient pain relief are IL-10-independent,
findings that support further investigation into potential MR-activated intracellular
cascades and their consequent modification in the presence or absence of antiinflammatory cytokines. This therapy may provide a framework upon which other nonviral gene therapy approaches can be adopted to treat central nervous system disease that
extend beyond chronic pain.
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CHAPTER 2 FIGURES

Figure 1: Intrathecal non-viral IL-10 gene therapy provides stable long-lasting relief
of allodynia in mice and is independent of endogenous IL-10.
Absolute threshold behavioral responses for (A) ipsilateral and (B) contralateral hindpaws
for WT and IL-10 KO mice are shown (N = 6-8 mice/group as indicated in figure legend).
At baseline (BL), responses to low threshold mechanical stimuli were similar between all
groups (ipsilateral, F(5, 33) = 1.01, P > 0.05; contralateral, F(5, 33) =1.31, P > 0.05). For data
collected between BL through Day 5 post-surgery, a main effect of time (ipsilateral, F(2, 66)
= 170.08, P < 0.001; contralateral, F(2, 66) = 134.35, P < 0.001) and an interaction between
time and surgical manipulation (ipsilateral, F(2, 66) = 79.76, P < 0.001; contralateral, F(2, 66)
= 64.04, P < 0.001) were observed. After behavioral assessment on Day 5 post-surgery, all
mice received an intrathecal (i.t.) co-injection of plasmid DNA encoding interleukin-10
(pDNA-IL-10; 3μg in 7.5μL) with D-mannose (DM; 25μg in 3μL) vs. pDNA-Control
(Ctrl; 3μg in 7.5μL) with isotonic sterile saline (saline; 3μL). Following injection, both
WT and IL-10 KO CCI-mice given i.t. DM/pDNA-IL-10 reveal bilateral reversal to normal
levels of hindpaw sensitivity (ipsilateral, F(2, 66) = 54.49, P < 0.001; contralateral, F(2, 66) =
34.34, P < 0.001). This reversal remains stable through Day 30 post-injection (ipsilateral,
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F(4.9, 162.5) = 0.432, P > 0.05; contralateral, F(4.9, 163.1) = 0.871, P > 0.05). Not surprisingly,
control injected CCI-mice demonstrate bilateral spontaneous reversal from allodynia
between Days 30-40 post-injection (ipsilateral, F(2, 66) = 141.30, P < 0.001; contralateral,
F(1.5, 48.5) = 48.54, P < 0.001), with all groups experiencing similar normal levels of light
touch sensitivity by Day 40 post-injection (ipsilateral, F(5, 33) = 0.81, P > 0.05; contralateral,
F(5, 33) = 0.193, P > 0.05). (C) Plasmid map of the pDNA-IL-10 construct. The modified
plasmid was derived from the expression cassette previously used for adeno-associated
virus-2. pDNA-IL-10 is a 5.9 Kb plasmid with gene transcription driven by a chicken βactin promoter (CB pro) hybridized with a cytomegalovirus enhancer (CMV enh). The
expression cassette contains the transgene for mouse IL-10 with a point mutation (serine
substitution for phenylalanine at amino acid 129) (IL-10F129S), and a viral SV40
polyadenylation signal (SV40 poly(A)), and is flanked by two inverted terminal repeat
(ITR) sequences. The plasmid vector also contains an intervening sequence (IVS; intron)
and an ampicillin-resistance (Ampr) gene.
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Figure 2: I.t. non-viral IL-10 gene therapy in IL-10 KO mice leads to expression of
IL-10 transgene in pain-relevant lumbar dorsal root ganglia.
Absolute threshold behavioral responses for (A) ipsilateral and (B) contralateral hindpaws
are shown. At baseline (BL), responses to low threshold mechanical stimuli were similar
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between all groups (ipsilateral, F(4, 39) = 1.39, P > 0.05; contralateral, F(4, 39) = 1.04, P >
0.05). For data collected between BL through Day 5 post-surgery a main effect of time
(ipsilateral, F(1.7, 66.1) = 184.69, P < 0.001; contralateral, F(2, 78) = 186.41, P < 0.001) is
observed. After behavioral assessment on Day 5 post-surgery, Sham- or CCI-treated mice
received an i.t. co-injection of DM (25μg in 3μL) with either pDNA-IL-10 (3μg in 7.5μL)
or pDNA-Ctrl (N = 6-12 mice/group). An additional control group consisted of CCI-treated
mice that received i.t. saline with pDNA-IL-10 (N = 7). Following injection, a main effect
of time (ipsilateral, F(6.0, 233.1) = 49.09, P < 0.001; contralateral, F(8, 312) = 46.2, P < 0.001)
and an interaction of time and treatment (ipsilateral, F(23.9, 233.1) = 29.11, P < 0.001;
contralateral, F(32, 312) = 25.13, P < 0.001) were observed. Comparisons between groups
reveal that on Day 2 post-injection, CCI+DM/pDNA-IL-10-treated mice exhibit bilateral
reversal from allodynia compared to mice lacking DM treatment (CCI+Saline/pDNA-IL10) (ipsilateral and contralateral, P < 0.001). Surprisingly, on Day 3 post-injection, mice
given DM and the control plasmid (CCI+DM/pDNA-Ctrl) reach levels of hindpaw
sensitivity similar to Sham+DM/pDNA-IL-10-treated controls (ipsilateral and
contralateral, P > 0.05). Beginning on Day 6 post-injection, CCI+DM/pDNA-Ctrl mice
begin to return to bilateral allodynia (ipsilateral, F(3, 117) = 19.67, P < 0.001; contralateral,
F(3, 117) = 9.73, P < 0.001), while mice treated with DM/pDNA-IL-10 never return to
allodynia. (C-E) mRNA isolated from DRG and cauda equina tissues collected on Day 12
post-injection (Day 17 post-surgery) reveal IL-10 expression. IL-10 (Il10) mRNA levels
were observed in WT Naïve positive controls (N = 3) but not in IL-10 KO Naïves (N = 2)
for (C) ipsilateral, (D) contralateral lumbar DRG, and (F) lumbar spinal cord tissues (*P <
0.05), but not (E) cauda equina, despite a strong trend for positive expression (P = 0.062).
IL-10 mRNA expression was not significantly different between Sham-treated conditions
for DRG, cauda equina, and lumbar spinal cord (P > 0.05). (C) IL-10 transgene mRNA
expression was significantly elevated in ipsilateral DRG of pain-relieved CCI+DM/pDNAIL-10-treated IL-10 KO mice compared to IL-10 KO mice given either CCI+DM/pDNACtrl or Sham+DM/pDNA-Ctrl (F(4, 28) = 7.72, P < 0.001). (D) No significant increase in
IL-10 transgene mRNA levels were detected in contralateral DRG following i.t. injection
(F(4, 29) = 2.20, P = 0.093). However, a priori comparison revealed that contralateral DRG
from CCI-treated mice given DM co-treated with the IL-10 transgene contained
significantly greater IL-10 mRNA levels than DRG from CCI-treated mice given DM with
the control plasmid (P < 0.05) or Sham-treated mice with DM and the control plasmid (P
< 0.05). (E) In the cauda equina, IL-10 transgene mRNA expression was greatly elevated
in pain-relieved CCI+DM/pDNA-IL-10 KO mice compared to negative control conditions
CCI+DM/pDNA-Ctrl and Sham/DM+pDNA-Ctrl (F(4, 23) = 4.19, P = 0.011). (G) IL-10
protein was detected in ipsilateral sciatic nerve (collected Day 12 post-injection) of WT
Naïve but not IL-10 KO Naïve mice (P < 0.05), but no significant increase in IL-10
expression was detected in any i.t. injection condition (F(4, 27) = 0.65, P > 0.05). For mRNA
and protein analyses, N = 5-7 mice/group. mRNA levels (Mean ± SEM) are normalized to
18S rRNA and graphically presented relative to mean WT Naïve levels. For protein
analyses, protein levels are presented as Mean + SEM. Post-hoc multiple comparisons via
Fisher’s LSD (α = 0.05; *P < 0.05; **P < 0.01; ***P < 0.001).
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Figure 3: Therapeutic expression of IL-10 transgene mediates pain relief through
anti-inflammatory changes in ipsilateral lumbar DRG.
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mRNA was isolated from ipsilateral and contralateral Lumbar DRG (L3-5) on Day 12 postinjection (Day 17 post-surgery). (A-F) Baseline transcript levels were compared between
WT Naïve (N = 3 mice) and IL-10 KO Naïve (N = 2 mice) groups. Transcript levels for
TNF mRNA are significantly higher in ipsilateral DRG from IL-10 KO Naïves compared
to WT Naïves (*P < 0.05), but not in contralateral DRG (P > 0.05). Tgfb1, Il1b, Mrc1, and
Il10ra mRNA transcript levels were not significantly different between WT and IL-10 KO
Naïve groups in either ipsilateral or contralateral DRG (P > 0.05). (A) Post-surgical mRNA
levels of pro-inflammatory cytokine TNF are greatly increased in ipsilateral lumbar DRG
from all CCI conditions compared to Sham+DM/pDNA-Ctrl treated mice, (F(4, 30) = 17.17,
P < 0.0001). However, TNF mRNA expression was significantly decreased in pain relieved
CCI+DM/pDNA-IL-10 mice compared to allodynic CCI+Saline/pDNA-IL-10 controls.
Interestingly, TNF mRNA expression was also significantly decreased in
CCI+DM/pDNA-Ctrl mice that recently returned to allodynia as compared to
CCI+Saline/pDNA-IL-10 controls. (B) No statistically significant difference was detected
for TNF mRNA levels in contralateral DRG by 1-way ANOVA (F(4, 31) = 2.4, P > 0.05).
(C) Transcript levels of the anti-inflammatory cytokine TGF-β1 (Tgfb1) are decreased in
lumbar DRG collected from chronically allodynic mice (CCI+Saline/pDNA-IL-10)
compared to Sham+DM/pDNA-Ctrl treated mice (F(4, 31) = 11.13, P < 0.0001). In contrast,
pain relieved CCI+DM/pDNA-IL-10 mice exhibited elevated TGF-β1 mRNA expression
compared to Sham+DM/pDNA-Ctrl treated mice (F(4, 30) = 8.67, P < 0.0001). TGF-β1
mRNA levels were significantly decreased in chronically allodynic CCI+Saline/pDNA-IL10 mice as compared to both CCI+DM/pDNA-Ctrl and pain-relieved CCI+DM/pDNA-IL10 mice. (D) No statistically significant difference was detected for TGF-β1 mRNA levels
in contralateral DRG (F(4, 31) = 0.03, P > 0.05). (E) No statistically significant difference
was detected for pro-inflammatory cytokine IL-1β (Il1b) mRNA transcript levels in
ipsilateral DRG (F(4, 27) = 1.36, P > 0.05). (F) Post-surgical mRNA levels for the mannose
receptor (Mrc1; MR; CD206) are increased in ipsilateral lumbar DRG from all CCI
conditions compared to Sham+DM/pDNA-Control treated mice, with MR transcript levels
significantly decreased in pain-reversed CCI+DM/pDNA-IL-10 mice and recently
allodynic CCI+DM/pDNA-Ctrl mice as compared to chronically allodynic
CCI+Saline/pDNA-IL-10-treated mice (F(4, 30) = 29.48, P < 0.0001). (G) For IL-10 receptor
alpha (Il10ra) mRNA levels, all CCI conditions exhibited significant increases compared
to Sham+DM/pDNA-Ctrl mice (**P < 0.01) (F(4, 30) = 6.82, P < 0.001). N = 5-9 mice/group
for treatment groups, as indicated on graphs. mRNA levels (Mean ± SEM) are normalized
to 18S rRNA and graphically presented relative to mean WT Naïve levels. Post-hoc
multiple comparisons via Fisher’s LSD (α = 0.05; *P < 0.05; **P < 0.01; ***P < 0.001;
****P < 0.0001).
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Figure 4: Pro-inflammatory characterization of the CCI-damaged sciatic nerve
following i.t. non-viral IL-10 gene therapy in IL-10 KO mice.
mRNA was isolated from ipsilateral sciatic nerve (ipsi SCN) collected on Day 12 postinjection (Day 17 post-surgery) from previously behaviorally verified animals (Fig 3). (AF) Baseline transcription levels are not significantly different between WT Naïve and IL10 KO Naïve groups (N = 2-3 mice/group) for all targets (P > 0.05): Tnf, Il1b, Tgfb1, Ccl2,
Itgam, and Cd3e. (A-B) Post-surgical mRNA levels of pro-inflammatory cytokines TNF
(Tnf) and IL-1β (Il1b) are greatly increased in ipsi SCN from all CCI conditions compared
to Sham+DM/pDNA-Control treated mice (F(4, 31) = 5.07, P < 0.01; F(4, 29) = 3.769, P =
0.0138, respectively). (C) mRNA levels of pro-inflammatory chemokine CCL2 (Ccl2) are
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greatly increased across all CCI conditions compared to Sham+DM/pDNA-Ctrl treated
mice (F(4, 30) = 5.92, P < 0.01). (D) Following CCI surgery, the macrophage activation
marker CD11b (itgam) is elevated in ipsi SCN, with CD11b mRNA levels significantly
increased across all CCI conditions compared to Sham+DM/pDNA-Ctrl treated mice (F(4,
29) = 3.77, P < 0.05). (E) The general T cell marker CD3 (Cd3e) is elevated in sciatic tissue
following CCI surgery, with CD3 mRNA expression significantly increased across all CCI
conditions compared to Sham+DM/pDNA-Ctrl treated mice (F(4, 29) = 3.77, P < 0.05). (F)
Post-surgical mRNA transcript levels of anti-inflammatory cytokine TGF-β1 are greatly
increased across all CCI conditions compared to Sham+DM/pDNA-Ctrl treated mice (F(4,
31) = 11.13, P < 0.0001). N = 5-9 mice/group for treatment groups, as indicated on graphs.
(G-L) Complementary protein analysis for ipsi SCN from the same animals previously
assessed for mRNA analysis (A-F). Baseline protein levels are not significantly different
between WT Naïve and IL-10 KO Naïve groups (N = 2-3 mice/group) for all targets (data
not shown; P > 0.05): TNF, IL-1β, IFN-γ, IL-6, CXCL1, and IL-12p70. No significant
differences were observed between Sham conditions (Sham+DM/pDNA-Ctrl and
Sham+DM/pDNA-IL-10) for all protein targets (P > 0.05). (G) Pro-inflammatory cytokine
TNF protein expression levels were elevated across all CCI conditions compared to
Sham+DM/pDNA-IL-10 (F(4, 28) = 15.54, P < 0.0001). (H) In most CCI conditions, protein
levels for the pro-inflammatory cytokine IL-1β are significantly increased in ipsi SCN
compared to Sham+DM/pDNA-IL-10 (F(4, 28) = 4.33, P < 0.01). (I) Protein levels for the
pro-inflammatory cytokine IFN-γ are greater in most CCI conditions compared to
Sham+DM/pDNA-IL-10 (F(4, 28) = 5.97, P < 0.01). (J) IL-6, a pro-inflammatory cytokine,
is significantly increased in ipsi SCN for most CCI conditions compared to
Sham+DM/pDNA-IL-10 (F(4, 27) = 3.47, P < 0.05). (K) CXCL1 (a.k.a. KC/GRO), a
neutrophil chemoattractant, is significantly elevated following CCI surgery compared to
Sham+DM/pDNA-IL-10 (F(4, 27) = 6.45, P < 0.001). (L) No significant increases in IL12p70, a pro-inflammatory cytokine downstream of CpG-activated TLR-9, were observed
for any condition (F(4, 28) = 1.46, P > 0.05). For protein analyses, N = 6-8 mice/group as
indicated, and protein levels are presented as Mean + SEM. For mRNA analyses, N = 5-9
mice/group as indicated, and mRNA levels (Mean ± SEM) are normalized to 18S rRNA
and graphically presented relative to mean WT Naïve levels. Post-hoc multiple
comparisons via Fisher’s LSD (α = 0.05; *P < 0.05; **P < 0.01; ***P < 0.001; ****P <
0.0001).
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Figure 5: Intrathecal non-viral IL-10 gene therapy alters lumbar cytokines and
decreases microglial activation.
Characterization of isolated cytokines and microglial-specific mRNA from the lumbar
spinal cord collected on Day 12 after i.t. IL-10 gene therapy injection (Day 17 postsurgery). (A-F) Baseline transcription levels are not significantly different between WT
Naïve and IL-10 KO Naïve groups (N = 2 mice/group) for all targets (P > 0.05): Tmem119,
Tnf, Il1b, Ccl2, and Tgfb1. (A) mRNA transcript levels for the pro-inflammatory cytokine
TNF (Tnf) and (C) the pro-inflammatory chemokine CCL2 (Ccl2) were elevated only in
allodynic controls, with significantly less TNF and CCL2 mRNA expression observed in
pain-relieved CCI+DM/pDNA-IL-10 vs. allodynic CCI+Saline/pDNA-IL-10 mice (TNF:
F(4, 26) = 6.18, P < 0.01) (CCL2: F(4, 26) = 8.10, P < 0.0001). (B) No significant differences
in mRNA transcript levels for the pro-inflammatory cytokine IL-1β (Il1b) were detected
(F(4, 24) = 0.6927, P > 0.05). (D) No significant differences in mRNA levels for antiinflammatory cytokine TGF-β1 (Tgfb1) were detected for any condition (F(4, 25) = 0.77, P
> 0.05). (E) mRNA transcript levels for the microglial marker TMEM119 (Tmem119) were
elevated in allodynic CCI controls, but not in pain-relieved CCI+DM/pDNA-IL-10 mice.
Additionally, TMEM119 mRNA levels in pain-relieved CCI+DM/IL-10 treated mice were
significantly less than for allodynic CCI+Saline/IL-10 mice (F(4, 26) = 8.24, P < 0.001).
mRNA levels (Mean ± SEM) are normalized to 18S rRNA and graphically presented
relative to mean WT Naïve levels. Post-hoc multiple comparisons via Fisher’s LSD (α =
0.05; *P < 0.05; **P < 0.01; ***P < 0.001).
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Figure 6: Intrathecal non-viral IL-10 gene therapy decreases astrocyte activation in
the lumbar spinal cord dorsal horn.
Absolute threshold behavioral responses for (A) ipsilateral and (B) contralateral hindpaws
are shown. Again replicating our prior results illustrated in Figs. 1 and 2, BL responses to
low threshold mechanical stimuli were similar between all groups (ipsilateral, F(4, 15) = 1.25,
P > 0.05; contralateral, F(4, 15) = 48.84, P < 0.001). For data collected between BL through
Day 5, a main effect of time (ipsilateral, F(2, 30) = 306.14, P < 0.001; contralateral, F(2, 30) =
221.66, P < 0.001) was observed, again replicating our prior data (Figs. 1 and 2). After
behavioral assessment on Day 5 post-surgery, all mice received an i.t. co-injection of
pDNA-IL-10 (3μg in 7.5μL) with DM (25μg in 3μL) vs. DM/pDNA-Control, pDNA-IL85

10 with saline, DM with saline, or saline alone. Following injection, a main effect of time
(ipsilateral, F(8, 120) = 35.817, P < 0.001; contralateral, F(8, 120) = 42.82, P < 0.001) and an
interaction of time and treatment (ipsilateral, F(32, 120) = 9.81, P < 0.001; contralateral, F(32,
120) = 13.53, P < 0.001) were revealed. Comparisons between groups show that on Day 2
post-injection, CCI+DM/pDNA-IL-10-treated mice exhibit bilateral reversal from
allodynia (ipsilateral, P < 0.001; contralateral, P < 0.001) compared to CCI+Saline/pDNAIL-10-treated control mice, and these mice never return to allodynia. Surprisingly, on Day
3 post-injection, DM/Saline and DM/pDNA-Ctrl treated mice reverse from allodynia
(ipsilateral, P < 0.001; contralateral, P < 0.001) but on Day 6 post-injection both control
groups begin to return to bilateral allodynia (ipsilateral, F(3, 45) = 6.27, P < 0.01;
contralateral, F(3, 45) = 5.62, P < 0.01). These transient effects of DM on pain thresholds
was previously observed in data from separate experiments represented in Fig. 2. N = 4
mice/group for all behavioral conditions. (C-J) Representative images (20x objective) of
GFAP-stained lumbar spinal cord dorsal horn sections from tissues collected on Day 12
post-injection that were part of the image analysis. (K-L) Image analysis of acquired
GFAP-stained images of ipsilateral and contralateral lumbar spinal cord dorsal horn
revealed a main effect of gene therapy treatment (F(7, 19) = 6.71, P < 0.001; F(7, 19) = 5.64, P
< 0.01, respectively). Acquired GFAP-stained images of contralateral lumbar spinal cord
dorsal horn are not shown, as the images appear highly similar to those from the ipsilateral
lumbar spinal cord. Statistical analyses reveal no significant ipsilateral or contralateral
differences in GFAP fluorescence intensity between WT Naïve and IL-10 KO Naïve
tissues. IL-10 KO+CCI un-injected mice exhibit heightened ipsilateral GFAP fluorescence
intensity compared to IL-10 KO Naïves and are not significantly different than CCI+Saline
or CCI+ DM/Saline conditions. Bilaterally, GFAP immunoreactive fluorescence intensity
levels are greater in IL-10 KO+CCI+DM/pDNA-Ctrl mice and CCI+Saline/pDNA-IL-10
mice compared to IL-10 KO Naïve mice, but do not differ significantly from each other.
Pain relieved IL-10 gene therapy treated mice (IL-10 KO+CCI+DM/pDNA-IL-10) reveal
significantly less GFAP fluorescence intensity compared to allodynic gene therapy controls
(IL-10 KO+CCI mice treated with either DM/pDNA-Ctrl or Saline/pDNA-IL-10), and are
not significantly greater than IL-10 KO Naïves. Bar graphs represent Mean + SEM.
Superimposed outlines in images (C-J) demarcate the unique dorsal horn regions of
interest for each slice. For immunohistochemical analyses, N = 3-4 mice per group, as
indicated. Post-hoc multiple comparisons via Fisher’s LSD (α = 0.05; *P < 0.05; **P <
0.01; ***P < 0.001).
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CHAPTER III
Mannose receptor-mediated anti-inflammatory effects are
independent of interleukin-10

Abstract

Mannose receptor (MR; CD206) activation by D-mannose (DM) induces antiinflammatory signaling and has been utilized as an effective adjuvant for improved nonviral interleukin-10 (IL-10) gene therapy for treatment of peripheral neuropathic pain. MRmediated anti-inflammation is IL-10-independent, but little is known about the cellular
mechanisms and intracellular pathways involved. Furthermore, the cellular inflammatory
environment required for MR-induced anti-inflammation and transgene adjuvant effects
are not well understood. To investigate these questions, combinations of DM and plasmid
DNA encoding a therapeutic IL-10 transgene (pDNA-IL-10) were incubated with
peritoneal macrophages (PMs) from C57BL/6 (wildtype; WT) and IL-10 deficient (IL-10
KO) mice under the following conditions: a) co-stimulation with lipopolysaccharide (LPS)
for 24 or 36 hours, b) 12 hours LPS priming followed by 12 or 24 hours of co-stimulation
with or without LPS, or c) 36 hours incubation in the absence of LPS (unstimulated).
Unstimulated WT PMs do not reveal any significant differences in nitric oxide (NO), a
critical pro-inflammatory mediator and indicator of cell stress, following treatment with
DM or DM/pDNA-IL-10. NO levels are effectively decreased by both DM and
DM/pDNA-IL-10 following LPS co-stimulation in both WT and IL-10 KO PMs.
DM/pDNA-IL-10 treatment following LPS priming resulted in significant decreases in NO
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produced by WT PMs. This effect was abolished in both WT and IL-10 KO LPS-primed
PMs when subsequently co-stimulated with either LPS+DM or LPS+DM/pDNA-IL-10.
IL-10 protein levels following co-stimulation with LPS+DM or LPS+DM/pDNA-IL-10 in
WT cells were not significantly higher than LPS alone, and no IL-10 protein was detectable
in any IL-10 KO treatment condition. Together, these preliminary data indicate that MRmediated anti-inflammation potently decreases NO production by an IL-10-independent
mechanism. Additionally, the current report indicates that the inflammatory status of MRexpressing cells plays a key role in the efficacy of DM as an anti-inflammatory adjuvant.
Future work is required to understand the (1) downstream signaling pathways responsible
for both MR-mediated decreases in NO, and (2) optimal DM/pDNA-IL-10 cell culture
dose-formulations to explore MR-mediated improvements in non-viral transgene therapy.
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1. Introduction
The mannose receptor (MR; CD206) is a C-type lectin receptor known to recognize
glycoconjugates that terminate in mannose, fucose, or N-acetyl glucosamine (Taylor et al.,
2005). MR is expressed by macrophages, dendritic cells, and microvascular endothelial
cells, as well as in nervous tissues by astrocytes, microglia, Schwann cells, and select
populations of neurons (Takahashi et al., 1998; Burudi et al., 1999; Linehan et al., 1999;
Burudi and Regnier-Vigouroux, 2001; Galea et al., 2005; Baetas-da-Cruz et al., 2009;
Martinez-Pomares, 2012). In addition to its role in clearance of endogenous molecules like
collagen, lysosomal hydrolases, and tissue-type plasminogen activator (t-PA), it has been
implicated in recognition of mannosylated residues present on certain pathogens (Otter et
al., 1991; Taylor et al., 2005; Martinez-Pomares, 2012; Sedaghat et al., 2014).
Though many simply consider MR to be an endocytic pattern recognition receptor
(PRR), a growing literature supports that MR activation is associated with antiinflammatory signaling. MR expression is increased on populations of anti-inflammatory
“alternatively activated” macrophages (Gordon, 2003; Martinez-Pomares, 2012; Martinez
and Gordon, 2014a). Additionally, activation of MR increases anti-inflammatory signaling.
For instance, crosslinking of MR on dendritic cells leads to increased secretion of antiinflammatory interleukin-10 (IL-10) and IL-1 receptor antagonist (IL-1RA) with
concurrent decreases in levels of pro-inflammatory cytokines like IL-1β and tumor necrosis
factor (TNF) (Chieppa et al., 2003). Administration of D-mannose (DM), a hexose sugar
and MR ligand, induces protective ant-inflammatory signaling that attenuates pathology in
a rodent model of acute lung injury (Zhang et al., 2004; Zhang et al., 2005; Xu et al., 2015).
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Heightened pro-inflammatory signaling is implicated in chronic peripheral
neuropathic pain. Following peripheral nerve damage glial cells (i.e. astrocytes, microglia,
and satellite glia) in the spinal cord and dorsal root ganglia (DRG), perhaps with help from
trafficking immune cells (i.e. macrophages), secrete an abundance of pro-inflammatory
mediators which are critical for the induction and maintenance of chronic neuropathic pain
symptoms (Milligan and Watkins, 2009; Grace et al., 2014; Ji et al., 2016). Interleukin-10
(IL-10) is a potent anti-inflammatory cytokine shown to reverse chronic pain by decreasing
glial activation and the expression of pain-relevant pro-inflammatory mediators like IL-1β,
TNF, nitric oxide (NO) (Milligan et al., 2012). One of the most effective routes has been
to administer IL-10 via intrathecal (i.t.) non-viral transgene using a naked plasmid
encoding the IL-10 gene (pDNA-IL-10) to treat neuropathic pain (Milligan et al., 2012).
Recent work has demonstrated that non-viral IL-10 gene therapy is dramatically improved
(e.g. enduring pain relief resulting from a single small dose of pDNA-IL-10) when coinjected with DM (Dengler et al., 2014; Vanderwall et al., 2018). Intriguingly, control i.t.
injections of DM alone or with a control plasmid are able to induce transient pain relief. It
has been hypothesized that DM-mediated transient pain relief occurred through MR
activation with consequent increased expression of endogenous IL-10 (Dengler et al.,
2014). However, both enduring and transient pain relief were observed following i.t.
DM/pDNA-IL-10 or DM alone, in neuropathic mice deficient in endogenous IL-10 (IL-10
KO) (Vanderwall et al., 2018). Together these data indicate that MR activation is
associated with both IL-10 dependent and IL-10 independent anti-inflammatory signaling
mechanisms.
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Macrophages express MR, are highly phagocytic, and are known migrate to the
DRG following peripheral nerve damage, making them prime targets for application of
both DM and DM/pDNA-IL-10 gene therapy. To better understand the cellular
mechanisms of MR-mediated anti-inflammation leading to transient pain relief and
improved transgene efficacy, MR stimulation was examined in vitro using macrophages
collected from C57BL/6 (WT) and IL-10 KO mice. While still preliminary, the current
report demonstrates that MR-mediated decreases in NO production are IL-10-independent.

2. Materials and Methods

2.1 Animals

All experiments were performed using adult male mice (8-9 weeks of age). C57BL/6J
(WT; RRID: IMSR_JAX:000664) or B6.129P2-Il10tm1Cgn/J (IL-10 KO; RRID:
IMSR_JAX:002251) mice were purchased from Jackson Laboratories (Bar Harbor, ME,
USA) and maintained in specific-pathogen free conditions. Prior to handling, all animals
were acclimated to the mouse colony at the University of New Mexico (UNM) Health
Sciences Center Animal Facility for a minimum of 7 days. Animals were housed in groups
of 3-5 at 23˚ + 2˚C in light controlled rooms (12:12 light:dark; lights on at 6:00am) and fed
standard rodent chow and water ad libitum. All procedures were approved by the
Institutional Care and Use Committee (IACUC) of the UNM Health Sciences Center and
conducted in accordance to the NIH Guidelines for the Care and Use of Laboratory
Animals.
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2.2 Cell Culture Media

Ex vivo cell culture experiments were performed with DMEM/F-12 media (Sigma-Aldrich;
Cat#: D6421) supplemented with 2mM GlutaMAX™ (Gibco; Cat#: 35050061), 20U/mL
penicillin with 20μg/mL streptomycin (Gibco; Cat#: 15140122), and with either 10% fetal
bovine serum (FBS) or 10% Cell-Ess® (Bio-Ess Laboratories). Cell-Ess® is a chemically
defined serum replacement that is free of any animal components. This approach was
initially chosen as an alternative to traditional serum based-supplements in an effort to
increase reproducibility and to avoid ill-defined effects of exposure to non-murine proteins.
Unfortunately, before full completion of these experiments, Bio-Ess business operations
were terminated, so subsequent experiments were performed with traditional 10% FBS
instead of 10% Cell-Ess.

2.3 Isolation and ex vivo culture of resident peritoneal macrophages (PMs)

Lavage of the peritoneal cavity provides easy access to a population of mature tissue
macrophages, and while anatomically distinct from peri-spinal meningeal tissue
macrophage (location of the i.t. route), peritoneal macrophages (PMs) provide an
approximation of spinal tissue macrophage responses to DM and/or DM/pDNA-IL-10 gene
therapy. Resident PMs were isolated as previously described (Zhang et al., 2008). Briefly,
mice were euthanized separately by CO2 inhalation. The abdomen was sprayed with 70%
ethanol. A small incision in the abdominal skin was made using forceps and blunt
dissection scissors, then manual retraction of the skin was applied to carefully expose the
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peritoneal wall. Using a 25-G needle (Becton Dickinson & Co.; Cat#: 305122) attached to
a 10mL syringe, 8-10mL of ice cold sterile PBS (pH = 7.4; Gibco; Cat#: 10010023) was
gently injected into the peritoneal cavity, avoiding puncture of internal organs. The
distended abdomen was vigorously shaken side-to-side for ~1.5min. A 20-G needle
(Becton Dickinson & Co.; Cat#: 305175) attached to a 10mL syringe was used to extract
~6-7mL of peritoneal lavage fluid. The needle was removed from the syringe prior to
deposition of the collected lavage fluid into a 50mL conical tube on ice. Lavage samples
from 6 animals were pooled per experimental round, such that each experiment represents
pooled PMs from 6 mice. Samples were spun at 400 x g for 10min at 4˚C. The resulting
pellet was resuspended in 1mL Red Blood Cell Lysis Buffer (Sigma; Cat#: R7757) and
incubated on ice for 5 minutes, diluted with 15-20mL of complete DMEM/F-12, pelleted
at 400 x g for 10min at 4˚C, and then resuspended in 1mL of complete DMEM/F-12 media
for counting. Live cells were quantified on a hemocytometer using trypan blue staining
exclusion criteria. Cell suspensions were then adjusted for plating.
PMs were distributed 2.0-2.5 x 105 cells/well on a 24-well tissue culture plate
(Corning; Cat#: 353847) in 500μL complete DMEM/F-12 and incubated at 37˚C. After
resting 13-14hrs, old media was replaced with fresh complete DMEM/F-12 media and
treatment conditions were applied, reaching a total volume of 500μL/well (2-3 well
replicates per treatment condition).
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2.4 Preparation of plasmid DNA

Plasmid DNA was prepared as previously described (Vanderwall et al., 2018). Briefly, the
plasmid vector pDNA-IL-10 (also called pTR2-CB-mIL10F129S) used in these studies is the
mouse IL-10 equivalent of a rat IL-10 plasmid that was fully described previously and is
derived from an adeno-associated virus-2 (AAV-2) expression cassette (Milligan et al.,
2005b; Milligan et al., 2006b). It consists of a 5.9 kilobase pair circular plasmid DNA
(pDNA) containing a transcriptional cassette consisting of a hybridized cytomegalovirus
enhancer/chicken beta-actin promoter (CMV enh/CB pro) driving expression of the mouse
Il10 gene containing a point mutation (mIL-10F129S), and a simian virus 40 (SV40)
polyadenylation signal (SV40 poly(A)). The transcription cassette is flanked by 149 bp
inverted terminal repeat (ITR) sequences. The plasmid backbone contains an ampicillin
resistance (Ampr) gene, as well as components unique to the original AAV-2 expression
cassette such as an intervening sequence (IVS; intron). The control plasmid (pDNA-Ctrl)
is an analogous plasmid cassette lacking the IL-10 transgene. Plasmids were amplified in
SURE2 Supercompetent Cells (Agilent Technologies; Cat#:200152) because the ITR
elements are often deleted in conventional E. coli strains (Milligan et al., 2006b) resulting
in reduced transgene expression. Plasmid DNA was isolated using an EndoFree Plasmid
Giga Kit (Qiagen; Cat#:12391) according to manufacturer’s instructions. Purified
endotoxin-free plasmids were resuspended in sterile Dulbecco’s PBS (1x) (Gibco;
Cat#:14190-144) with 3% sucrose, aliquoted, and stored at -20˚C.
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2.5 Stimulation and Transfection Experimental Approaches

Experimental Approach #1. Following collection of BL supernatant for NO
assessment (see section 2.5), media was replaced and WT PMs were incubated for 36 hours
at 37˚C in 500mL complete DMEM/F-12 (w/ 10% Cell-Ess) with various stimulation
conditions. Treatment conditions are as follows: a) 50mM DM, b) 100mM DM, c) pDNACtrl (5ug/well), d-g) 50mM DM + pDNA-IL-10 (0.005, 0.05, 0.5, or 5.0μg per well), or h)
100mM DM + pDNA-IL-10 (0.5μg/well). Cells were incubated with treatment media for
36 hours. Supernatant samples were collected after 36 hours of treatment for NO detection
(see section 2.5). D-mannose (Sigma-Aldrich; Cat#:M6020) was dissolved in sterile
isotonic sterile saline (0.9% w/v sodium chloride; Ricca Chemical Company; Cat#: 721032). N = 2 wells per condition.
Experimental Approach #2. Performed similarly to Experimental Approach #1, but
with the following changes. After the initial resting period, PMs from IL-10 KO or WT
mice were primed by incubation for 12 hours at 37˚C in 500mL complete DMEM/F-12 (w/
10% FBS or 10% Cell-Ess as indicated in figure legends) with or without
lipopolysaccharide (LPS; 500ng/mL). After this priming step, supernatants were replaced
with fresh media containing the following treatment conditions: a) media alone, b) LPS
(500ng/mL), c) LPS + 100mM DM, or d) LPS + DM + pDNA-IL-10 (5μg/well). Cells
were allowed to incubate with treatment media for 12 or 24 hours. Supernatant was
collected for NO detection at BL, following LPS priming, and at 12 and 24 hours treatment.
Supernatant was collected for IL-10 protein detection at 24 hours of treatment. N = 2-3
wells per condition.
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Experimental Approach #3. Performed similarly to Experimental Approach #2, but
with the following changes. After the initial resting period, PMs from IL-10 KO or WT
mice were co-stimulated for 24 or 36 hours with the following treatment conditions: a)
media alone, b) LPS (1μg/mL), c) LPS (500ng/mL), d) LPS + 100mM DM, or e) LPS +
DM + pDNA-IL-10 (5μg/well). Supernatant was collected for NO detection at BL, and at
12, 24, and 36 hours of treatment. Supernatant was collected for IL-10 protein detection at
36 hours of treatment. N = 2-3 wells per condition.

2.6 IL-10 protein and nitric oxide production

Supernatant samples (50μL per biological replicate) for assessment of NO production were
collected (see section 2.4 for timepoints). Samples were immediately measured using a
commercially available Griess Reagent System following the manufacturer’s instructions
(Promega Corp.; Cat#: G2930).
Supernatant samples (120uL per biological replicate, per target) were collected at
the terminal timepoint and stored at -20˚C for future protein analysis. Frozen supernatant
samples were later thawed at room temperature and assessed in duplicate for IL-10 protein
content by enzyme-linked immunosorbent assay (ELISA) via a mouse IL-10 Quantikine
ELISA kit (R&D Systems; Cat#: SM1000B) per the manufacturer’s instructions.
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2.7 Statistical Analyses

Nitric oxide and IL-10 protein data were analyzed by one-way ANOVA in GraphPad
PRISM version 7.02 (GraphPad Software Inc.; RRID:SCR_002798). To control the type I
error rate during all multiple comparisons, Fisher’s LSD test (reported with adjusted P
values) was applied for post hoc examination of possible group differences selected a
priori. Unpaired t-tests were applied to NO and IL-10 data for additional group
comparisons selected a priori. The threshold for statistical significance for all comparisons
was set a priori to α = 0.05. All data are presented as the Mean + Standard Error of the
Mean (SEM).

3. Results

3.1 MR-mediated modulation of nitric oxide in unstimulated wildtype PMs

Preliminary in vitro studies were designed with the goal of understanding in vivo
parameters under which MR activation induces anti-inflammatory signaling that may aid
in non-viral IL-10 transgene uptake. Prior in vivo studies indicate that MR-mediated
improvements in IL-10 gene therapy may be most efficacious in a pre-existing
inflammatory environment (e.g. the DRG of a neuropathic mouse), perhaps due to
increased MR availability (Vanderwall et al., 2018). To test this, DM/pDNA-IL-10
treatment was first examined in unstimulated PMs collected from WT mice (Fig. 1A).
Plated cells were exposed for 36 hours to various combinations and concentrations of DM,
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pDNA-IL-10, and pDNA-Ctrl. Nitric oxide levels were within detectable range, but no
significant differences were detected by unpaired t-tests for any a priori selected
comparisons. These results support that exposure to plasmid DNA, whose inherent CpGs
could induce a pro-inflammatory response via toll-like receptor 9 (TLR9), is not
stimulatory at the chosen concentrations. These data further suggest DM-mediated antiinflammation and improvement in non-viral IL-10 gene therapy require pre-existing
pathology.

3.2 MR-mediated modulation of nitric oxide in LPS stimulated wildtype PMs

To recapitulate in vitro the in vivo DRG conditions in which DM and DM/pDNA-IL-10
had therapeutic effects in neuropathic rodents (Dengler et al., 2014; Vanderwall et al.,
2018), DM/pDNA-IL-10 therapy was examined in the context of LPS co-stimulation and
LPS priming (Fig. 1B-C). For LPS co-stimulation, WT PMs were treated with either
media, LPS (500ng/mL), or co-stimulated with LPS plus DM/pDNA-IL-10 (500mM;
5μ/well) for 24 hours (Fig. 1B). Cells stimulated with LPS alone had significantly higher
(P < 0.05) NO levels than untreated controls at the 24 hour timepoint (F(2, 3) = 23.11, P <
0.05). Interestingly, co-stimulated cells treated with LPS+DM/pDNA-IL-10 had
significantly less NO than cells stimulated with LPS alone (P < 0.05).
For LPS priming (Fig. 1C), WT PMs were incubated for 12 hours with LPS, at
which time the LPS-containing media was replaced with fresh media (no LPS) and
incubated for 12 hours with or without DM/pDNA-IL-10. LPS pre-treated cells that did
not receive DM/pDNA-IL-10 had significantly higher levels of NO at 12 hours of treatment
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(t(2) = 5.72, P < 0.05). Taken together, these findings further support that DM-mediated
effects are not readily discernable outside the context of an inflammatory environment.

3.3 MR activation decreases nitric oxide in an IL-10-independent manner

In preliminary studies (Fig 1), the observed decreases in NO production following
treatment with DM/pDNA-IL-10 could have resulted from successful IL-10 transgene
expression, DM alone, or a synergistic combinatorial effect. To address whether IL-10
transgene expression is critical for the observed suppression of NO, DM vs. DM/pDNAIL-10 treatment was examined in the presence or absence of endogenous IL-10 by utilizing
WT vs. IL-10 KO PMs (Fig. 2).
For co-stimulation (Fig 2A), cells were incubated for 36 hours with combinations
of LPS (0.5μg/mL), DM (100mM), and pDNA-IL-10 (5μg/500μL). Additional cells
exposed to either a high dose of LPS (1.0μg/mL) or media alone served as positive and
negative controls, respectively, for both NO and IL-10 production. A statistically
significant difference in NO production was detected by one-way ANOVA for both WT
and IL-10 KO treatment conditions (F(9, 18) = 13.26, P < 0.0001). In WT PMs, multiple
comparisons reveal a significant decrease in NO production in LPS+DM co-stimulated
cells compared to cells that received LPS alone (P < 0.05). A significant decrease in NO
was also observed in WT PMs treated with LPS+DM/pDNA-IL-10 compared to LPS alone
(t(4) = 7.36, P < 0.01). Significant decreases in NO were also observed in IL-10 KO PMs
given either LPS+DM (P < 0.0001) or LPS+DM/pDNA-IL-10 (P < 0.0001). Interestingly,
while WT and IL-10 KO cells given the high dose LPS were not significantly different (P
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> 0.05), when given low dose LPS, IL-10 KO cells produced significantly higher levels of
NO compared to WT cells (P = 0.001). Despite a dramatic LPS response of NO in the
absence of endogenous IL-10, both DM and DM/pDNA-IL-10 returned NO production to
basal levels in co-stimulated IL-10 KO cells (P > 0.05).
For LPS priming (Fig. 2B), WT and IL-10 KO PMs were incubated for 12 hours
with or without LPS, at which time the priming media was removed and replaced with
fresh media containing no stimulants (media alone), LPS, LPS+DM, or LPS+DM/pDNAIL-10. These cells were then incubated in these treatment conditions for 24 hours. A
statistically significant group difference in NO production was detected by one-way
ANOVA for both WT and IL-10 KO treatment conditions (F(7, 16) = 9.64, P < 0.001).
Multiple comparisons reveal increased NO production following LPS stimulation in both
WT (P < 0.01) and IL-10 KO PMs (P < 0.0001). As before, IL-10 KO PMs produce
significantly higher NO levels compared to WT (P < 0.01). Surprisingly, regardless of WT
or IL-10 KO background, neither DM nor DM/pDNA-IL-10 led to significant decreases in
NO levels in LPS-primed PMs compared to those given LPS alone (P > 0.05).
IL-10 protein production was assessed (Fig 2C-D) at the termination of both LPS
co-stimulation and LPS priming culture paradigms. For LPS co-stimulated WT PMs (Fig
2C), statistically significant group difference in IL-10 protein production was detected by
one-way ANOVA (F(7, 16) = 9.64, P < 0.001). Multiple comparisons reveal significantly
elevated IL-10 protein production in PMs treated with high dose LPS (P < 0.0001), low
dose LPS (P < 0.05), LPS+DM (P < 0.01), and LPS+DM/pDNA-IL-10 (P < 0.01)
compared to unstimulated controls. Surprisingly, no significant differences were observed
in IL-10 protein levels between LPS, LPS+DM, and LPS+DM/pDNA-IL-10 treated WT
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PMs (P > 0.05). For LPS pre-treated WT PMs (Fig 2D), no statistically significant group
difference in IL-10 protein production was detected by one-way ANOVA (F(3, 8) = 3.18, P
> 0.05). IL-10 levels were below the level of detection across all IL-10 KO conditions in
both stimulation paradigms (data not shown).
Though still preliminary, these data further support an IL-10-independent antiinflammatory pathway downstream of MR that decreases expression of nitric oxide.
Additionally, current findings indicate that the timing of pro-inflammatory stimulation has
a major impact on the ability of MR activation to promote anti-inflammation.

4. Discussion

The current pilot data provide new clues into the cellular mechanisms underlying MRmediated anti-inflammation. The function of MR activation as an adjuvant for non-viral
gene therapy required further refinement of the experimental conditions. Preliminary
studies in PMs indicate that MR activation by DM mediates decreased NO in LPS
stimulated cells by an IL-10-independent mechanism. Additionally, MR effects were most
significant when DM was applied simultaneously with LPS/TLR4 stimulation, as NO was
unaffected by DM in LPS pre-treated PMs. DM alone vs. DM/pDNA-IL-10 were
indistinguishable regarding modulation of NO. Interestingly, NO production by IL-10 KO
and WT PMs were indistinguishable when exposed to high dose LPS, but low dose LPS
unmasked significant increased NO production in IL-10 KO PMs. Though not statistically
significant, a clear trend was observed for increased IL-10 production in WT PMs costimulated with LPS+DM/pDNA-IL-10 or LPS+DM compared to LPS alone, with the

101

highest IL-10 protein levels observed in gene treated cells (excluding high dose LPS).
Thus, these data support that MR activation induces anti-inflammatory signaling that are
independent of IL-10, and that further work is required to identify ideal culture conditions
by which to unambiguously observe DM/pDNA-IL-10 effects in vitro.

4.1 IL-10 regulation of nitric oxide production in stimulated PMs

IL-10 KO mice have previously been shown to have exaggerated pro-inflammatory
immune responses following stimulation that predispose this mouse strain to significant
disease pathology (Kuhn et al., 1993; Berg et al., 1995). For instance, IL-10 KO mice
experience higher mortality levels and increased production of serum pro-inflammatory
mediators, including NO, following acute endotoxic shock compared WT mice (Berg et
al., 1995). Splenocytes from IL-10 KO mice infected with Helicobacter hepaticus produce
higher levels of NO than WT counterparts when both cell types were re-challenged ex vivo
with bacterial antigen (Kullberg et al., 1998). The current data are consistent with prior
findings and demonstrate heightened NO production in IL-10 KO vs. WT PMs following
LPS stimulation. Interestingly, this effect was not observed following stimulation with a
higher dose of LPS. It is possible that a ceiling effect caused by heightened TLR4
stimulation prevents further discrimination between the IL-10 KO and WT backgrounds.
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4.2 IL-10 transgene expression in reduced nitric oxide levels

Though no exogenous IL-10 protein was detected by ELISA in IL-10 KO PMs, IL-10
transgene may still have been successfully expressed at low levels. It is possible that the
clinically relevant low levels of pDNA-IL-10 applied in these studies might only allow for
very low levels of IL-10 protein production. This could hinder the ability to detect IL-10
in IL-10 KO PMs or to distinguish endogenous from exogenous IL-10 in WT PMs. Prior
studies in IL-10 KO mice indicate that a very low level of IL-10 transgene expression is
necessary for potent therapeutic effects (Vanderwall et al., 2018). For proof of concept,
future studies may aim to increase the doses of pDNA-IL-10 or the adjuvant DM applied.
Additionally, mRNA analysis may provide a more sensitive assay for detection of IL-10
transcriptional activation.

4.3 Mannose receptor regulation and inflammation

A goal of this report was to examine whether an ongoing pro-inflammatory environment
was necessary or beneficial for DM-mediated improvement of non-viral IL-10 gene
therapy. Relevant to these culture studies, in vivo pro-inflammatory mediators increase in
expression at the level of the DRG following peripheral nerve damage. For instance,
damaged peripheral neurons express the pro-inflammatory chemokine CCL2 and
consequently recruit macrophages to the DRG (Schreiber et al., 2001; Kwon et al., 2015;
Zhang et al., 2016). TLR4 signaling has also been implicated in both neuropathic pain
pathogenesis and activation of macrophages (Tanga et al., 2005). Prior work by Vanderwall
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et al. demonstrate that i.t. injection of DM/pDNA-IL-10 into IL-10 KO mice leads to IL10 transgene expression in the ipsilateral, but not contralateral, DRG of neuropathic mice
while not expressed in sham controls (Vanderwall et al., 2018). Furthermore, ipsilateral
DRG of neuropathic IL-10 KO mice have increased mRNA levels for MR and the IL-10
receptor as compared to sham controls (Vanderwall et al., 2018). Therefore, to recapitulate
the in vivo DRG environment, the TLR4 ligand was applied as either a co-stimulant or a
priming agent.
While co-stimulation of WT and IL-10 KO PMs with LPS plus DM or DM/pDNAIL-10 resulted in decreased NO production compared to those given LPS alone, this effect
was not observed in LPS pre-treated cells. This is surprising, as it was hypothesized that
the priming paradigm more readily replicates the in vivo model in which DM or
DM/pDNA-IL-10 produce pain relief in chronically allodynic animals. This incongruity
could be explained by evidence that macrophage stimulation, especially via TLR4, can be
linked to decreased expression and functionality of MR. For instance, bone marrowderived macrophages (BMDMs) treated with LPS or LPS/PMA have 60% and 70% less
surface binding, respectively, of radiolabeled mannose-BSA (Shepherd et al., 1990;
Chroneos and Shepherd, 1995). A similar effect is observed in microglia from neonatal
rats, which when cultures with LPS for 48 hours exhibit 45% less MR protein in whole cell
lysates (Marzolo et al., 1999). In a more recent study, in a mouse model of acute lung
injury, mice given intratracheal LPS have significantly less MR mRNA levels 6 hours later,
but this effect is dose-dependently reversed by co-administration with i.v. DM (Xu et al.,
2015). These data suggest LPS priming results in decreased availability of MR, thereby
preventing efficacy of either DM or DM/pDNA-IL-10. The discrepancy in MR-mediated
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anti-inflammation between the two priming experiments (Figs. 1C and 2B) may be due to
the change in experimental design by which LPS exposure, which had been previously
been completely removed after priming (Fig 1C), was extended into the treatment window
in Fig. 2B. The reprieve from LPS exposure in the initial priming experiment (Fig. 1C)
may have allowed for less MR downregulation, thereby allowing for DM efficacy. These
findings further support that the DM and DM/pDNA-IL-10-mediated decreases in NO
production occur through an MR-dependent process. Future investigations aim to
unambiguously confirm the role of MR in these effects via blockade with MR antagonists.

4.4 MR and IL-10-independent mechanisms of nitric oxide regulation

The current report provides intriguing evidence that MR-mediated decreases in nitric oxide
production is IL-10-independent. TGF-β signaling may provide an alternative to IL-10
downstream of MR-activation. TGF-β is an anti-inflammatory cytokine previously shown
to decrease expression of NO. For instance, application of TGF-β prevents increased NO
expression in BMDMs co-stimulated with LPS/IFN-γ (Corradin et al., 1993). In an in vitro
model of myocardial hypoxic-ischemia, TGF-β pretreatment of cardiomyocytes prevents
hypoxia-induced increases in both inducible nitric oxide synthase (NOS) mRNA levels and
NO production (Chen et al., 2001).

TGF-β may also be linked to increased activity of

arginase, an enzyme that antagonizes the effect of NOS (Boutard et al., 1995).
Interestingly, MR-mediated arginase induction appears to be utilized as an escape
mechanism by intracellular pathogens, an effect that may be linked to MR-induced changes
in MAPK signaling cascades (Garrido et al., 2011; Nzoumbou-Boko et al., 2017). There is
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significant cross-talk between the TGF-β and MAPK signaling pathways (Gui et al., 2012).
While no single pathway has been definitively described to be responsible for MRmediated intracellular signaling, TGF-β may serve as an intriguing target of future
investigation.

5. Conclusion

In summary, these data provide evidence that MR activation induces anti-inflammatory
effects that are IL-10-independent, and which potently suppress NO production in LPS costimulated cells. Additionally, the current report indicates that the timing of cellular
activation and MR expression are key determinants of DM-induced anti-inflammatory
signaling. Further work is required to better understand the downstream signaling pathways
that are critical for MR-mediated anti-inflammatory and transgene adjuvant effects.
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CHAPTER III FIGURES

Figure 1: MR activation decreases nitric oxide production in LPS-stimulated WT
peritoneal macrophages
Peritoneal macrophages (PMs) were pooled from six WT mice and cultured ex vivo for 1314 hours prior to stimulation or treatment (N = 2 wells per condition; 2-2.5 x 105 cells in
500μL/well; 24 well plate). (A) Unstimulated PMs were incubated for 36 hours with
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combinations of DM (50mM or 100mM), pDNA-IL-10 (0.005μg, 0.05μg, 0.5μg, or
5μg/well), or a control plasmid (pDNA-Ctrl; 5μg/well) as indicated. No significant
differences in NO levels were detected by unpaired t-tests for any a priori selected
comparisons were detected after 36 hours treatment (P > 0.05). (B) PMs were co-stimulated
for 24 hours with combinations of LPS (500ng/mL), D-mannose (DM; 100mM), and nonviral plasmid DNA encoding interleukin-10 (pDNA-IL-10; 5μg/well). A statistically
significant difference between groups for NO production was detected (F(2, 3) = 23.11, P <
0.05). Cells stimulated with either LPS had significantly higher NO levels than untreated
controls at 24 hours (P < 0.05). Cells co-stimulated with LPS+DM/pDNA-IL-10 had
significantly less NO than LPS stimulated PMs (P < 0.05). (C) PMs were primed for 12
hours with LPS (500ng/mL) prior to stimulation in the absence of LPS for 12 hours with
either DM/pDNA-IL-10 or media alone. A statistically significant difference between LPSprimed groups for NO production was detected (t(2) = 5.72, P < 0.05), with less NO
observed following 12 hours of DM/pDNA-IL-10 treatment vs. media. For NO analyses,
levels are presented as Mean + SEM. Post-hoc multiple comparisons via Fisher’s LSD or
unpaired t-test (α = 0.05; *P < 0.05).
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Figure 2: MR-mediated anti-inflammation is independent of interleukin-10
Peritoneal macrophages (PMs) were pooled separately from six WT and six IL-10 KO mice
and cultured ex vivo for 13-14 hours prior to stimulation or treatment (N = 2-3 wells per
condition; 2.5 x 105 cells in 500μL/well; 24 well plate). (A) PMs were co-stimulated for
36 hours with combinations of LPS (0.5μg/mL), D-mannose (DM; 100mM), and non-viral
plasmid DNA encoding interleukin-10 (pDNA-IL-10; 5μg/well). Additional PMs exposed
to either a high dose of LPS (1.0μg/mL) or media alone served as positive and negative
controls, respectively, for both NO and IL-10 production. At 36 hours of co-stimulation, a
statistically significant difference between groups for NO production was detected (F(9, 18)
= 13.26, P < 0.0001). In WT PMs, multiple comparisons reveal a significant decrease in
NO production in LPS+DM co-stimulated cells compared to cells that received LPS alone
(P < 0.05). WT PMs treated with LPS+DM/pDNA-IL-10 had significantly more NO
compared to LPS treatment alone (t(4) = 7.36, P < 0.01). Significant decreases in NO were
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also observed in IL-10 KO PMs given either LPS+DM or LPS+DM/pDNA-IL-10 also had
significantly less NO than LPS treatment alone (P < 0.0001). WT and IL-10 KO cells given
the high dose LPS were not significantly different (P > 0.05), but low-dose LPS-stimulated
IL-10 KO PMs produced significantly more NO compared to WT cells (P = 0.001). Both
DM and DM/pDNA-IL-10 returned NO production to basal levels in co-stimulated IL-10
KO cells (P > 0.05). (B) PMs were primed with either LPS (0.5μg/mL) or media for 12
hours prior to a 24 hour treatment with either LPS, LPS+DM (100mM), or
LPS+DM/pDNA-IL-10 (5μg/well). At 24 hours of treatment, a statistically significant
difference was detected between groups for NO production (F(7, 16) = 9.64, P < 0.001).
Multiple comparisons reveal increased NO production following LPS stimulation in both
WT (P < 0.01) and IL-10 KO PMs (P < 0.0001), with IL-10 KO NO levels significantly
higher than for WT (P < 0.01). Neither DM nor DM/pDNA-IL-10 had significantly
different NO levels than LPS alone (P > 0.05). (C-D) Supernatant IL-10 protein levels
were assessed at the termination of both LPS co-stimulation and LPS priming paradigms.
IL-10 levels were below the level of detection across all IL-10 KO conditions in both
stimulation paradigms (data not shown). (C) IL-10 protein levels were significantly
elevated following LPS co-stimulation in WT PMs (F(7, 16) = 9.64, P < 0.001), with elevated
IL-10 detected for WT PMs treated with high dose LPS (P < 0.0001), low dose LPS (P <
0.05), LPS+DM (P < 0.01), and LPS+DM/pDNA-IL-10 (P < 0.01) compared to
unstimulated controls. There were no significant differences in IL-10 protein levels
between LPS, LPS+DM, and LPS+DM/pDNA-IL-10 treated WT PMs (P > 0.05). (D) Pretreated WT PMs reveal no statistically significant group difference in IL-10 protein
production (F(3, 8) = 3.18, P > 0.05). For NO and IL-10 protein analyses, levels are presented
as Mean + SEM. Post-hoc multiple comparisons via Fisher’s LSD or unpaired t-test (α =
0.05; *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001).
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CHAPTER IV
DISCUSSION

1. Chronic pain as a chronic inflammatory disease

1.1 Chronic inflammatory diseases

Acute inflammation is protective, occurs in response to infection or injury, has both
rapid onset (minutes to hours) and a short duration (hours to days), and works to help an
organism return to homeostasis (Medzhitov, 2008; Kumar et al., 2015). In contrast, chronic
inflammation may last weeks to months, often well beyond the regulated phase of
protective usefulness (Kumar et al., 2015). Though the mechanisms of chronic
inflammation are less well understood than for acute inflammation, chronic inflammatory
diseases are typically associated with abnormal or inappropriate activation or accumulation
of immune competent cells, such as T cells and macrophages, and expression of proinflammatory mediators such as cytokines, chemokines, reactive oxygen species or
nitrogen species (Medzhitov, 2008). Pathological chronic inflammatory processes are key
components of many immune disorders, including rheumatoid arthritis (RA), inflammatory
bowel disease (IBD), psoriasis, multiple sclerosis (MS), cancer, and systemic lupus
erythematosus (SLE) (Lassmann et al., 2012; Rubin et al., 2012; Holmdahl et al., 2014;
Boehncke, 2015; Joosten et al., 2016).
In the central nervous system (CNS), resident glial cells, including astrocytes and
microglia, are implicated in the pathogenesis of chronic neuroinflammatory diseases such
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as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), and Parkinson’s disease
(PD) (Becher et al., 2016). A growing body of evidence supports that chronic pain should
also be categorized as a chronic inflammatory disease (De Leo et al., 2006; Scholz and
Woolf, 2007; Milligan and Watkins, 2009; Grace et al., 2014). The aim of this section,
“Chronic pain as a chronic inflammatory disease”, is to explore the etiology of key pain
pathologies and the pre-clinical rodent findings that demonstrate underlying chronic
neuroimmune dysfunction.

1.2 HIV-associated sensory neuropathies

Human immunodeficiency virus (HIV) has reached pandemic levels, with an estimated
36.7 million people infected as of 2015 and roughly 5,700 possible new infections per day
(Aziz-Donnelly and Harrison, 2017). The introduction of highly active antiretroviral
therapy (HAART) in 1996 has allowed for prolonged lifespans and improved disease
prognosis in many HIV-infected individuals (Chesney, 2003; Wang et al., 2004; Verma et
al., 2005). In regions where HAART is accessible, HIV is now considered a chronic illness
rather than an acute fatal illness (Verma et al., 2005). Due to increased patient survival, the
prevalence of neuropathic disorders resulting from HIV and antiretroviral therapies have
increased in incidence. Of the various types of neuropathy observed in HIV-infected
patients, HIV sensory neuropathy (HIV-SN) is the most common with an estimated
prevalence of 31-50% (Aziz-Donnelly and Harrison, 2017).
Because they are difficult to clinically distinguish, the term “HIV-SN” is generally
accepted to encompass both HIV-associated distal sensory polyneuropathy (HIV-DSP) and
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antiretroviral toxic neuropathy (ATN) (Hao, 2013; Aziz-Donnelly and Harrison, 2017).
The most common complaints of HIV-SN are hyperalgesia and allodynia which typically
initiate at the soles of the feet, gradually ascending proximally up the lower extremity and
which may eventually involve the fingertips in a bilateral “stocking and glove” distribution
(Hao, 2013).
Histologically, HIV-SN is characterized by significant changes at the level of the
dorsal root ganglion (DRG). Loss of sensory neurons with Wallerian degeneration of long
axons (e.g. those that innervate the extremities) and unmyelinated C fibers is observed
alongside infiltration of the DRG by HIV-infected macrophages (Hao, 2013; AzizDonnelly and Harrison, 2017). These trafficking leukocytes release pro-inflammatory
cytokines and chemokines that serve to activate the surrounding neuroimmune milieu,
sensitizing nearby sensory neurons, enabling the appearance of allodynia and hyperalgesia.
There are no naturally occurring rodent lentiviruses, so pre-clinical rodent models
of HIV-SN involve application of the HIV viral envelope protein gp120 (Milligan et al.,
2000; Herzberg and Sagen, 2001; Milligan et al., 2001; Oh et al., 2001) or use of transgenic
mice engineered to express gp120 (Burdo and Miller, 2014). Gp120 interacts with both
neurons and glia through binding to both CXCR4 and CXCR5 chemokine receptors leading
to neurotoxicity and peripheral axonal damage (Pardo et al., 2001; Jaggi et al., 2011a).
Recombinant gp120 administered intrathecally induces rapid onset thermal hyperalgesia
and mechanical allodynia (Milligan et al., 2000; Milligan et al., 2001). Similar symptoms
were observed following peripheral application directly to the sciatic nerve (Herzberg and
Sagen, 2001). In both exposure paradigms, either direct or indirect glial activation resulted
in observed pain behaviors. Like macrophages, both astrocytes and microglia can become
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HIV infected (Hao, 2013). Further, astrocytic and microglial activation by viral proteins
like gp120 lead to additional increases in pro-inflammatory cytokines, like IL-1β, TNF,
and IL-6, resulting in enhanced pain states (Milligan et al., 2001; Schoeniger-Skinner et
al., 2007).
Though less obvious than for HIV-DSP, ART is also linked with chronic
inflammatory processes. Nucleoside reverse transcriptase inhibitors (NRTIs), a key
component of the HAART pharmacologic cocktail, are known to be neurotoxic and to
cause dose-dependent peripheral neuropathy (Manji, 2000). Systemic administration of
NRTIs have been used to model HIV-SN mediated by ATN (Hao, 2013). Pre-clinical
studies in rodents and examination of human tissue samples indicate that ATN is closely
linked to mitochondrial dysfunction, with NRTIs able to inhibit replication of
mitochondrial DNA (mtDNA) (Gardner et al., 2014). The resulting depletion in mtDNA in
turn causes neurotoxicity via mitochondrial

respiratory chain and oxidative

phosphorylation deficits (Yamaguchi et al., 2002). Spinal microgliosis also occurs in
response to NRTI administration (Blackbeard et al., 2012). Additionally, increased
expression of the astrocyte activation marker glial fibrillary acidic protein (GFAP) is
observed in the spinal cord dorsal horn with concurrent increases in colocalization of proinflammatory TNF (Zheng et al., 2011).

1.3 Cancer-related and chemotherapy-induced peripheral neuropathy

Cancer-related pain has multiple causes and mechanisms. The tumor, its metastases, or
anticancer treatments themselves can induce both nociceptive and neuropathic pain
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(Bouhassira et al., 2017). In a recent systematic review with meta-analysis, pain prevalence
in cancer patients was found to be 39.3% after curative treatment, 55.0% during anti-cancer
treatment, and 66.5% in advanced, metastatic, or terminal disease (van den Beuken-van
Everdingen et al., 2016). Additionally, moderate to severe pain was reported in 38% of all
cancer patients (van den Beuken-van Everdingen et al., 2016). Another systematic review
calculated that the prevalence of cancer patients with neuropathic pain ranges from 19% to
39.1% (Bennett et al., 2012). The World Health Organization (WHO) promotes a threestep analgesic ladder for management of cancer-related pain, starting with non-opioids for
mild pain, combinations of weak opioids and non-opioids for mild-moderate pain, and the
addition of strong opioids like morphine for severe pain (Dalal and Bruera, 2013).
Unfortunately, many patients are unable to achieve adequate pain control, and opioids
themselves put patients at risk of a host of unwanted side effects, including tolerance and
addiction.
Chronic inflammation is indicated in the pathogenesis of cancer-related
neuropathic pain. It has been shown that malignant cells, tumor infiltrating lymphocytes
(TILs), and tumor stromal cells release numerous pain-modulating molecules, including
pro-inflammatory cytokines like TNF, IL-1β, and IL-6, pro-inflammatory mediators like
prostaglandins, and even hydrogen ions from the often hypoxic tumor core (Brown and
Ramirez, 2015).
Use of anti-cancer agents themselves are known to cause chemotherapy-induced
peripheral neuropathy (CIPN) which presents as a length-dependent peripheral neuropathy
characterized by ‘die-back’ of unmyelinated sensory fibers (Brown and Ramirez, 2015).
Neuronal cell bodies housed in DRG reside outside the blood-brain-barrier and are
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particularly vulnerable to the neurotoxic effects of cancer chemotherapeutics (Carozzi et
al., 2015).
Rodent models of CIPN have been critical in understanding the role of chronic
inflammation in this pathological pain process. For instance, paclitaxel-mediated CIPN has
been shown to induce heightened expression of pain-related pro-inflammatory cytokines
IL-1 and TNF mRNA alongside increased expression of the macrophage marker CD11b in
the DRG. These markers of inflammation were significantly decreased in pain-relieved
rodents treated with anti-inflammatory non-viral interleukin-10 gene therapy (Ledeboer et
al., 2007c). Additionally, intravenous paclitaxel-based mouse models have demonstrated
activation of satellite glial cells and infiltration of macrophages to the DRG and increased
immunoreactivity of astrocytic GFAP in the spinal cord (Peters et al., 2007). Interestingly,
paclitaxel-treated rodents also reveal activated satellite glial cells with increased gapjunction mediated coupling, a feature that likely contributes to the spread of neuropathic
pain resulting in a diffusive pain pattern (Warwick and Hanani, 2013). Astrocytic gap
junctions in the spinal cord have also been implicated in the pathogenesis of oxaliplatinmediated CIPN (Yoon et al., 2013). Both DRG neurons and spinal astrocytes increase
expression of the chemokine CCL2 in paclitaxel-induced CIPN (Zhang et al., 2013).

1.4 Fibromyalgia

Fibromyalgia describes chronic widespread musculoskeletal pain for which no alternative
cause can be identified (Sluka and Clauw, 2016). Though fibromyalgia is characterized as
having no apparent tissue damage, patients often present with diffuse hyperalgesia and
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allodynia (Sluka and Clauw, 2016). This widespread sensitivity suggests that the main
disorder may be caused, at least in part, by changes in spinal pain processing machinery as
opposed to a localized disease (Clauw, 2009). Fibromyalgia is not considered an
inflammatory process, but inflammatory mediators may play a role in this pathologic pain
process (Gur and Oktayoglu, 2008; Slade et al., 2011; Sturgill et al., 2014; Mendieta et al.,
2016; Sluka and Clauw, 2016). For instance, a systematic review demonstrated consistent
increases in serum levels of IL-6, IL-8, and IL-1 receptor antagonist in patients with
fibromyalgia (Üçeyler et al., 2011). Other literature supports that serum levels of antiinflammatory IL-10 are decreased in the patients with chronic widespread pain, a disease
category of which fibromyalgia is a major subgroup (Üçeyler et al., 2006). Additionally, a
growing body of evidence suggests that individuals with fibromyalgia may have
abnormalities in the function of the hypothalamic-pituitary-adrenal (HPA) axis, a system
known for potent modulation of the immune system. For instance, females with
fibromyalgia have significantly increased circulating levels of ‘neuroendocrine-stress’
markers, such as cortisol and noradrenaline, compared to healthy controls (Bote et al.,
2012).
Unfortunately fibromyalgia does not yet have a well-established “go-to” animal
model (DeSantana et al., 2013). The most common and well-characterized models involve
repeated insults to musculature. For instance, in a “non-inflammatory model”, acidic saline
(pH = 4.0-5.0) is repeatedly injected intramuscularly leading to widespread hyperalgesia
in the absence of tissue damage or inflammation (DeSantana et al., 2013; Sluka and Clauw,
2016). A related model combines repeated acid saline injections with muscle fatigue, also
providing hyperalgesia without overt inflammation or tissue damage (DeSantana et al.,
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2013; Sluka and Clauw, 2016). In a different approach, stress, such as exposure to loud
sounds, also seems capable of producing muscular and cutaneous hyperalgesia lasting
weeks after the initial stressor (DeSantana et al., 2013; Sluka and Clauw, 2016).
Though these models claim to be “non-inflammatory” in nature, a growing body of
evidence supports that immune activation is involved in pathogenesis of fibromyalgia-like
symptoms. For instance, following repeated intramuscular acid saline injection, depletion
of macrophages from the injection site via local application of clodronate liposomes
prevents exercise-induced hyperalgesia (Gregory et al., 2016). In a separate model of
fibromyalgia, an inflammatory insult is applied intramuscularly (carrageenan or IL-6),
inducing acute hyperalgesia. After sensitivity resolves, prostaglandin E2 (PGE2), a proinflammatory mediator associated with inflammatory pain, is injected into the same
muscle, leading to hyperalgesia that lasts for at least 2 weeks. In contrast, animals that do
not receive the initial inflammatory insult experience hyperalgesia that resolves within 4
hours (Dina et al., 2008b; Dina et al., 2008a). Additionally, in the sound stress model of
chronic widespread pain, IL-6 and TNF appear to play a critical role in enhancement of
muscular hyperalgesia to in response to subsequent immune challenge (Dina et al., 2011).
There is still much unknown about the pathophysiology of fibromyalgia. Despite
the lack of overt tissue damage or inflammation, the data from human patients and preclinical animal models suggest that pathological pain in this disease may result, at least in
part, from inappropriate activation of immune cells with production of pro-inflammatory
mediators that may in turn modulate neuronal function in the CNS and/or PNS. Whether
resident tissue cells, such as myocytes may also be a pathologic source of these proinflammatory mediators is yet to be determined.
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1.5 Chronic low back pain

Low back pain is estimated to affect upwards of 80% of all individual at some point in their
lifetime and is reported to be the fifth most common reasons for all physician visits in the
United States of America (Patrick et al., 2014). Chronic low back pain can be caused by
problems with lumbar intervertrebral disc damage (e.g. herniation, displacement, or
degeneration), compression of spinal nerve roots, or inflammatory conditions such as
autoimmune disorders (Strong et al., 2013). Thus far, no therapy for back pain investigated
in randomly assigned clinical trials has shown substantial benefit for symptoms associated
with this broad condition (Borenstein, 2013).
Though lower back pain is typically initiated by a mechanical disorder, proinflammatory signaling pathways can be engaged that lead to enhanced pain states. This
paradigm is commonly observed in discogenic lower back pain. The intervertebral disk
(IVD) becomes more vulnerable to damage with age with progressive weakness of the
nucleus pulposus and degeneration of the annulus fibrosus. If sufficient pressure is then
placed on the IVD, the nucleus pulposus may experience protrusion, herniation, or
sequestration (Borenstein, 2013). Radicular pain may develop if a nearby spinal nerve root
becomes compressed by extruded disc material (Borenstein, 2013). Interestingly, IVD
tissue samples from patients with chronic low back pain show increased expression of painrelated pro-inflammatory molecules, including TNF, IL-1, IL-6, IL-8, PGE2, neutrotrophic
growth factor (NGF), and inducible nitric oxide synthase (Ohtori et al., 2015). Beyond
exacerbating radiculopathy, these pro-inflammatory mediators could increase pain
pathology by directly activating nerve endings present within the IVD itself, the neuronal
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cell bodies of which reside in the DRG. Immunohistochemical studies indicate that many
different sensory fibers present within the IVD are sensitive to classical pain
neurotransmitters like substance P (SP) or calcitonin gene-related peptide (CGRP) (Ohtori
et al., 2015).
Animal models support a role for inflammatory processes in the pathogenesis of
discogenic low back pain. For example, Li et al. demonstrated that posterior puncture of
the annulus fibrosus in rats induces 3 weeks of mechanical allodynia (Li et al., 2014).
Expression levels of mRNAs for TNF, IL-1β, and IL-6 were significantly elevated for 2-3
weeks following puncture, a timeframe that coincides with observed pain behavior.
Immunohistochemical evidence also suggested that TNF and IL-1β protein expression is
elevated in the DRG of allodynic animals that received posterior annulus fibrosus puncture
(Li et al., 2014). Cytokine signaling is also implicated in radicular back pain models. Sasaki
et al. developed a model in which nucleus pulposus harvested from a coccygeal disk is
applied to the nearby L5 spinal nerve root (Sasaki et al., 2007). This results in at least 4
weeks of mechanical allodynia that could be temporarily relieved by single intravenous
administration of TNF-neutralizing antibodies at early timepoints (0 or 6 days postsurgery), but not at a later timepoint (20 days post-surgery) (Sasaki et al., 2007). These
data support that the cytokine TNF is important for the initial stages of pain pathology but
may not be as important for maintenance of allodynia in this model of radicular back pain.
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2. Interleukin-10: Small but mighty

2.1 Cellular sources of IL-10

Discovered nearly 30 years ago by Mosseman and colleagues (Fiorentino et al., 1989;
Moore et al., 1990), interleukin-10 (IL-10) was originally called cytokine synthesis
inhibitory factor (CSIF). First identified to be produced by type 2 helper T cells (Th2), IL10 was shown to limit the actions of Th1 cells through potent inhibition of proinflammatory cytokines like tumor necrosis factor (TNF) and interferon-γ (IFNγ), while
simultaneously limiting proliferative capacity by decreasing levels of IL-2 (Fiorentino et
al., 1989). It is now appreciated that this powerful anti-inflammatory cytokine is expressed
by almost all leukocytes, including T and B cells, dendritic cells, γδ T cells, NK cells,
neutrophils, and eosinophils (Saxena et al., 2015). Microglia and astrocytes are known to
express IL-10 in the central nervous system (Kwilasz et al., 2015). Other non-immune
sources of IL-10 include keratinocytes, epithelial cells, and some tumor cells (Mosser and
Zhang, 2008). It has been hypothesized that the broad cellular capability of expression
allows for rapid availability, but that it may also be important for the
“compartmentalization” of IL-10’s actions (Saxena et al., 2015). This is supported by IL10’s very short half-life (~1-2hrs) (Li et al., 1994; Le et al., 1997; Milligan et al., 2005a;
Mosser and Zhang, 2008).
Cell type-specific roles for IL-10 expression seem to be key in the regulation of
autoimmune and physiological inflammatory responses. For instance, regulatory T cells
(Tregs) are key expressers of IL-10 and suppress inflammation and autoimmunity, a
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function that was first appreciated following examination of Treg dysfunction in mouse
models of inflammatory bowel disease (Groux et al., 1997; Asseman et al., 1999). IL-10 is
also known to promote proliferation of B cells, and regulatory B cell-derived IL-10 is
protective against experimental autoimmune encephalomyelitis (EAE) (Fillatreau et al.,
2002).

2.2 IL-10 Expression and signaling

The genes for both mouse IL-10 (mIL-10; Il10) and human IL-10 (hIL-10; IL10) are found
on chromosome 1 and encoded by 5 exons (Moore et al., 2001). Several intracellular
signaling cascades are important for induction of IL-10 expression, including mitogen
activated protein kinase (MAPK), extracellular signal-regulated kinase (ERK), and p38
(Saraiva and O'Garra, 2010). These cascades are commonly initiated by stimulation of key
pathogen recognition receptors (PRRs), like toll-like receptor 4 (TLR4), by pathogen
associated molecular patterns (PAMPs; e.g. bacterial lipopolysaccharide [LPS]) (LoboSilva et al., 2016).
Though not well understood, IL-10 expression may also be stimulated following
activation of PRRs by endogenous alarmins, also called danger associated molecular
patterns (DAMPs). For example, heat shock protein 70 (HSP70) is a DAMP known to
activate TLR2 and TLR4, and appears to have anti-inflammatory activity through induction
of IL-10 in a variety of cell types (Luo et al., 2008; Wieten et al., 2009; Wachstein et al.,
2012; Borges et al., 2013). Similarly, surfactant protein-A (SP-A) is a possible TLR4
agonist and in vitro stimulation of bone marrow-derived macrophages with this DAMP
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dose-dependently increased protein expression of both IL-10 and pro-inflammatory tumor
necrosis factor (Guillot et al., 2002). High mobility group box protein I (HMGB1), a
DAMP known to activate both toll-like receptor 4 (TLR4) and receptor for advanced
glycation endproducts (RAGE), increases myeloid-derived suppressor cell (MDSC)mediated production of IL-10 in vitro (Parker et al., 2014). Interestingly, following
instances of severe tissue damage (e.g. trauma, major surgery, or pancreatitis) some
patients develop an immune suppression similar to sepsis-induced immunoparalysis
(Nakos et al., 2002; Allen et al., 2006; Ho et al., 2011; Cornell et al., 2012). It is thought
that DAMP activation of PRRs may be linked to increased IL-10 expression, though
current data is correlational in nature, e.g. demonstrating increased IL-10 serum levels.
While significant room for investigation is evident, these findings suggest that at least some
DAMPs may serve to “dampen” the immune system in order to prevent an overzealous
immune response to tissue damage.
Following PRR activation, IL-10 expression is regulated both at transcriptional and
post-transcriptional stages (Powell et al., 2000; Mosser and Zhang, 2008). IL-10 is the
target of many transcription factors, such as Sp1, Sp3, STAT3, C/EBPβ, C/EBPδ, IRF-1,
c-Maf, AP-1, CREB, MEF2d, and NF-κB (Mosser and Zhang, 2008; Yang et al., 2015;
Lobo-Silva et al., 2016). Post-transcriptional instability of IL-10 mRNA is influenced by
the presence of a long segment of 3’-untranslation region (3’-UTR) which contains class
II AU-rich elements which can be targeted by the RNA-binding protein tristetraprolin
(TTP), leading to rapid degradation (Anderson, 2008). IL-10 is also known to be regulated
by microRNAs (miRs) (Lobo-Silva et al., 2016). For example, miR-466l-3p inhibits IL-10
production in microglia following stimulation of the PRR TLR4 (Brown and Yin, 2013).
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In contrast, miR-181 overexpression has been shown to increase IL-10 production
following lipopolysaccharide (LPS) stimulation (Hutchison et al., 2013).
Following translation and extracellular release, IL-10 monomers homodimerize
and bind to the IL-10 receptor, a class II receptor which itself functions as a heterotetramer
of IL-10R1 (IL-10Rα) and IL-10R2 (IL-10Rβ) (Moore et al., 2001). IL-10R1 is critical for
high affinity binding with the IL-10 homodimer that in turn leads to IL-10R2-mediated
intracellular signal transduction via engagement of both Janus kinase 1 (Jak1; associated
with IL-10R1) and Jak kinase 2 (Tyk2; associated with IL-10R2) with subsequent
phosphorylation and activation of transcription factors like STAT3 (Sabat et al., 2010).

2.3 Biological effects

IL-10 signaling pleiotropically suppresses inflammation. For instance, IL-10 reduces
antigen presenting capability in monocytes/macrophages by decreasing trafficking of
major histocompatibility complex class II (MHCII) to the cellular membrane and by
inhibiting expression of the co-stimulatory molecule CD86 (Kwilasz et al., 2015). IL-10
also suppresses production of numerous pro-inflammatory cytokines, chemokines, reactive
oxygen species, and nitrogen species. For example, IL-10-mediated SOCS1 and SOCS3
production prevents nuclear translocation of NF-κB, which thereby prevents transcription
of pro-inflammatory cytokines like interleukin-1β (IL-1β) or tumor necrosis factor (TNF;
a.k.a. TNFα), and pro-inflammatory chemokines like C-C motif chemokine ligand 2
(CCL2) (Schottelius et al., 1999; Murray, 2005; Yoshimura et al., 2007; Milligan et al.,
2012). IL-10 is known to enhance expression of natural antagonists to pro-inflammatory
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signaling, for instance, by increasing production of IL-1 receptor antagonist (IL-1RA) and
a soluble form of TNF receptor (Moore et al., 2001).
IL-10 is a powerful modulator of immune cell activation and proliferation. IL-10
promotes differentiation of anti-inflammatory macrophages, often called “M2”
alternatively activated cells (Mantovani et al., 2004; Martinez and Gordon, 2014b). It also
limits CD4+ T cell proliferation and pro-inflammatory cytokine production, thereby
diminishing functionality of TH1 and TH17 cells (Schuetze et al., 2005; McKinstry et al.,
2009). IL-10 is not only a key product of Tregs, but it also promotes differentiation of this
anti-inflammatory cell type (Asseman et al., 1999; Palomares et al., 2014; Brockmann et
al., 2017).
IL-10 plays a critical role in suppression of innate immune cell function. IL-10
production by stimulated innate immune cells, like macrophages, is considered “late”
compared to the initial pro-inflammatory response, with robust expression appearing hours
after stimulus exposure (Sabat et al., 2010; Iyer and Cheng, 2012). Delayed expression
appears to temper the acute inflammatory response, thereby preventing uncontrolled
inflammation. In addition to decreasing pro-inflammatory signaling, IL-10 acts on local
innate immune cells to promote “scavenger” functions, such as increased phagocytic
activity, which consequently aid in peripheral tolerance against persistent antigen exposure
(Buchwald et al., 1999; Saxena et al., 2015).
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2.4 Role of IL-10 in disease

IL-10 expression is tightly regulated, and inappropriate under- or overproduction can result
in a host of immune diseases. For instance, IL-10 overproduction is pathologic in systemic
lupus erythematosus (SLE), EBV-associated lymphomas, and skin malignancies such as
melanoma (Stewart et al., 1994; Yue et al., 1997; Grondal et al., 1999). Additionally, IL10 overexpression can be detrimental to host defense and clearance of infectious agents
(Sabat et al., 2010).
Decreased IL-10 expression is often present in diseases for which persistent or
aberrant immune activation exists. In humans, polymorphisms in IL-10 have been
identified in association with inflammatory bowel disease (IBD) by genome wide
association studies (GWAS), and IL-10R mutations have been observed in patients with
severe IBD (Schreiber et al., 1995; Franke et al., 2008; Moran et al., 2013). In pre-clinical
studies, IL-10 deficient (IL-10 KO) mice develop spontaneous enterocolitis over the course
of months, reflecting a loss of mucosal homeostasis in the normal response to commensal
bacteria (Kuhn et al., 1993; Berg et al., 1996; Ward et al., 1996; Sartor, 1997; Sellon et al.,
1998; Asseman et al., 1999). The role of IL-10 in intestinal homeostasis by Tregs is
critically important for maintenance of healthy responses to gut microbiota that interface
with intestinal mucosa, and when lost can result in IBD (Asseman et al., 1999). Other
diseases for which decreased IL-10 expression has been identified, often linked to
enhanced clinical severity, include neuropathic pain, multiple sclerosis, rheumatoid
arthritis, psoriasis, type 1 diabetes (T1D), and multiple sclerosis (Sabat et al., 2010;
Kwilasz et al., 2015; Saxena et al., 2015). Interestingly, decreased IL-10 expression is
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observed in pain-relevant neural tissues in animal models and is correlated with
neuropathic pain behaviors, as further discussed below.

2.5 Utilization of IL-10 therapeutics for treatment of neuropathic pain and other chronic
inflammatory diseases

Given that decreased IL-10 expression is linked to a variety of immune pathologies,
numerous therapeutic approaches to increase IL-10 protein levels have been examined.
Unfortunately, due to IL-10’s short half-life and blood brain barrier impermeability,
systemic administration of IL-10 is not likely to be clinically feasible for most diseases (Li
et al., 1994; Kastin et al., 2003). Psoriasis is a disease for which direct IL-10 application
by subcutaneous injection of IL-10 protein at the site of psoriatic plaques has had promising
results in a phase 2 clinical trial (Asadullah et al., 1999; Khusru et al., 2004). While direct
application of IL-10 protein to the site of pathology is capable of producing immediate
symptom relief, effects are often transient and may require repeated injections (Milligan et
al., 2005a).
A hallmark of efficacious IL-10-based therapeutics is the ability to increase local
concentrations of IL-10 in a timely manner (Saxena et al., 2015). A novel approach for the
treatment of IBD has been administration of transgenically modified bacteria, such as
Lactococcus lactis, that secrete IL-10 directly into the intestinal lumen. This method
successfully prevented the onset of colitis in IL-10 KO mice, reduced inflammation in other
mouse models of IBD (Steidler et al., 2000), and was successfully applied in a phase 1 and
2a clinical trials (http://ClinicalTrials.gov identifier NCT00729872) (Braat et al., 2006;
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Marlow et al., 2013). While intriguing, use of bacterial vectors for local IL-10 production
may not be feasible for all other inflammatory diseases, though recent work suggests that
it may be translatable for the treatment of T1D (Robert and Steidler, 2014).
IL-10 gene therapy has also proven to be a promising approach, especially for
treatment for chronic pain. For instance, non-replicating adeno virus, adeno-associated
virus, and herpes simplex viral vectors carrying an IL-10 transgene have all been examined
for intrathecal (i.t.) treatment of neuropathic pain. While potent pain relief was observed
in animal models of chronic pain, effects were short-lived (Wood et al., 1996; Milligan et
al., 2005a; Milligan et al., 2005b; Beutler and Reinhardt, 2009; Lau et al., 2012; Zheng et
al., 2014b, a). It is hypothesized that transient pain relief is a result of complications
associated with the use of a viral vector, such as an immune response following exposure
to viral antigens (Kwilasz et al., 2015). Non-viral gene therapy is a safer, easier, and less
expensive approach that avoids many of the problems associated with the use of viral
vectors (Glover et al., 2005). Paradoxically, though non-viral gene therapy is considered
the least efficient method of gene transfer, it has been repeatedly demonstrated to provide
profound and long-lasting pain relief in a variety of animal models (Milligan et al., 2006b;
Milligan et al., 2006a; Ledeboer et al., 2007b; Sloane et al., 2009b; Sloane et al., 2009a;
Soderquist et al., 2010b; Milligan et al., 2012; Dengler et al., 2014; Grace et al., 2017;
Vanderwall et al., 2018).
An interesting new approach in IL-10-oriented chronic pain treatments is the
enhanced or stabilized production of the body’s own endogenous IL-10 to basal or
homeostatic levels. Cannabinoids offer one potential option, especially those targeting the
cannabinoid 2 receptor (CB2R). CB2R agonists have been shown to provide profound pain
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relief in two rodent pain models: sciatic chronic constriction injury (CCI) (Wilkerson et
al., 2012a; Wilkerson et al., 2012b) and human immunodeficiency virus (HIV)-1
glycoprotein-120 (gp120)-induced spinal inflammation (Wilkerson et al., 2012a). For
example, AM1710 prevented IL-10 protein deficiency in the spinal cord dorsal horns and
dorsal root ganglia (DRG) of pain-relieved CCI-rats, achieving similar to the levels found
in non-neuropathic sham controls (Wilkerson et al., 2012a). This was observed in concert
with significantly decreased protein expression of the pain-associated pro-inflammatory
mediators IL-1β, phospho-p38MAPK, and glial markers of activation. Similarly, AM1710
decreased IL-1β production in the DRG of pain-relieved gp120-rats (Wilkerson et al.,
2012a). Interestingly, AM1710 failed to reverse light touch sensitivity in CCI-treated IL10 KO mice, supporting a requirement for IL-10 in AM1710-mediated pain relief
(unpublished observations by Erin D. Milligan).
The therapeutic benefit for inducement of basal IL-10 expression levels has been
demonstrated by Dengler and colleagues. They demonstrated that i.t. D-mannose (DM), a
known mannose receptor ligand, induces transient pain relief following a single low-dose
injection in CCI-treated rats. Additional in vitro examination of DM applied to cultured
RAW 264.7 mouse macrophages under conditions mimicking a pro-inflammatory
neuropathic environment (i.e. co-stimulation with LPS) reveal enhanced IL-10 protein
expression when compared to LPS stimulation alone (Dengler et al., 2014). These data
provided rationale for the hypothesis that DM-mediated activation of the mannose receptor
leads to temporary increases in endogenous IL-10 production that underlies transient pain
relief (Dengler et al., 2014).
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The role of increased IL-10 downstream of MR activation has been both supported
and contradicted by investigations of MR signaling in IL-10 KO mice. The NLRP3
inflammasome, which can be induced experimentally by co-stimulation with ATP and
LPS, activates caspase-1 that in turn leads to production of bioactive pro-inflammatory IL1β protein. In a preliminary study, DM pretreatment prior to LPS/ATP co-stimulation
decreased the population of cells that were double positive for NLRP3 protein and caspase1 activation in peritoneal macrophages from wildtype but not IL-10 KO mice (Vanderwall
unpublished data; Appendix A). This early report suggests that IL-10 may be important for
MR-mediated inhibition of the NLRP3-inflammasome. However, IL-10 is not required for
all MR-mediated anti-inflammation. For instance, a recent report by Vanderwall et al.
provides unexpected evidence that i.t. DM continues to provide transient pain relief in IL10 KO mice in the absence of endogenous IL-10 (Vanderwall et al., 2018), refuting the
hypothesis that IL-10 is the required for MR-mediated transient pain relief in IL-10sufficient neuropathic rats. While these data do not exclude a role for enhanced IL-10
production following D-mannose application in wildtype animals, it proves that Dmannose engages other powerful anti-inflammatory mediators sufficient for pain relief.
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Figure 1: Possible IL-10 transgene therapeutic effects and the DRG. (A) The cell
bodies of primary nociceptive neurons reside in the dorsal root ganglia (DRG), with
peripheral terminals in target tissues, and central projections in the spinal cord dorsal horn.
Primary nociceptors communicate with second order neurons that in turn project to the
brain. DRG are encased within a dural sleeve, but reside outside of the subarachnoid space
(SA). A small volume of cerebrospinal fluid (CSF) exits the SA by draining along the
spinal nerves. Lumbar DRG are in close proximity to the cauda equina (not shown), caudal
to the spinal cord proper. Following peripheral damage to the sciatic nerve (e.g. chronic
constriction injury), sensory neurons release neuronal injury signals, such as the chemokine
CCL2, at the level of the DRG and the spinal cord dorsal horn. These injury signals induce
activation of glia (i.e. astrocytes, microglia, and satellite glia), leading to increased
production of pro-inflammatory mediators in both locations. Pro-inflammatory mediators
and neuronal injury signals in the DRG leads to local accumulation of macrophages.
Recruited macrophages may facilitate further production of pro-inflammatory mediators in
the DRG. (B) Intrathecal (subarachnoid) injection of plasmid DNA encoding antiinflammatory IL-10 transgene (pDNA-IL-10) with D-mannose (DM) induces enduring
relief of peripheral neuropathic pain. In potential pathway I, meningeal macrophages may
locally internalize pDNA-IL-10. Chemokines produced in the DRG could attract such
macrophages, leading to local therapeutic expression of the IL-10 transgene. Alternatively,
as in potential pathway II, pDNA-IL-10 and D-mannose may diffuse to the DRG, traveling
with draining CSF. Once present in the DRG, pDNA-IL-10 may be internalized and
expressed by previously recruited macrophages. (C) Local expression of anti-inflammatory
IL-10 transgene in the DRG leads to increased production of anti-inflammatory TGF-β1 as
well as decreased production of pro-inflammatory mediators. This in turn may decrease
production of neuronal injury signals (e.g. CCL2) at the DRG and at the spinal cord dorsal
horn, thereby decreasing activation of both satellite glia and spinal glia and allowing a
return to physiologic pain signaling.
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3. D-mannose: More than just a gene therapeutic adjuvant

3.1 Mannose receptor-mediated anti-inflammatory effects: IL-10 independent pathways

A growing body of evidence supports that mannose receptor (MR; CD206) activation leads
to anti-inflammatory effects. These include increased expression of anti-inflammatory
mediators, like IL-10 or IL-1R antagonist, and decreased expression of pro-inflammatory
mediators, like IL-12, TNF, IL-1β, and NO (Nigou et al., 2001; Chieppa et al., 2003; Pathak
et al., 2005; Zhang et al., 2005; Gazi and Martinez-Pomares, 2009; Allavena et al., 2010;
Dengler et al., 2014). However, though MR activation has been linked with increased IL10, recent work by Vanderwall et al. indicates that IL-10 is not required for a MR-mediated
anti-inflammatory signaling. They demonstrated that intrathecal application of DM in
neuropathic IL-10 KO mice induces transient pain relief (Vanderwall et al., 2018). Given
that pro-inflammatory signaling is critical for the pathogenesis of peripheral neuropathic
pain, this evidence indicates that other anti-inflammatory mediators must be engaged
downstream of MR.
Transforming growth factor-β (TGF-β) may offer a potential avenue for MRmediated anti-inflammation. Virtually all cell types are responsive to TGF-β, which is
expressed by numerous tissues types, including mesenchyme, connective tissue,
endothelium, platelets, glia, and immune cells (Bottner et al., 2000; Sanjabi et al., 2009).
TGF-β signaling, while less predictable than IL-10, can often lead to potent antiinflammatory effects (Bottner et al., 2000; Colak and Ten Dijke, 2017). One of TGF-β’s
most important roles is in generation of regulatory T cells (Tregs). TGF-β1 is important for

133

development of natural thymic-derived (nTregs), as well as peripherally derived Tregs
(pTregs) like T regulatory 1 (TR1) cells or T helper 3 (TH3) cells, and in vitro induced Tregs
(iTregs) (Mills, 2004; Hadaschik and Enk, 2015). Tregs in turn help control autoimmune
responses and regulate normally inflammatory processes by producing anti-inflammatory
cytokines, like TGF-β and IL-10, and other suppressive mechanisms such as conversion of
pro-inflammatory ATP to AMP and adenosine by ectoenzymes (Safinia et al., 2015).
An intriguing new study by Zhang et al. implicates MR signaling in the generation
of Tregs, both in vivo and in vitro (Zhang et al., 2017). They initially observed that naive
CD4+CD25- T cells cultured with 25mM DM for 3 days significantly increase their coexpression of the Treg markers CD25 and Foxp3. They also found that ingestion of Dmannose beginning at 7.5 weeks of age by NOD mice (autoimmune model of type 1
diabetes) prevents the onset of diabetic symptoms until at least 23 weeks of age, whereas
80-90% of control-treated NOD mice developed diabetes by the same age. Interestingly,
they further demonstrated that DM increases Treg production via TGF-β. However, this
does not appear to be accomplished by increasing TGF-β mRNA or total TGF-β protein,
but rather by increasing conversion of latent TGF-β to its active form by an integrin αVβ8dependent mechanism (Zhang et al., 2017).
The report by Vanderwall et al. provides complementary evidence that MR
signaling may be associated with Treg production (Vanderwall et al., 2018). Intrathecal
injection of DM plus a control plasmid (DM/pDNA-Ctrl) or DM plus a plasmid encoding
an IL-10 transgene (DM/pDNA-IL-10) in neuropathic IL-10 KO mice led to transient or
enduring pain relief, respectively, with significantly increased expression of TGF-β mRNA
detected in the ipsilateral lumbar DRG of pain relieved mice that received DM/pDNA-IL-
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10 (Vanderwall et al., 2018). Though mice that received DM/pDNA-Ctrl had TGF-β
mRNA levels similar to sham controls, it is tantalizing to hypothesize that DM/pDNA-Ctrl
mice might also have exhibited elevated TGF-β mRNA levels at an earlier timepoint,
perhaps near the peak of transient pain relief. In this study, DM was administered at only
one timepoint, whereas the most significant effects of DM observed by Zheng et al.
occurred following prolonged exposure to DM (days in vitro, weeks in vivo). This suggests
that the transient pain relief observed in DM treated animals in the absence of IL-10
transgene may have been more stable should repeated injections been applied.
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Figure 2: Pleiotropic effects of D-mannose in spinal non-viral IL-10 gene therapy for
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neuropathic pain. (1) In the absence of gene therapeutic adjuvants like D-mannose (DM),
naked plasmid DNA encoding IL-10 (pDNA-IL-10) likely enters cells by endocytosis. (23) Following internalization, early endosomes containing pDNA-IL-10 may mature to late
endosomes. (4) To avoid degradation by the lysosome, pDNA-IL-10 must escape the
endosome. (5) pDNA-IL-10 must access transcription machinery in the nucleus to produce
mRNA. (6) Transgenic IL-10 mRNA must then survive the intracellular environment long
enough to be translated into therapeutic protein. (7) IL-10 protein expression decreases
pro-inflammatory signaling allowing for relief of neuropathic pain. Free DM is recognized
by the mannose receptor (MR). This interaction may increase phagocytic activity, possibly
improving likelihood of pDNA internalization. MR itself is internalized but recycles from
the early endosome to the plasma membrane, avoiding lysosomal degradation. This
mechanism may improve pDNA endosomal escape (4). Endosomal escape may also be
influenced by signaling effects downstream of MR activation, including increases in antiinflammatory mediators including TGF-β1, IL-10, IL-1 receptor antagonist (IL-1Ra), and
arginase, with decreased expression of pro-inflammatory IL-1β, TNF, and NO (4). These
anti-inflammatory effects may in turn improve survival of transgenic IL-10 mRNA (6).
Anti-inflammatory signaling downstream of MR also likely mediates transient pain relief
when DM is administered in the absence of pDNA-IL-10 (7). Extracellular plasmid
survival may be improved by MR-mediated anti-inflammatory signaling. This, in
combination with MR-mediated increases in phagocytosis, could allow for increased
likelihood of plasmid internalization (1).
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3.2 D-mannose for treatment of chronic pain

D-mannose and MR-mediated anti-inflammatory signaling may be clinically relevant for
the treatment of a variety of chronic pain conditions, not just sciatic peripheral neuropathy,
as explored in this dissertation. DM’s potentially broad applicability stems from its
engagement of both IL-10-independent and IL-10-mediated anti-inflammation (Dengler et
al., 2014; Vanderwall et al., 2018). This means DM may be effective for pain relief in
patients with known IL-10 gene polymorphisms that would prevent normal IL-10
production in response to other therapeutic approaches. DM may also be beneficial for
treatment of pain diseases linked to decreased IL-10 expression, like fibromyalgia (Üçeyler
et al., 2006; Milligan et al., 2012).
DM may be especially helpful in the treatment of pain pathologies that involve proinflammatory signaling at the level of the DRG, such as HIV-SN, discogenic lower back
pain, and CIPN. The DRG is a unique nervous tissue in that it can be therapeutically
accessed by direct, intrathecal, and systemic approaches (Sapunar et al., 2012; Berta et al.,
2017). For instance, DRG lack protection from a capsule, have a very high blood capillary
density, and possess vascular endothelial cells with large fenestrations (Jimenez-Andrade
et al., 2008; Berta et al., 2017). Though prior studies in animal models have treated
neuropathic pain with intrathecal DM, the unique features of the DRG may make systemic
DM treatment a useful approach for patients who are not yet candidates for intrathecal
interventions (Dengler et al., 2014; Saulino et al., 2014; Vanderwall et al., 2018). Systemic
DM may also offer a successful approach for chronic pain processes where the source of
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pathologic pro-inflammatory cytokine production is not well understood or may not be
localized, such as observed in fibromyalgia (Clauw, 2009).
While DM holds promise for the treatment of many pain pathologies, not all pains
or inflammatory processes are equal. For instance, though acute injury may result in
significant physiological pain signaling that may be amplified by local inflammation, it is
unclear whether DM would be useful, or even desirable, for pain control in this scenario.
Non-steroidal anti-inflammatory agents (NSAIDs) are often utilized for their analgesic
actions in acute pain, though whether they are detrimental to normal wound healing that
require inflammatory processes remains controversial (Anderson and Hamm, 2012; Chen
and Dragoo, 2013; Geusens et al., 2013). Therefore, consideration of DM for modulation
of acute inflammatory pain should be approached cautiously. Additionally, it is unclear
whether the same inflammatory processes modified by DM in treatment of chronic
pathological pain would be relevant during acute inflammation. Pain associated with
muscle spasm is another pain pathology that may not be amenable to DM therapy. Muscle
spasm is characterized by a painful brief involuntary tonic contraction that can result from
overstretching of a previously weakened muscle, protective splinting of an injury, muscle
fatigue, or as a centrally mediated phenomenon such as dystonia (Skogseid, 2014; Fricton,
2016). Muscle spasm does not yet appear linked with any inflammatory processes and
therefore DM may not be a likely therapeutic option.
Another therapeutic application for DM may exist as an adjuvant analgesic to
improve efficacy and tolerability of other pain medications, like opioids. An analgesic
adjuvant is a molecule that may not itself possess classical analgesic properties, but is found
to have beneficial properties when used with opioids (Khan et al., 2011). This may allow
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for decreases in opioid tolerance, dosing frequency, or dose size (Khan et al., 2011). There
are a variety of clinically available adjuvant analgesics (e.g. NSAIDs, GABA agonists,
antidepressants, antiepileptics, benzodiazepines, etc.), however many of these induce side
effects that may limit their safety and utility. For instance, benzodiazepines may potentiate
opioid neuropsychological side effects, and NSAIDs are connected with increased risk of
gastrointestinal and renal toxicity (Khan et al., 2011; Harirforoosh et al., 2013). Opioids
are known to induce spinal pro-inflammatory signaling in glial cells through activation of
TLR4, and this signaling has been linked to opioid tolerance (Hutchinson et al., 2008;
Hutchinson et al., 2011). Naloxone, especially the (+)-naloxone isomer, is a TLR4
antagonist that has been shown in pre-clinical and clinical studies to act as an analgesic
opioid adjuvant, reducing tolerance associated with opioidal pain management
(Hutchinson et al., 2008; Hutchinson et al., 2011; Lewis et al., 2012; Leppert, 2014;
Firouzian et al., 2016; Wang et al., 2016). Similarly, it is possible that DM co-treatment
may be useful in the mitigation of opioid-induced pro-inflammatory signaling via its
demonstrated anti-inflammatory effects. Further investigations are required to better
understand the full range of clinical applicability of DM in the treatment of chronic pain
disorders.

4. Research Limitations

While promising, there are several key limitations that must be considered in the
interpretation of this dissertation: (a) use of IL-10 KO mice, (b) mRNA vs. protein
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analyses, (c) utilization of in vitro experimental approaches, and (d) small sample sizes
during in vitro cell culture experiments.
IL-10 KO mice served as a powerful tool to unambiguously assess the therapeutic
biodistribution of exogenous IL-10 transgene expression following intrathecal injection.
They were also critical for investigating the role of endogenous IL-10 in both the efficacy
of non-viral IL-10 gene therapy and in the effects of DM as an adjuvant for non-viral
transgene therapy. However, the developmental absence of IL-10 could lead to
compensatory changes in similar or alternative biological pathways (Keubler et al., 2015).
Therefore, it is possible that pain relief observed IL-10 KO mice given non-viral IL-10
gene therapy engages alternative mechanisms that may not be available in wildtype or
conditional Il-10 knockout mice. The same must be considered for the “IL-10independent” adjuvant and anti-inflammatory effects of DM, both in vitro and in vivo.
Assessment of mRNA levels offered key insight regarding the molecular and
cellular changes that occur following intrathecal non-viral IL-10 gene therapy. While this
approach allows for assessment of many targets despite small tissue volumes (e.g. DRG),
it must be recognized that changes in mRNA levels do not always reflect changes in levels
of corresponding proteins. Production of cytokines is often tightly regulated, as for IL-1β
and TGF-β1, with a pro- or latent forms that must be converted to a mature bioactive forms.
Therefore, following mRNA analysis, assessment of protein levels can offer a more
comprehensive understanding of the systems in question. For instance, while pain relieved
IL-10 KO mice given CCI+DM/pDNA-IL-10 express elevated mRNA levels for TGF-β1,
whether this results in increased levels of bioactive TGF-β1 protein has not been assessed.
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In vitro primary cell culture offers numerous advantages, including control of
chemical conditions (e.g. pH, temperature, osmolarity, etc.), control of the physiological
exposures (e.g. nutrients, hormones, growth factors, etc.), ease of treatment manipulation
(e.g. drug exposure or intervention), enrichment of specific cell types (e.g. macrophage vs.
T cell), and similarity in phenotype of primary cells to in vivo cells (Stansley et al., 2012).
However, this approach is not without its limitations. For instance, cells in vivo rarely exist
in single cell-type populations and instead co-exist in a diverse population of cells within
a given tissue type. Furthermore, cells in vitro are often grown in a 2-dimensional (2D)
monolayer which is not particularly representative of the natural in vivo microenvironment
of cells (Fennema et al., 2013). Additionally, while great care is taken to develop culture
media that is beneficial for maintenance of cellular viability, experimenters cannot possibly
replicate all the variables present in the in vivo cellular milieu. Media is commonly
supplemented with serum (e.g. fetal bovine serum) to provide supportive growth factors,
hormones, lipids and other undefined components. However, use of serum is plagued by
lot-to-lot variability as well as presentation of xenobiotic antigens that may unintentionally
alter immune cell phenotypes (Vogel et al., 1988; Gstraunthaler, 2003). Therefore, while
primary cell culture offers a powerful investigative tool, cell culture conditions may not
always be reflective of in vivo mechanisms and could explain different dosage for
successful non-viral IL-10 gene therapy in vitro vs. in vivo.
Finally, small sample sizes must be taken into consideration. The sample sizes
utilized for investigations in Chapter 3 consisted of 2-3 wells per condition within a single
experimental round. A power analysis was performed (G*Power 3.0.10 software) using
preliminary data (Ch.3, Fig. 2A and 2C), separately for NO and for IL-10 data. For NO
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analyses, assuming a pooled standard deviation (across WT and IL-10 KO cells) of 1.828,
α = 0.05, power set at 95%, and an effect size of 3.01, n = 2 wells per condition are required
for ANOVA statistical analyses to detect significance. This supports that while replicate
studies ought to be performed, the presented data were sufficiently powered for assessment
of NO. For IL-10 protein power analysis, only WT data was considered. Assuming a pooled
WT standard deviation of 23.955, α = 0.05, power set at 95%, and an effect size of 1.37, n
= 4 wells per condition in IL-10 protein analyses. Future analyses of IL-10 protein
expression will therefore require greater sample sizes, including replicates, in order to
reject the null hypothesis.
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APPENDIX A

D-mannose disrupts the NLRP3-inflammasome in peritoneal macrophages:
Peritoneal macrophages (PMs) were separately pooled from 3 WT or 3 IL-10 KO mice and
cultured ex vivo for 13 hours prior to stimulation or treatment (N = 2 wells per condition;
2 x 105 cells in 500μL/well; 24 well plate). At time zero, cells were stimulated 4hrs with
LPS (1μg/mL), then 1hr with D-mannose (D-man; 100mM), and finally 1hr with adenosine
triphosphate (ATP; 25mM). Cells were collected and stained for flow cytometric analysis.
To assess caspase-1 activation in stimulated PMs, a Fluorochrome-Labeled Inhibitor of
Caspases Assay (FLICA) was used per manufacturer’s instructions with a FAM-FLICA
Assay Kit (ImmunoChemistry Tech) prior to other staining steps. Staining was performed,
with modification, as previously described (Clark et al., 2011; Noor et al., 2017). PMs
were stained with a fixable viability dye, then incubated with Fc block. Surface staining
antibodies included: CD11b-PE-Cy7 and F4/80-PerCP-Cy5.5, CD45-APC-Cy7. Cells
were fixed in 4% PFA prior to intracellular staining with NLRP3-Alexa Fluor 700. Flow
cytometric analysis was performed with a BD LSRFortessa (BD Bioscience), and the data
were analyzed with FlowJo software (Tree Star). Macrophages were identified as
CD45+/CD11b+/F4/80+ and analyzed for Active Caspase-1 vs. NLRP3. Control stimulated
cells (A, E) are NLRP3+, but few are positive for Caspase-1 activation. LPS only (B, F)
cells exhibit increases in the proportion of cells that are double positive for NLRP3 and
Active Caspase-1, and this increase is enhanced in LPS/ATP treated cells (C, G). These
trends are consistent in both WT and IL-10 KO cells. D-mannose prior to ATP stimulation
(LPS/ATP/D-man) dramatically decreases the proportion of double positive cells and
increases the proportion of double negatives in WT cells (D), but these effects are not
observed in IL-10 KO cells (H). Representative plots are shown.
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